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Low bioavailability of drug candidates due to poor water solubility accounts for one of 
the greatest obstacles facing the pharmaceutical industry. Poorly soluble compounds represent 
40% of the top 200 oral drugs marketed in the US and 90% of new chemical entities in 
development, highlighting the importance of establishing comprehensive methodologies to 
improve the bioavailability of these compounds. Supercritical fluid (SCF) technologies have 
been used as alternative manufacturing methods to overcome this property, mostly through 
solid-state control and particle size reduction. Supercritical CO2 (scCO2), the most common 
SCF, allows for a wide range of methods to be developed for the production of pharmaceutical 
materials due to its ability to act as a solvent, antisolvent and/or additive/spray enhancer.  
This thesis investigates the development of batch and continuous supercritical CO2 
methodologies which can induce precipitation of active pharmaceutical ingredients (APIs). 
Different approaches and strategies have been investigated in this thesis to control the solid-
state of APIs, specifically, polymorphic control and the generation of pharmaceutical 
cocrystals. An introduction to the topics and technologies that are employed to address the most 
common concerns in the pharmaceutical industry are described in Chapter 1 and a detailed 
description of the characterization techniques employed in this thesis is described in Chapter 
2. The experimental chapters are arranged as research articles with introductory summaries at 
the beginning of each. 
The first phase of this thesis (Chapter 3) describes the control over the polymorphism 
of carbamazepine (CBZ), a highly polymorphic BCS class II drug, using anionic additives in a 
gas antisolvent (GAS) method. A design of experiments (DoE) approach was performed to 
assess the impact of CO2 antisolvent processing variables such as pressure, temperature and 
CO2 addition rate when anionic additives (sodium stearate or sodium dodecyl sulfate) were 
employed on the outcome of CBZ polymorphism. Statistical analysis revealed that the 
combination of temperature and CO2 addition rate show statistically significant impact (p < 
0.05) on the final CBZ polymorphic form obtained when no additive was present during short 
hold studies. However, when 5% w/w of additives sodium stearate (SS) or sodium dodecyl 
sulfate (SDS) were used, CBZ form II and III were obtained, respectively, regardless of the 
processing condition used. An additional investigation into the polymorphic stability of these 
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CBZ samples was undertaken, allowing the precipitated CBZ to remain immersed in the 
supercritical media (scCO2 and methanol) for a prolonged period (sixty hours) which 
demonstrated moderate conversion for metastable forms (form II) and minimal conversion for 
stable forms (form III) of CBZ, which occurred close to the transition temperature between 
stable and metastable forms of this API (CBZ).  
The second phase of this thesis (Chapter 4) investigates if the results produced in the 
batch GAS method could be reproduced using a supercritical-CO2-assisted spray drying 
method (SASD). A DoE approach was used to investigate the impact of (1) additive quantity 
and (2) solution flow rate, which changes the ratio between drug solution and scCO2 
antisolvent, on the polymorphic form of CBZ.  The results of this investigation show a similar 
effect caused by the anionic additives SS and SDS, presented in the previous chapter, using the 
SASD method with minimal influence caused by the processing variables investigated. 
Additionally, the SASD method offers a greater degree of control with respect to particle size 
evidenced by the production of CBZ particles in the submicron/nano sized range (0.5-5 µm). 
Similar experiments using a conventional spray dryer (Büchi B-290) were completed but did 
not exhibit the polymorphic control achieved using the SASD method, suggesting that the 
antisolvent effect was the governing crystallization mechanism.  
The final phase of this thesis (Chapter 5) reports the use of two SCF methods (GAS and 
cocrystallization with supercritical solvent [CSS]) to generate a recently reported cocrystal of 
the poorly soluble API, posaconazole (PSZ) using 4-aminobenzoic acid (4AMB) as a coformer. 
A DoE approach is applied to investigate the impact of critical processing variables (pressure, 
temperature and stirring rate) on PSZ-4AMB formation. This study highlights that both 
methods can be employed to form PSZ-4AMB, however, samples produced by the GAS 
method were of a higher purity than those produced by the CSS method. Reaction time was 
investigated as an opportunity to improve the purity of the cocrystal samples produced by the 
CSS method but did not appear to play an influencing role. The low purity of CSS samples is 
likely caused by the low solubility of PSZ and 4AMB in scCO2. Further optimization, 
potentially by using a co-solvent, may be required for the CSS method, while the GAS method 
displayed that higher purity samples (compared to the CSS method) can be obtained across a 




Graphical Abstract: Schematic of the CSS, GAS and SASD methods featured in this thesis 
utilizing each of the three unique roles of supercritical CO2, namely its solvent, antisolvent and 
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Chapter 1. Introduction 
 
1.1 Solid State Pharmaceuticals 
In 2017, the global pharmaceutical market was worth almost $1 trillion, and by next year 
(2021), it is expected to surpass this figure.1 While this figure provides an insight into the scale 
of this sector, when compared to previous years, a decline in growth rate is observed.1 There 
are multiple factors that can influence this growth rate, such as disease prevalence, drug 
affordability, political climate and, most recently, global pandemics.2-3 Despite this slowing 
growth rate, the pharmaceutical industry has the second highest research and development 
(R&D) spending (expenditure as a share of sales) of any sector. A report by EvaluatePharma 
in 2018 suggests that R&D spending is expected to grow by 3% each year up to 2024.4 This 
increase in investment, despite a slowing market, highlights the significant return that can be 
achieved in this sector. In 2018, the Food and Drug Administration (FDA) approved 59 new 
drugs (42 new chemical entities (NCEs) and 17 biologics). Biologics are defined as being 
typically large molecule, complex mixtures that use aseptic manufacturing steps while NCEs 
are usually chemically synthesized, small molecules drugs that do not require the same 
stringent manufacturing steps as they are less susceptible to microbial contamination. This 
figure is the largest amount of drug approvals to date, surpassing the previous record of 53 drug 
approvals in 1996, and highlights the competitive market which exists.5 In 2019, this figure 
dropped to 48 and some potential reasons for this decrease are provided below. Figure 1 
describes the drugs (NCEs and biologics) approved in the last two decades by the FDA.5-6 
Analysts have been cautious in predicting future trends due to unpredictability of the above 
mentioned factors such as the shutdown of the United States government in 2019 or the impact 
of the expected global recession in 2020 caused by COVID-19.7 However, the focus of this 
thesis will consider the various physicochemical factors, specifically poor solubility, that may 
negatively impact the final number of drugs approved and the various approaches that exist to 
combat these factors. 
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Figure 1. Drugs (new chemical entities and biologics) approved by the FDA in the last two 
decades.5-6 
 
1.2 Crystallization  
Crystallization is considered to be a critical operation in the pharmaceutical industry which can 
govern the shape, particle size and crystal forms, which influence the solubility and, therefore, 
bioavailability of active pharmaceutical ingredients (APIs).8-9 It can be utilized as a separation 
method during the synthesis of APIs or as the final step in the manufacturing process where 
the target molecule can be isolated.9   For crystallization to occur, a solution must exist in either 
the metastable or supersaturated zone meaning that it must contain a sufficient amount (above 
the equilibrium solubility) of solute in the corresponding solvent. This can be achieved by (1) 
the evaporation of a solvent, (2) cooling of a solution, and (3) through the addition or mixture 
of an antisolvent.10-14 Crystallization begins by the aggregation of API molecules, leading to 
clusters being formed in the solution, in a process called nucleation which will be discussed in 
greater detail in section 1.2.1.15-16 These clusters continue to form until the growth of nuclei of 
a critical size (minimum number of molecules required for new phase) occurs. These nuclei 
continue to grow, through diffusion of molecules on the surface, until a solid crystal is formed. 
Figure 2 describes a typical phase diagram of an API with different zones influencing 
crystallization. The undersaturated region, which occurs below the purple curved line, contains 
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a lower proportion of solute than the equilibrium solubility at that temperature while the 
supersaturated region, which occurs above the red curved line, contains a greater concentration 
of solute than the equilibrium solubility. In the undersaturated region, crystallization cannot 
occur, and the concentration or temperature must be controlled in order to induce nucleation 
and thus, crystallization. In between the undersaturated and supersaturated zones, exists the 
metastable zone, where crystallization can occur, but it is not spontaneous. In this region, if the 
solution is seeded (addition of homogenous or heterogeneous crystals to a solution), crystal 
growth may occur, and this approach is often utilized in API manufacturing to induce 
crystallization and control the solid-state form of the resulting API.17-18  
 
Figure 2.  Schematic illustration of typical undersaturated, metastable and supersaturated zones 
in a conventional crystallization process. Adapted from Dai et al.18 
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1.2.1 Nucleation 
As discussed in Section 1.2, the aggregation of API molecules to form clusters of critical nuclei 
is commonly referred to as nucleation. This is the first step in a crystallization process and, 
according to classical nucleation theory, is decisive in determining the crystal structure and 
size.19 The other theory, known as the two-step mechanism, is discussed in greater detail in the 
next section but proposes that solute molecules are trapped in a highly disordered droplet which 
grows until crystallization occurs. Figure 3 illustrates the different steps 
(aggregation/clustering, nucleation and growth) required for crystallization to occur. 
Nucleation can further be broken down into different categories, namely homogenous 
(primary) or surface catalysed (secondary) and will be discussed in greater detail in the sections 
below. 
 
Figure 3.  Schematic of nucleation and crystallization process involving aggregation or 
clustering of molecules to form a critical nucleus followed by nucleation and growth. 
 
1.2.1.1 Primary Nucleation 
Primary nucleation refers to the aggregation of molecules from the bulk homogenous solution. 
Two theories currently exist which describe the nucleation process.20 The first, classical 
nucleation theory (CNT) assumes that the formation of these critical nuclei is based upon the 
addition of solute molecules.15, 21 However, some shortcomings were observed in CNT, such 
as failure to provide understanding of measured kinetic curves, nucleation rates and other 
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phases possible in solution, and, as a result, the two-step nucleation mechanism was proposed 
by Ten Wolde and Frenkel.22-23 This mechanism suggests that a highly disordered liquid droplet 
with solute molecules trapped within arrange themselves to a crystalline nucleus inside the 
droplet and growth occurs until a crystal is formed.22 Figure 4 presents the CNT and two-step 
nucleation theory and compares the primary differences in free energy between both 
mechanisms.  
 
Figure 4.  Schematic comparing a) classical nucleation theory (CNT) and b) two-step 
nucleation. CNT is a one step process involving the growth of critical nuclei while two-step 
nucleation involves the arrangement of solute molecules in a droplet followed by their growth 
leading to crystallization. Adapted from Myerson and Trout. 24  
 
1.2.1.2 Secondary Nucleation 
Secondary nucleation involves aggregation of solute molecules to form a crystal nuclei on a 
parent crystal.25-26 The mechanisms involved in secondary nucleation are more complex than 
primary nucleation but have been reported to reduce the energy required for nucleation to 
occur, meaning crystallization can occur across a broader range of operating conditions.27 
Seeding a reaction, which utilizes the principles of secondary nucleation, involves the addition 
of smaller seed crystals of the desired material in order to reduce the time required for  (1) 
crystallization, (2) control the crystal form produced or  (3) induce crystallization at a specific 
period.28-29 Figure 5 compares primary and secondary nucleation steps leading to crystal growth 
and illustrates the growth step (c) involved in crystal formation.30 In the scheme which 
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illustrates secondary nucleation (b), the aggregation of API molecules (identified in yellow) 
can be observed on the presence of the heterogeneous seed crystal (green) leading to the 
formation of new crystals and their growth (c). 
 
Figure 5.  Schematic process of; (a) primary nucleation using classical nucleation theory, (b) 
secondary nucleation involving the growth of nuclei on the solid-liquid interface of another 
parent crystal. Crystal growth in (c). Adapted from Linse. 30  
 
1.2.2 Solubility of Solid-State Pharmaceuticals 
Solubility is defined as “the amount of the solute dissolved in the solvent at the equilibrium 
state” and the rate at which this state is attained is known as the dissolution rate. Solubility is 
a thermodynamic property, while dissolution is related to the kinetics. The solubility can be 
determined using the following Gibbs free energy equation31: 
∆𝐺𝑚𝑖𝑥 = ∆𝐻𝑚𝑖𝑥 −  𝑇∆𝑆𝑚𝑖𝑥  
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In this equation, ΔGmix is the free energy of mixing, ΔHmix is the enthalpy of mixing, T is 
temperature (measured in Kelvin) and ΔSmix is the entropy of mixing. Phases which have a 
lower Gibbs’ free energy (ΔG), will be the more stable component and typically have a lower 
solubility than those with a higher ΔG. The solubility or dissolution rate of a drug compound 
can be improved through several different approaches, illustrated in Figure 6, such as particle 
size reduction, polymorphic control, salt formation and the generation of cocrystals.11, 31-34 
These approaches will be discussed in greater detail throughout this chapter and some of these 
methods will be applied to the experimental chapters in this thesis. The dissolution rate profiles 
of APIs produced by each of these different approaches typically influence the decision of 
pharmaceutical companies on whether to adopt this approach for large-scale manufacturing.35 
However, improving the dissolution rate may negatively impact another critical property, such 
as stability changes from metastable solid-state forms and careful consideration must be 
applied to this decision.36 
 
Figure 6.  Common strategies which exist and are currently employed to address issues of low 
drug solubility in pharmaceutical compounds during drug discovery and development. Adapted 
from Williams et al.37 
 
- 8 - 
 
1.2.2.1 Biopharmaceutics Classification System (BCS) 
In 1995, the biopharmaceutics classification system (BCS) was created to define the most 
critical properties of a drug product; aqueous solubility and intestinal permeability.38 This 
system, shown in Figure 7, has four classes (I, II, III and IV) and new compounds are assigned 
to one of these four categories based on their solubility and permeability properties.38 
According to this system, a drug is classified as having ‘high solubility’ if the highest dosage 
of the API dissolves in less than 250 ml of water and having ‘highly permeability’ when the 
extent of absorption in humans is determined to be 90% or more of the administered dose. In 
2004, Yazdanian et al. suggested that this system was too restrictive for some APIs, 
specifically, acidic drugs. In this study, they found that 15 of 18 acidic drugs that were tested, 
demonstrated ‘low solubility’ according to the existing BCS guidelines.39 However, these 
drugs demonstrated an improved solubility, sufficient to move from class II to class I, at other 
pH ranges that they would be subjected to in the gastrointestinal tract, suggesting that the BCS 
guidelines may be too restrictive for acidic drugs and might not be applicable to every NCE 
discovered.39 Despite this, the BCS is used, by both industry and regulatory bodies and helps 
to provide an insight into the shortcomings of NCEs such as the poor solubility experienced by 
up to 90% of these compounds in the pipeline.40 Additionally, drugs that fall into certain classes 
(typically class I and III) can qualify for biowaivers, meaning that in vivo bioavailability and/or 
bioequivalence studies are not required for regulatory approval. This clause makes drugs that 
fall into these categories extremely attractive for the pharmaceutical industry. 
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Figure 7. The Biopharmaceutics Classification System (BCS) as defined by the FDA. Adapted 
from Wu and Benet. 41-42 
 
Currently, 40% of the top 200 oral drugs marketed in the US, 75% of compounds under 
development and 90% of new chemical entities can be characterised as having poor solubility 
(class II or IV). These figures highlight the importance of establishing a comprehensive method 
to improve the solubility, and thus bioavailability, of these compounds. 40, 43  
 
1.2.3 Particle Size Reduction  
The reduction in size of a drug particle is often the easiest and most popular way to enhance 
the dissolution rate of a drug product. As drug particles become smaller, they have a greater 
interaction with the solvent/intestinal fluids and dissolution rate is typically increased. 
According to the Noyes-Whitney equation (below), when particle size is reduced, the total 
effective surface area of drug particles are increased, influencing the dissolution rate44 











 is the dissolution rate of the drug particles, D is the diffusion coefficient of the drug 
in the gastrointestinal media, A is the effective surface area of the drug particles in contact with 
the gastrointestinal fluids, h is the thickness of the diffusion layer around each drug particle, Cs 
is the saturation solubility of the drug in solution in the diffusion layer and Cb is the 
concentration of the drug in the gastrointestinal fluids. 
Particle size control can be achieved by various top-down and bottom-up methods. Currently, 
top-down methods, specifically milling, is the most common method to reduce the size of 
pharmaceutical compounds. Although any level of particle size reduction will typically result 
in an increased dissolution rate, reduction of API particles to the nanoscale (<1 µm) will 
generate significant improvements in the dissolution rate of a material. Of the 17 
nanocrystalline-based drug products approved by the FDA, 14 of these have used wet media 
milling (WMM) as the method to reduce the particle size while one (Triglide®) employs high-
pressure homogenization (HPH). Only two products (Cesamet® and Gris-Peg®) employ 
bottom-up approaches (antisolvent precipitation) to generate nano-sized drug products. One 
potential reason for this is that bottom-up approaches can affect suspensions through the 
formation of various polymorphs, solvates and hydrates as well as unfavourable morphologies 
as a result of rapid growth in one direction. Table 1 details the nanocrystalline drug products, 
their indication and the method used to generate these nano-sized particles. In this table, the 
size criteria for a ‘nanocrystalline’ material falls between the ranges of 50-1000 nm.45 This 
thesis will discuss the potential for an alternative bottom-up method as a new approach for 
producing submicron/nano materials. 
 
Table 1. Nanocrystalline-based products approved by the FDA45 
Trade Name Company Indication  Method Used Year 
Avinza ® King Pharma Pain Medication WMM 2002 
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Azopt ® Alcon Ocular hypertension WMM 1998 
Cesamet ®  Lilly  Antiemetic  Precipitation 2005 
Emend ®  Merck Antiemetic  WMM  2003 
Focalin XR ®  Novartis ADHD WMM 2001 
Gris-Peg ®  Novartis Antifungal Precipitation 1982 
Herbesser ®  Misubishi Hypertension WMM 2002 
Invega Sustenna ®  Johnson & 
Johnson 
Antipsychotic WMM 2009 
Megace ES ® Par 
Pharmaceutical 
Appetite stimulant WMM 2005 
Naprelan ®  Wyeth NSAID WMM 2006 
Rapamune ®  Wyeth Immunosuppressant WMM 2000 
Ritalin LA ®  Novartis ADHD WMM 2002 
Theodur ®  Mitsubishi 
Tanabe Pharma 
Asthma, COPD WMM 2008 
Tricor ®  Abbott Hypercholesterolemia  WMM 2004 
Triglide ®  SkyePharma Hypercholesterolemia HPH 2005 
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Verelan PM ®  Schwarz Pharma Hypertension WMM 1998 
Zanaflex ®  Acorda Muscle Relaxant WMM 2002 
 
1.2.4 Polymorphism   
Polymorphism can be described as the ability for a solid compound to exist in more than one 
crystal structure and is estimated to be present in more than 50% of APIs.11, 46-47 These different 
polymorphs, referred to as “forms”, can exhibit different physical and thermodynamic 
properties such as density, melting point and solubility making it a viable approach to improve 
the bioavailability of APIs, provided the polymorphic form can be controlled. Although 
polymorphism was first observed as far back as 1798 by Klaproth who reported two distinct 
forms of calcium carbonate48, polymorphism did not come to the attention of the 
pharmaceutical industry until 1998 when Ritonavir, an antiretroviral medication used to treat 
HIV, exhibited polymorphic transition leading to a less soluble but more stable form.49-50   A 
full market recall was required for this drug while a new formulation was developed causing 
numerous patient difficulties in addition to significant financial consequences for Abbott. 
Currently, regulatory bodies, such as the FDA, require stringent testing protocols from 
pharmaceutical companies to examine, as much as reasonably practicable, if a new chemical 
entity will exhibit polymorphism in order to prevent situations, similar to that of 1998.51 
Despite this, issues of poor drug solubility may be addressed if complete control over the 
polymorphism of a drug can be achieved. Thermodynamically stable polymorphs will exhibit 
a lower Gibbs free energy and thus, will exhibit a lower solubility according to section 1.2.2. 
Conversely, less stable (metastable) polymorphs will have higher solubility and dissolution 
rates than the stable forms and can be a lucrative approach for pharmaceutical companies, 
provided that transformation to a more stable form can be prevented. Abramov investigated 
153 polymorph pairs and showed that the ratio of equilibrium solubilities (C*metastable/C*stable) 
is less than 1.2 for 50% of these pairs and less than 2.0 for 95% of these pairs. Additionally, 
Verma and Hodnett propose that the change in relative kinetic accessibility of the polymorphs 
can become very small which increases the critical nucleation free energy of the metastable 
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polymorph. 178, 179 The thermodynamic properties of polymorphic transformation can be broken 
down into two categories, namely monotropic and enantiotropic systems. For a given 
monotropic system (capable of existing in two polymorphic forms: Polymorph A and 
Polymorph B), shown in Figure 8 (a), Polymorph B will be more stable than Polymorph A at 
all temperatures below the melting temperature and thus, will have a lower solubility. For an 
enantiotropic system, shown in Figure 8 (b), a crossing point exists (at a point below the melting 
temperature) where the stability of the polymorphs is reversed. This crossing point is known 
as the transition temperature, T0 and can often serve a guide towards suitable operating 
conditions that should be employed. 
 
Figure 8. Schematic representation of the two categories of polymorphs. a) Monotropic and b) 
enantiotropic polymorphs. T0 signifies the transition temperature where one polymorph can 
reversibly transition to another. Adapted from Li et al.52 
 
During nucleation, Ostwald’s rule of stages, illustrated in Figure 9, states that, in general, the 
least stable form tends to form first.53-54 If time permits, this crystalline form will continue to 
transition, provided it is in a suitable medium, to a more stable crystalline form and continue 
to do so until it has reached the most thermodynamically stable form. Various crystallization 
processes make use of this phenomenon to control the solid form obtained.55-56 During solution 
crystallization, the rate at which the solvent is evaporated can be controlled, meaning that a 
slower rate of evaporation can lead to a more stable polymorph produced while a quicker rate 
can lead to metastable polymorphs.57-58 Another method which utilizes this phenomenon is 
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conventional spray drying which typically has a nucleation and crystallization timescale of 
milliseconds and tends to lead to the formation of amorphous (least stable) or metastable forms 
of an API.59-60 Figure 9 describes Ostwald’s rule of stages with respect to free energy and 
diameter axes. In this figure, the metastable polymorph (red line) has a lower initial free energy 
value until the particle reaches a certain radius during the growth stage (after an elapsed time) 
and is no longer the favourable (stable) form. 
 
Figure 9. Schematic representation of energetics of two different polymorphs as a function of 
particle radius. Adapted from Navrotsky.61  
 
1.2.5 Pharmaceutical Cocrystals 
Cocrystals were first reported in 1844 by Friederich Wöhler who synthesized Quinhydrone.62 
However, at this time it was not reported as a cocrystal and until only recently, a clear cocrystal 
definition has been provided to settle the topical debate over what can be classified as a 
cocrystal. Initially the definition stated that a cocrystal is a mixed crystal or crystal that contains 
two different molecules.63 This broad definition was refined by Aakeröy in 2005 who suggested 
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that “cocrystals are made from reactants that are solids at ambient temperature” and added that 
hydrates and solvates should not be classified as cocrystals.64 In 2011, the FDA released a draft 
guidance concerning the regulatory classification of pharmaceutical cocrystals.65 This new 
guidance classified pharmaceutical cocrystals as drug product intermediates meaning that 
additional regulations would be required, which was expected to hinder the field of cocrystals 
based on the potential risk incurred by the pharmaceutical industry.65-66 Soon after this 
guidance was released, the Indo-U.S. Science and Technology forum met and discussed the 
new classifications of pharmaceutical cocrystals from the FDA and published works which 
summarised this discussion.67 In this manuscript, a proposed definition, that was consistent 
with scientific literature but broader than the FDA definition proposed that ‘cocrystals are 
solids that are crystalline single phase materials composed of two or more different molecular 
and/or ionic compounds generally in a stoichiometric ratio which are neither solvates nor 
simple salts’.66-67 In a recent update of the regulatory classification of cocrystals, the FDA 
announced that new cocrystals would be subject to clinical testing similar to that of a new 
polymorph, rather than a drug product intermediate or a new chemical entity.65 This ruling, 
which significantly reduces the level of testing required, is expected to encourage further 
research by academia and the pharmaceutical industry into cocrystal discovery.68 
Pharmaceutical cocrystals typically involve an API bonded (via hydrogen bonding) to 
another component, called a coformer.69 Briefly explained in Figure 6, Figure 10 shows a more 
detailed explanation of the various solid state pharmaceutical forms and how a cocrystal differs 
from polymorphs, hydrates, solvates and salts. Cocrystals can also exhibit polymorphism 
which can lead to an even greater improvement of physicochemical properties.33 The coformer 
bonded to the API, is typically a GRAS (Generally Regarded As Safe) component, approved 
by the FDA but can also be another active ingredient, observed in marketed cocrystals such as 
Entresto®.66 The advantages of pharmaceutical cocrystals is that the physicochemical 
properties, such as stability, solubility and permeability, of drugs can be tailored and improved 
which can positively impact the bioavailability of the API component.70-76 Additionally, 
manufacturing cocrystals should not be significantly different than that of APIs meaning that 
this approach offers a low-risk but high reward towards novel pharmaceutical materials.66 
Furthermore, coformers are typically GRAS  (generally regarded as safe) compounds that have 
a low cost associated with them, thereby increasing the financial incentive of this approach in 
addition to reduced bioequivalence studies.77 
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Figure 10. Various solid-state pharmaceutical crystal forms. Adapted from Vioglio et al.69 
 
Figure 11 reveals the impact that cocrystals have had on the academic community with an 
almost exponential rise in publications after 2004. Kavanagh et al. has also shown that a similar 
trend can be observed in the frequency of patent applications relating to cocrystals.66 As a result 
of the recent FDA regulatory classification in 2018, the number of publications, as well as 
patent applications, is expected to increase.66  
 
Figure 11. Cocrystal publications from 2014 to 2019 generated from a search of the Web of 
Science® database for terms ‘cocrystal’ OR ‘co-crystal’. 
- 17 - 
 
1.2.5.1 Molecular Cocrystals 
There are two main categories of cocrystals, namely molecular and ionic (or charge assisted). 
Molecular cocrystals (MCCs) contain two or more different neutral components in a 
stoichiometric ratio and are typically sustained by hydrogen bonds. This type of cocrystal was 
the composition of the first cocrystal (quinhydrone) discovered by Wöhler, who was unaware 
at the time.62 As a result of the uncertainty surrounding a cocrystal definition until 201267, some 
MCCs have been inadvertently labelled as organic molecular compounds and hydrogen bond 
complexes.78 Most pharmaceutical cocrystals reported in academia fall into this category 
however, of the 8 FDA approved cocrystals on the market, 4 are classified as MCCs (Cafcit®, 
Betachlor®, Suglat® and Steglatro®).66 Molecular cocrystals are particularly advantageous 
when an API cannot form a salt. Figure 12 describes the differences between MCCs (A) and 
ionic cocrystals (B), which will be discussed in the next section.  
 
Figure 12. Schematic representation of (A) a pharmaceutical cocrystal where the API and 
coformer are organic molecules and (B) where coformer is a metal ion. Adapted from 
Sathisaran et al.79 
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1.2.5.2 Ionic Cocrystals 
Ionic cocrystals (ICCs) differ from MCCs by replacing the neutral coformer with inorganic 
salts.66 This means that they have a wider diversity as they will have three components (organic 
compound, cation and anion).80 Although it is difficult to determine the number of publications 
that relate to ICCs or MCCs as authors typically do not identify what type of cocrystal their 
study relates to, ICCs are considered to be less frequently published compared to MCCs. Of 
the 8 FDA approved cocrystals, ICCs account for four of these (Entrestro®, Odomzo®, 
Lexapro® and Depakote®) showing a greater interest in these type of cocrystals by the 
pharmaceutical industry, compared to academia.66 The interaction between the salt and organic 
molecule is typically electrostatic with additional contribution from hydrogen bonding.80 As a 
result of these stronger interactions (compared to those exhibited by MCCs), the 
physicochemical properties that are typically increased through cocrystallization are more 
dramatic for ICCs compared to MCCs.81 Despite this promising advantage for ICCs, one major 
drawback for these components is that the inorganic salt can sometimes be more 
thermodynamically stable compared to the ICC meaning that additional challenges during 
formulation may be observed. Figure 13 describes the interaction between an organic solid 
(API) and a metal salt to form an ICC, coined by Braga et al. for their uses in the pharmaceutical 
industry as well as the food and agriculture industry.80, 82 
 
 
Figure 13. Representation of ionic cocrystal formation through organic solid (API) and metal 
salt interaction. Adapted from Braga et al.80 
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1.3 Supercritical Fluid (SCF) Technology 
A supercritical fluid (SCF) is defined as a substance above its critical point, where distinct 
liquid and gaseous phases do not exist. Supercritical fluids were first discovered in 1822 by 
listening to differences in sounds from rolling cannon balls by a French physicist named Baron 
Charles Cagniard de la Tour.83 Figure 14 illustrates the phase diagram for a typical compound, 
including the critical point where this compound enters a supercritical phase at which it can 
effuse through solids like a gas and dissolve materials similar to that of a liquid.84 Carbon 
dioxide is the most commonly used supercritical fluid because of its mild critical parameters 
(Tc = 31.1 °C and Pc = 73.8 bar).
85 The low critical temperature of CO2 is of particular interest 
as it allows manufacturers to process thermally sensitive compounds, such as pharmaceuticals. 
The solubility behaviour of many compounds in supercritical CO2 (scCO2) increases with 
increasing pressure meaning separation and purification processes can be designed employing 
SCF as extraction solvents. Supercritical CO2 is most frequently employed for extraction 
processes, most commonly for the decaffeination of coffee in industry and for the extraction of 
essential oils and food products in academia.86-88 However, this technology has recently 
attracted attention as a novel approach for the production and generation of pharmaceutical 
compounds.85, 89-90 
 
Figure 14. Phase diagram of a typical compound including the critical point where a substance 
behaves as a supercritical fluid.90    
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Supercritical CO2 has three unique roles which makes it an excellent candidate for the 
generation of pharmaceutical compounds. The first role is when scCO2 acts as a solvent, the 
second is when scCO2 acts an antisolvent or a co-antisolvent and induces precipitation of APIs 
from organic solutions and the final role is when scCO2 acts as an additive or spray enhancer.
85 
The decision on which scCO2 role to select can depend on various factors but is heavily 
influenced by the solubility of the organic solvent and API in scCO2. Each of these roles and 
the different processes associated with them will be discussed in greater detail in the sections 
below and all three roles will feature during the experimental chapters (3, 4 and 5) of this thesis. 
 
1.3.1 Supercritical CO2 (Solvent) 
The first role of scCO2 that will be considered is when the SCF acts as a solvent to dissolve all 
or part of the solutes involved in the final formulation, specifically the APIs and other 
substances such as coformers and salts. This role can eliminate or greatly reduce the 
requirement for organic solvents and thus reduce the number of steps required for drug 
processing. However, this role faces some limitations as the solubility of APIs vary in scCO2, 
many of which possess a low solubility in scCO2.
91 The solubility of APIs in scCO2 is 
influenced by its polarity with non-polar compounds exhibiting an increased solubility in 
scCO2 compared to polar compounds. This variability means that employing these methods 
needs to be selected on a case-by-case basis rather than a universal approach. The most 
common method which employs scCO2 in this role is the rapid expansion of supercritical 
solutions (discussed in section 1.3.1.1) and a derivative of this method (controlled expansion 
of supercritical solutions) is currently used for the industrial production of pharmaceutical 
materials by Nanoform, a Finnish pharmaceutical company.92  
 
1.3.1.1 Rapid Expansion of Supercritical Solutions (RESS) 
The first method which employed scCO2 as a solvent was called the rapid expansion of 
supercritical solutions (RESS), which was first reported in the 1980s by Smith et al.93-95 This 
method begins by dissolving a solute(s) in scCO2 in a solubilization vessel. The pressure and 
- 21 - 
 
temperature of scCO2 can be adjusted in order to achieve a saturated (or near-saturated) fluid 
solution. This solution containing the dissolved API flows through a pre-expansion zone and 
is then rapidly expanded through a capillary nozzle into a collection chamber (expansion 
vessel) where CO2 is removed via a vent.
85 The rapid depressurization causes a high degree of 
supersaturation which results in homogenous nucleation and causes fine solute particles (<1 
µm) to precipitate with a narrow particle size distribution.85, 96-97 Figure 15 describes a typical 
schematic for the RESS method.  
 
Figure 15. Schematic diagram of a typical RESS setup. Adapted from Salem et al.96 
 
In order to accommodate for APIs with poor solubility in scCO2, several adaptations of this 
method were created, which include a liquid solvent being present in the expansion vessel 
(RESSOLV) and the use of a solid co-solvent (RESS-SC) which aided the solvation of APIs 
in the solubilization vessel. Drugs which have a low solubility in scCO2 are usually the main 
constraint when deciding whether to employ this method and, although several variations have 
been created to accommodate for this, is the primary reason why this method is considered on 
a case by case basis for the production of pharmaceutical materials.  
However, despite the poor solubility of some APIs, another derivative of this method 
briefly mentioned in the previous section is called the controlled expansion of supercritical 
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solutions (CESS) and is currently employed in the pharmaceutical industry to produce APIs 
with improved solubility. The CESS method differs from RESS by allowing a greater degree 
of control over mass transfer, flow, pressure reduction and particle collection.98 A greater 
degree of control over mass transfer is achieved by dividing the immediate pressure drop and 
expansion step observed in the classical RESS method into two controlled steps. The first 
pressure drop occurs in the tube connecting the pressure chamber to the collection chamber. 
The solution reduces in pressure from (approximately) 230-250 bar to 30-45 bar. Particles of 
the API begin to form as the pressure drops and the solubility in scCO2 reduces. The next stage 
involves the solution passing through a nozzle, similar to the classical RESS method, but at a 
lower initial pressure (30-45 bar). As the solution is sprayed, the pressure inside the chamber 
is kept at atmospheric (1 bar) and this reduction causes complete particle formation and 
prevents any conversion to other solid-state forms. Additionally, the drop in temperature 
experienced by the pressure reduction and explained by the Joule-Thompson effect, causes the 
particles to be encapsulated by dry ice which prevents aggregation in the collection chamber. 
The dry ice eventually sublimates, and the particles can be harvested.98 The primary benefits 
of this improved control is that particle growth and aggregation, experienced in the RESS 
method, can be prevented and nanoparticles can be formed. This method is used by the Finnish 
pharmaceutical company, Nanoform for the production of APIs. In March 2020, Nanoform 
announced a partnership with the pharmaceutical company Orion to employ the CESS 
technology to improve the solubility and bioavailability of selected early-development 
compounds.99 This collaborative effort highlights the potential of SCF technologies in the 
pharmaceutical sector. 
 
1.3.1.2 Cocrystallization from Supercritical Solutions (CSS) 
Another method which employs scCO2 as a solvent is the cocrystallization from supercritical 
solution (CSS) method. This method was first reported by Padrela et al. in 2009 for the 
cocrystallization of the API indomethacin with saccharin and has subsequently been utilized 
for several other poorly soluble APIs such as theophylline and carbamazepine.100-101 This 
method involves placing the starting materials (API and coformer) directly in a precipitation 
unit such as a high-pressure vessel, rather than an initial solubilization unit used by the RESS 
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method. Supercritical CO2 is introduced to the vessel where it can completely or partially 
dissolve the API and coformer so that the materials can react together when they precipitate 
from the scCO2. This mechanism is repeated (provided that a suitable reaction time is 
employed) until all the starting material has been converted. This method is usually operated 
in batch unit operations and offers control over the supersaturation of the slurry mixture by 
changing the pressure of scCO2 until it reaches a value where it can dissolve the starting 
materials. This method typically generates high yields but is limited by the solubility of the 
API and coformer in scCO2. To overcome solubility concerns, the use of cosolvent or extended 
reaction times may be necessary to ensure a high purity product. The addition of a co-solvent 
and an extended reaction time has been recently highlighted by Cuadra et al. as necessary steps 
to facilitate cocrystallization of the anti-cancer drug, 5-fluorouracil.102 This method (CSS) is 
beginning to generate interest due to the inherent advantages towards the production of drug 
cocrystals without the requirement for an organic solvent or large-volume pressure vessels.100-
103 Figure 16 describes a typical schematic for the CSS method which is employed during 
Chapter 5 for the generation of posaconazole cocrystals.  
 
Figure 16. Schematic representation of a CSS setup. BPR; back pressure regulator, P; pressure 
measurement, V; valve, TC; temperature controller, T; temperature measurement. Adapted 
from Pando et al. 103 
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1.3.2 Supercritical CO2 (Anti-Solvent) 
Using scCO2 as an anti-solvent is, by far, the most popular approach with respect to drug 
processing using SCFs.85, 89 This is primarily due to the improved solubility and miscibility of 
organic solvents in scCO2 compared to APIs.
91, 104 Due to the popularity of this role, there are 
multiple different methods that have been developed for the production of APIs which employ 
scCO2 as an antisolvent.
85, 103 The antisolvent effect provides a unique mechanism to induce 
precipitation of APIs through extremely high supersaturation levels. Using scCO2 as an 
antisolvent can provide greater control over the solid state (crystalline or amorphous) of the 
APIs in addition to as other physical properties such as particle size and shape.85, 103 
 
1.3.2.1 Gas Antisolvent Crystallization (GAS) 
First reported in 1989, Gallagher and Krukonis proposed that scCO2 could be utilized for drug 
particle formation purposes in a method called gas antisolvent crystallization (GAS).105-106 In 
this method, CO2 can be used in a gaseous, liquid or supercritical state to supersaturate an 
organic solution that contains the dissolved API. As this occurs, the solution will expand and 
induce precipitation of the API. The precipitation of the API will be more likely when a denser 
or higher proportion of CO2 is present due to its high miscibility with organic solvents
104 and 
this density can be directly controlled by processing parameters such as pressure. Figure 17 
shows the typical setup for the GAS method which can be adapted based on the requirements 
of the system. This method does not feature an atomization step and is, therefore, typically used 
in batch or semi-continuous unit operations.85 In operation, CO2 at a predetermined pressure 
and temperature is introduced at a controlled rate to a vessel which contains the solute(s) 
dissolved in an organic solvent. Precipitation of the dissolved solute occurs, provided an 
adequate volume of CO2 is present. Separating the CO2 and solvent mixture from the 
precipitated solute(s) is performed by flushing CO2 through the reactor until all the solvent has 
been removed as described by several authors.10, 107 Once the organic solvent has been 
removed, the particle formation vessel is depressurized, and the API particles can be collected. 
Pessoa et al. recently employed this method for the generation of resveratrol cocrystals while 
Cuadra et al. has demonstrated how the solid-state form of carbamazepine-saccharin cocrystals 
can be affected by processing parameters using this method.108-109  Supersaturation levels can 
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be calculated for the GAS method, although not common, with Bristow et al. having 
demonstrated that supersaturation levels can reach as high as 7 for acetaminophen in ethanol.180 
Although these levels are considered to be high compared to conventional crystallization 
methods, with respect to SCF methods, they do not exceed those observed during spraying 
methods which will be discussed below. The supersaturation levels of the contents of the high-
pressure vessel can be increased by increasing the volume of the vessel, changing the solvent 
or by reducing the amount of drug solution in the vessel. These examples referenced are some 
of the many publications which employ this method for the production of micro- and nano-
sized drug particles, co-precipitated drugs and drug-excipient formulations.85, 103, 110-111 
 
Figure 17. Schematic representation of a typical GAS method. Adapted from Silva and 
Meireles.112 
 
One drawback of the GAS method, that particularly affects industrial applications, is the 
difficulty in separating CO2 and solvent streams.
85 During large scale processing, gases such 
as N2 for conventional spray drying or CO2 for multiple different applications are frequently 
recycled due to the large quantity used. However, unless efficient downstream separation 
processes are employed (such as high-efficiency cyclones), adding to the overall cost of this 
method, it can be difficult to re-obtain pure CO2, increasing the financial burden for companies 
interested in employing this technology. Additionally, as mentioned earlier in this section, the 
GAS method is usually operated in batch modes of operation which is becoming less prominent 
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in the pharmaceutical industry for novel methodologies such as SCF technology.113 Like many 
scCO2 methods, variations of the GAS method have been developed to improve the 
physicochemical properties of the solute(s). Three derivatives of the GAS method currently 
include GASR (gas antisolvent recrystallization), GASP (gas antisolvent precipitation) and 
SFEE (supercritical fluid extraction of emulsions). In GASR and GASP methods, there are 
only minimal differences which differentiate these methods with the classical GAS method.105 
These minor differences are that the solute(s), which are dissolved in the organic solution 
during processing, have been previously crystallized (GASR) or precipitated (GASP) prior to 
CO2 processing. It has been demonstrated by Nordström et al. that dissolving crystalline 
materials can leave molecular assemblies in solution that retain the features of the crystalline 
structure.114 During GASR or GASP, these materials may have a greater tendency to revert 
back to their previous crystalline structure by generating a ‘memory effect’ which may 
influence the physicochemical properties of an API, specifically the solid state form.85 These 
methods (GASR and GASP) are not commonly selected and often study the effect of multiple 
processing parameters which make it difficult to determine if the final form is influenced by 
the mechanism described above or rather the impact of other operating variables.115-116  
The final variation of the GAS method is SFEE. This method commonly uses an oil-in-
water emulsion where a hydrophobic API is dissolved in the oil component.85, 117 This emulsion 
comes in contact with scCO2 in an experimental setup similar to the GAS method. As scCO2 
is introduced to the emulsion, expansion of the oil phase occurs, mechanistically identical to 
the classical GAS method using organic solvents. The API precipitates from the oil droplets 
and a micro- or nano-suspension is formed.85  This method has been successfully applied to the 
generation and, more commonly, the encapsulation of hydrophobic pharmaceutical materials 
such as griseofulvin and megestrol acetate.117-120 
 
1.3.2.2 Supercritical Antisolvent Crystallization (SAS) 
One of the most frequently employed scCO2 methods is supercritical antisolvent crystallization 
(SAS). Although this method primarily employs scCO2 as an antisolvent, the ‘spray-enhancer’ 
role can also be observed within this method. In operation, SAS involves passing a solution, 
which contains the solute(s) dissolved in an organic solvent, through a nozzle into a 
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precipitation chamber containing scCO2. As the solution passes through the nozzle, it is 
atomized and enters the chamber as fine droplets. As the droplets enter the chamber, they 
interact with scCO2 which induces a volumetric expansion of the solvent droplets, resulting in 
precipitation of the API particles.85 The geometry of the nozzle as well as the conditions in 
spray drying processes can typically provide greater control over the droplet size and thus, 
particle size.121 This was demonstrated by Rantakylä et al. in 2002 who employed a low 
temperature and pressure (304 K and 80 bar) which resulted in smaller droplet sizes and lower 
mean particle sizes (4 µm) compared to those produced using greater temperature and pressure 
values (308-232 K and 100-140 bar) which resulted in a larger final particle size range (8-14 
µm) of polylactic acid.122 Once the solute(s) have precipitated, the particles are collected in a 
filter while the organic solvent and scCO2 are continuously flushed through the system through 
a vent.85 Careful consideration is required (similar to that in GAS methods) when selecting the 
organic solvent as it must be able to dissolve the solute(s) while also having high solubility and 
miscibility in scCO2. The most commonly used solvents for most scCO2 antisolvent methods 
are: ethanol, methanol, acetone, dimethyl sulfoxide (DMSO) and tetrahydrofuran (THF) due 
to their high miscibility with scCO2.
104 As described by Said-Galiev et al. scCO2 dissolves well 
many non-polar organic compounds, specifically those with short length alkyl radical or those 
lacking an aromatic functional group.104 Figure 18 describes a typical SAS setup with a heated 
water jacket attached to the precipitation chamber. This method (SAS) is becoming 
increasingly popular as it can; be easily adapted to continuous operations; produce micro- and 
nano-sized APIs with narrow size distributions; and generate API particles very quickly 
without time-consuming drying and filtration steps.85, 123-126 In 2009, Padrela et al. used this 
method for the first time to generate a pharmaceutical cocrystal using the API, indomethacin 
and coformer, saccharin.100 Since then, other researchers such as Hiendrawan et al. and Neurohr 
et al. have investigated this method as a novel approach for the generation of paracetamol and 
naproxen cocrystals, respectively.103, 127-128 One drawback of this method is that particle 
agglomeration and aggregation can occur during processing.100 Particle aggregation can be 
addressed by using high concentrations of surfactants for stabilization while concerns of 
particle agglomeration can be offset by immediately bringing processed materials to the 
formulation stage.85, 129  
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Figure 18. Schematic representation of a typical SAS method. Adapted from Abuzar et al.130 
 
Due to the popularity of this method, several variations of the SAS method exist, which include: 
SAS-EM (supercritical antisolvent with enhanced mass transfer), SAS-DEM (supercritical 
antisolvent with drug-excipient mixing), ELAS (expanded liquid antisolvent) and SEDS 
(solution-enhanced dispersion of solids). Gupta et al. has patented and researched the SAS-EM 
method since 2003.131-132 In this method, the organic solution containing the solute(s) is 
subjected to ultrasonication at the injection nozzle which disperses the solution into fine 
droplets as it enters the precipitation vessel, leading to smaller particles than what can be 
obtained by classical SAS methods.131, 133 Additionally, the vibrating surface also generates a 
vibrational flow field within the scCO2 phase that enhances mass transfer through increased 
mixing.132 The SAS-DEM method, also researched heavily by Gupta et al., introduces a 
suspended excipient to the precipitation vessel and when the drug solution passes through the 
nozzle, it induces surface deposition of the drug and prevents agglomeration of these solute 
particles, which addresses one of the primary disadvantages observed by the classical SAS 
method.134-135 
 The ELAS method involves the use of a co-antisolvent to improve the antisolvent 
effect of scCO2 in the precipitation chamber.
85 This method has been investigated by the group 
of Reverchon for its use in the production of polymers and proteins and have reported that the 
use of different co-antisolvents can influence the particle size of proteins produced by the 
ELAS method.136   In addition to the work by Reverchon, Bouchard et al. suggest that the use 
of stronger co-antisolvents such as methanol and ethanol promote the formation of metastable 
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polymorphs of glycine, phenylalanine and lysozyme when compared to weaker co-antisolvents 
such as 2-propanol and acetone. 136-137  
Finally, the SEDS method is another derivative of the SAS method however this 
method differs in both design and mechanism. In this method, the solution containing the 
dissolved solute(s) mixes with scCO2 through a coaxial nozzle before passing through the 
nozzle into the precipitation vessel. The mixing chamber can be adjusted to control the 
residence time between the solution and antisolvent. The benefits of this ‘pre-mixing stage’ 
include an increase in the mass transfer efficiency as well as the solvent removal rate, reducing 
drying time.138 This method has been used by different authors for the production and 
encapsulation of pharmaceutical materials.85, 139 
 
1.3.2.2 Atomization and Antisolvent Crystallization (AAS) 
The atomization and antisolvent (AAS) method is another derivative of the SAS method but 
differs in a major concept, making it an interesting and attractive opportunity for industrial 
applications. In this method, the antisolvent (scCO2) and an organic solvent containing the 
dissolved solute(s) mix in a co-axial nozzle where supersaturation and nucleation is induced. 
The main difference between this method and the classical SAS method is that the vessel 
labelled as the ‘precipitation vessel’ in Figure 18 is no longer under high pressure. Instead, this 
vessel is maintained at atmospheric pressure throughout the operation. The antisolvent 
mechanism method induces supersaturation and nucleation of the organic solution in a small 
mixing chamber prior to passing the nozzle, rather than in the precipitation vessel, and then 
solute particles are separated from solvent and antisolvent streams through thermal processes, 
similar to conventional spray drying.140 The considerable advantage that this method possesses 
over many other supercritical fluid methods is that it can be easily adapted to existing 
equipment present for conventional spray drying provided a high-pressure nozzle can be 
installed.141 Additionally, this method is typically run in continuous or semi-continuous 
operation modes making it a viable choice for the pharmaceutical industry and has been 
demonstrated by Rodrigues et al. as an alternative approach for the production of nanoparticles 
of lysozyme.140 In addition to the production of enzymes, Padrela et al. demonstrated that this 
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method can be applied for the production of the pharmaceutical cocrystal, indomethacin-
saccharin.100 Figure 19 describes the coaxial nozzle used by Padrela et al. for the production of 
this cocrystal.100 The mixing volume of this nozzle, shown below, is estimated to be 30 µL, 
where scCO2 and solution mix for a very short time so that antisolvent nucleation, but not 
crystallization, is induced. 
 
Figure 19. Schematic representation of the coaxial nozzle used by Padrela et al. using the AAS 
method to generate indomethacin-saccharin cocrystals.100 
 
A derivative of the AAS method is called the atomization and supercritical antisolvent induced 
suspensions (ASAIS). This method is quite similar to AAS and only differs by increasing the 
mixing volume in the coaxial nozzle, described in Figure 19. This increased volume allows for 
a greater residence time and promotes crystal growth. Rodrigues et al. investigated the effect 
of this method towards API polymorphism, producing metastable forms of poorly soluble APIs 
such as carbamazepine, theophylline and indomethacin.141-142 In this work, a computational 
fluid dynamic (CFD) model was developed to understand the antisolvent-driven 
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supersaturation inside the ASAIS nozzle.141 This author describes how the mixing chamber 
reported in the ASAIS method “acts as a small volume SAS precipitator” and suggests the 
relative ease in adapting this technology to those which currently exist in the pharmaceutical 
industry.141 Despite the numerous advantages to this method, one potential drawback to 
increasing the residence time is an increased risk of crystallization in the mixing chamber 
resulting in clogging before the solution is able to pass through the nozzle. If this occurs, the 
process may have to be stopped and cleaned causing unnecessary time delays, therefore careful 
consideration, experimental data and modelling must be applied when selecting a system to be 
processed by ASAIS.141  
 
In conclusion, using scCO2 as an antisolvent for the production of pharmaceutical compounds 
is an approach which is becoming increasingly popular due to its ability to control the solid 
state, residence time, particle size, composition and morphology of pharmaceutical materials.85, 
89, 103 Figure 20 highlights the main differences between the four most common scCO2 
antisolvent methods and their respective variations. In addition to the above advantages, most 
of the methods described in Figure 20 that feature atomization can be processed in a continuous 
or semi-continuous mode of operation, which is of particular interest to the evolving 
pharmaceutical industry.113  
 
Figure 20. Schematic representation and differences of the various scCO2 antisolvent 
methodologies and their derivatives. Adapted from Padrela et al.85 
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1.3.3 Supercritical CO2 (Additive/Spray Enhancer) 
The third and final role that scCO2 can be utilized in is as an additive or spray enhancer, 
specifically as a co-solvent, co-solute or high-mobility solute. Usually, this role is utilized in 
combination with one of the previously discussed roles (solvent and antisolvent) as this role 
can be regarded as a complimentary role to many methods. Supercritical CO2 has several 
properties which make it an attractive candidate to feature as an additive or an atomizing fluid 
(spray enhancer). Firstly, it possess the density like that of a liquid at mild temperature and 
pressures.143 Secondly, it has the ability to dissolve in many compounds such as polymers, 
typically reducing their melting temperature, so that they are able to be used in conjunction 
with thermally labile pharmaceutical materials.104, 144 The third and final feature, which was 
observed when scCO2 is employed as an antisolvent, is that it can be easily atomized allowing 
the breakup of solutions into fine droplets, resulting in a greater level of control over the 
physicochemical properties of pharmaceutical materials.85  
 
1.3.3.1 Particle Formation from Gas-Saturated Solutions (PGSS) 
The particle formation from gas-saturated solutions (PGSS) method is one of the most 
frequently selected methods for API formation which employs scCO2 for its role as an 
additive.85, 144 This method, first reported in 1995 by Weidner et al., involves substances that 
are in their molten or ‘melted’ state and is typically selected for lipophilic drugs or polymers.145-
146 In this method, scCO2 is mixed with the molten solute(s) until it becomes dissolved which 
reduces the melting temperature of the polymer/lipid and reduces the viscosity.145 This solution 
then passes through a nozzle into a vessel which is maintained at atmospheric pressure, similar 
to that observed in the AAS/ASAIS method. As the mixture passes through the nozzle, the 
depressurization of scCO2 causes the solute(s) to crash out and breakup into droplets which are 
separated from the gaseous CO2 by a filter or cyclone.
144 Figure 21 describes a typical PGSS 
setup where the solute can be an API and polymer or a lipophilic drug that can be melted.89, 144 
This method is advantageous for particle formation as; it consumes a low amount of CO2, 
relative to other supercritical methods; it is scalable in both batch and continuous unit 
operations; it does not require organic solvent to be used; and it reduces or eliminates time-
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consuming drying steps observed in a typical pharmaceutical process.85, 144 The main constraint 
of this method is that the solutes (API and/or polymer) selected must be able to dissolve in 
scCO2 in relatively high amounts, which limits the range of APIs which can be selected.
104 
Some frequently used APIs that are relatively soluble in scCO2 include naproxen, theophylline, 
carbamazepine and indomethacin.85 Additionally, these solutes need to be melted which can 
be an issue as many pharmaceutical substances melt at temperatures above their thermal 
stability.85, 147 However, studies have shown that when dissolving scCO2 in the solute, the 
melting temperature of the solute can be significantly reduced which may benefit thermally 
labile pharmaceutical materials and this method can be used to produce materials in the nano-
sized range.148-149  
Figure 21. Schematic representation of a typical PGSS method. Adapted from Rabinarayan et 
al.89 
 
1.3.3.2 Carbon Dioxide Assisted Nebulization with a Bubble-Dryer (CAN-BD) 
A modification of the PGSS method is the carbon dioxide assisted nebulization with a bubble 
dryer (CAN-BD) method which processes hydrophilic solutes. An aqueous solution containing 
the API is mixed with scCO2 in a low dead volume tee where an emulsion is formed.
150 This 
emulsion passes through a nozzle and is rapidly decompressed, forming an aerosol of bubbles 
and droplets in a drying chamber where a stream of heated nitrogen isolates the solute particles. 
As CO2 is one of the most soluble gases in water, its use in this method enhances the expansion 
step.150 The main advantage of this method is that organic solvents do not need to be used 
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during processing and the CAN-BD method can be easily applied to various pharmaceutical 
materials, including proteins. 151-154 However, a limitation of this method involves the high 
water solubility required by the pharmaceutical materials to be processed by this method. With 
up to 90% of new chemical entities estimated to have poor solubility in water, this severely 
limits the range of materials that may be able to be processed by this method.40
 
Figure 22. Schematic representation of CAN-BD method. Adapted from Rabinarayan et al.89  
 
1.3.3.3 Supercritical Enhanced Atomization (SEA) 
Supercritical enhanced atomization (SEA) is a method that is quite similar to AAS/ASAIS, 
mentioned in section 1.3.2.3. The primary difference involved with the SEA method, compared 
to those previously mentioned, is that the mixing experienced between the solution containing 
dissolved API(s) and antisolvent (scCO2) occurs very quickly (millisecond timescale) in a 
small volume short-length nozzle.155 As antisolvent crystallization does not occur for this 
method, the primary role of the scCO2 can be categorized as an additive or spray enhancer. 
This allows the SEA method to be compared to conventional spray drying (using N2) with an 
improved breakup of solution droplets from the scCO2. Once the API solution has passed 
through the nozzle and been atomized, the solvent is separated from the API by heated nitrogen 
or alternative thermal methods.11 Figure 23, which is adapted from Rodrigues et al. highlights 
the main differences between SAS, ASAIS and SEA methodologies with respect to mixing 
volumes and pressures after passing through the nozzle.142 The short contact time between both 
- 35 - 
 
streams (API solution and antisolvent) can facilitate a ‘pre-nucleation’ stage where the 
templating of API molecules occurs and provides greater control over the final solid-state 
structures generated using this method.11, 142 This method has been reported to produce a wide 
variety of pharmaceutical materials including APIs, cocrystals, vaccines and proteins by the 
Azevedo research group and coworkers.142, 156-159 Similarly to the AAS/ASAIS methods, the 
SEA method can be easily adapted to existing conventional spray drying technology with 
minimal equipment expenses incurred as this method is operated at atmospheric pressure after 
passing through the nozzle. 
 
Figure 23. Schematic comparison between three popular scCO2 methods with respect to 
mixing volume and pressure after the nozzle. Adapted from Rodrigues et al.142 
 
1.3.3.4 Supercritical-Assisted Atomization (SAA) 
Ernesto Reverchon, one of the prominent members of the SCF community, first proposed the 
supercritical-assisted atomization (SAA) method in 2002 and employed it to generate micro- 
and nanoparticles of various APIs.160 This method is quite similar to the one observed to the 
SEA method, described in the previous section (1.3.3.3) and illustrated in Figure 22. However, 
this method differs by passing the stream containing the API solution and scCO2 through a 
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saturator (packed column) to facilitate an improved mixing efficiency.160 As both streams pass 
through the saturator, there is an increased residence time and contacting surface experienced 
which aims to generate a more efficient, secondary, type of atomization.161 Figure 24 shows a 
typical SAA setup with heated nitrogen included to improve drying efficiency.162 The primary 
advantage of this method over SEA is a greater control of the particle size distribution caused 
by enhanced mixing in the saturator.85, 160, 162 Similar to previously mentioned methods 
(SEA/ASAIS), the set-up of this method can be easily applied to existing equipment such as 
those which facilitate conventional spray drying or the SEA method by the addition of a high-
pressure saturator. One drawback associated with this method, similar to the ASAIS method, 
is that the increased residence time may lead to crystallization in the saturator and cause 
unnecessary blockages before the solution and scCO2 mixture can pass through the nozzle and 
be atomized. However, this limitation can be easily avoided if sufficient information about the 
API system, such as its solubility in scCO2 and the pressures at which the API precipitates at, 
can be obtained.11 
 
Figure 24. Schematic representation of SAA apparatus with heated nitrogen to facilitate drying 
of the atomized supersaturated drug solution. Adapted from Porta et al.162 
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1.3.3.5 Supercritical-Assisted Injection in a Liquid Antisolvent (SAILA) 
Lastly, a method which is considered a combination of ELAS and ASAIS methods is called 
supercritical-assisted injection in a liquid antisolvent (SAILA).85 This method involves the 
mixing of an API solution with scCO2 in a high-pressure mixing chamber (nozzle). The scCO2 
expands the organic solvent and then passes through the nozzle where it is sprayed into a new 
liquid antisolvent, typically water.163  This method provides a major advantage over the ELAS 
method as the chamber where the scCO2 and solution mixture is sprayed into, does not need to 
be at high pressure, reducing the costliness of equipment and improving the overall safety.85 
The main limitation of this method is that the API selected for processing must have a low 
solubility in the organic solvent in the initial solution preparation so that the liquid antisolvent 
can cause precipitation of the API meaning that a low throughput is likely when employing this 
method. Campardelli and Reverchon have used this method to generate micron and nano-sized 
particles, suspensions and even managed to encapsulate several non-steroidal anti-
inflammatory drugs in a polymer composite.163-165 Figure 25 describes the process of how a 
suspension is made using the SAILA method.164 
 
Figure 25. Conceptual representation of the SAILA method. Adapted from Campardelli and 
Reverchon.164 
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1.3.4 Summary of Supercritical Fluid Technology 
In summary, scCO2 methods provide the ability to generate API particles through unique setups 
and tuneable processing conditions. These methods allow control over particle size, particle 
size distributions, solid-state form (crystalline and/or amorphous), co-crystallization, and other 
physical properties of APIs.85, 89, 144 Although SCF technology has primarily focused on 
extraction processes, it has recently attracted attention towards its application for 
pharmaceutical particle generation.99 This attention can be attributed to the vast range of 
methods that can be customised towards a specific system. Although several companies are 
beginning to use supercritical fluids as their primary particle generation method, there are still 
some concerns from other interested companies over the lack of experimental data and reliable 
models to predict the outcome of these processes.166 In addition, the scale up of these processes 
can introduce additional safety and financial concerns when large volume, high-pressure 
reactors need to be obtained. Despite this, several companies such as Nanoform and 
CrystecPharma have emerged with modified supercritical methods for the generation of 
pharmaceutical materials.99, 167  
 
1.3.4.1 Particle Size Reduction using Supercritical Fluids 
As discussed in section 1.2.3, the Noyes Whitney equation describes how an increased surface 
area, typically caused by a reduction in particle size, can influence the dissolution rate of a 
material. Supercritical fluid technology is frequently reported to reduce the particle size of 
pharmaceutical material in addition to other physicochemical improvements, such as solid-
state control. Padrela et al. explains in a comprehensive review of SCF methods that can be 
used to obtain nano-sized pharmaceutical material that the definition for a ‘nano’ sized drug is 
usually extended to the sub-micron scale in the field of nanomedicine.85 When API particles 
can be reduced to this scale, a significant improvement in the dissolution rate can be observed 
as the saturation solubility (Cs) value in the Noyes Whitney equation no longer becomes a fixed 
value based on temperature.  
 Obtaining nano-sized pharmaceutical material has been reported for a vast majority of 
the SCF methods described in Chapter 1 across a wide range of API polymorphs, cocrystals 
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and biological materials.85 However, it must be noted that methods that employ scCO2 as a 
spray enhancer tend to generate smaller sized particles than those that do not feature an 
atomization step (e.g. the GAS method).  Reverchon et al. described a likely reason why this 
is the case when first reporting the SAA method in 2002.160 In this study, it is mentioned that 
as scCO2 passes through a nozzle and expands, it causes the atomized droplets to undergo a 
‘secondary atomization’ which can result in smaller droplets and thus, smaller particle sizes. 
Additionally, in methods which employ scCO2 in this role, a nozzle is usually featured in the 
equipment design. The geometry of this nozzle can significantly impact the droplet and final 
particle sizes obtained by these methods as it can control the residence time and, therefore, the 
opportunity for crystal growth. Table 2 shows a list of different nanoparticles of APIs obtained 
using as many of the methods mentioned in the sections above as possible. The smallest 
possible reported particle size that could be found in the literature was used for this table. 









RESS Raloxifene Solvent 18-137 
RESSOLV Retinyl palmitate Solvent 30-342 
RESS-SC Phenytoin Solvent <75 
GAS Paclitaxel Antisolvent 117-200 
SAS Lysozyme Antisolvent 59-247 
SAS-EM Thalidomide Antisolvent 400-8000 
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ELAS  Bovine Serum Albumin Antisolvent 50-1640 
AAS Lysozyme Atomization and Antisolvent 100-5000 
ASAIS Theophylline Atomization and Antisolvent <1000 
PGSS Coenzyme Q10 Atomization and Antisolvent 190 
CAN-BD Naproxen Atomization and Antisolvent 650-1000 
SAILA α-Tocopherol Atomization and Antisolvent 150-1190 
SAA Rinfampicin-PDLLA Atomization and Antisolvent 123-148 
SEA Lysozyme Atomization 100-5000 
  
As observed in table 2, it is possible to obtain nanoparticles using most of the SCF mentioned 
techniques in this thesis. Two notable exceptions to this list include the CSS method and the 
RESS-N method. The CSS method is a relatively new SCF technique that has yet to be 
frequently used by researchers which may explain why there is little data to choose from. 
Additionally, this method does not feature an atomization step which may indicate that little 
control over crystal growth in the SCF phase.11 The other method, RESS-N, involves the 
coating of API particles in a polymer which influences the final measured particle size of the 
product obtained when employing this method. 
Some interesting innovations to overcome the particle growth can also be observed in 
this table. Hu et al. employed the PGSS method to obtain nanoparticles of the coenzyme Q10 
by coating these particles in a water-soluble polymer. Upon completion of the process, the 
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resulting product was washed and nanoparticles as small as 190 nm were obtained.148 
Rodrigues et al. showed that it was possible to obtain nanoparticles of a bioactive material 
(lysozyme) using the AAS method. Interestingly, when low pressures (80 bar) or scN2 (which 
does not employ an antisolvent effect) are used, spherical particles are produced that retain a 
high level of activity. However, when the pressure is increased for scCO2 to 120 bar, the 
activity is significantly reduced, and fibres are generated which can affect the particle size 
measurements using this method. This study highlights the importance of processing 
parameters when attempting to control particle size in SCF methods.  
 
1.3.4.2 Polymorphic Control using Supercritical Fluids 
Polymorphic control is a critical feature that is necessary for all novel manufacturing methods 
involving pharmaceutical materials. In 1998, the infamous case of spontaneous conversion of 
ritonavir to a more stable polymorph highlighted the need for comprehensive control over the 
sold-state form of pharmaceutical materials.49,50 Supercritical fluid methods are frequently used 
to generate various polymorphic forms as well as produce unique crystalline forms that cannot 
be obtained by conventional methods.85 
 In 2016, Rodrigues et al. studied the extent at which polymorphism could control three 
model drugs, namely, carbamazepine (CBZ), indomethacin (IND) and theophylline (THP).142 
In this work, three scCO2 methods were compared to each other with the primary output being 
the polymorphic form of the three components before and after processing to assess if 
crystalline conversion had occurred. The three methods used in this study were SAS, ASAIS 
and SEA. Excluding theophylline, the remaining APIs and all scCO2 methods showed that the 
same polymorphic form was obtained, indicating that the atomization step in the process was 
critical to the final polymorphic form rather than the effect of scCO2. This was supported by 
obtaining similar results using the SEA method which does not employ scCO2 as an antisolvent 
and, instead, utilizes its atomization ability, making this method comparable to conventional 
spray drying. The same authors reported a novel polymorphic form for theophylline, unique to 
scCO2, in 2011 using the ASAIS method and later showed that the same polymorphic form 
was obtained by the SAS method.141 The proposed reason why the same polymorphic result 
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was not observed in the 2016 study for THP is influenced by the high solubility of theophylline 
in scCO2 compared to the other model APIs studied (CBZ and IND). In 2014, the same authors 
were able to report a new polymorphic form (β-minocycline) for the first time caused by the 
antisolvent effect of scCO2 which highlighted the potential for SCF technology to feature as a 
screening tool for novel polymorphic forms.21  
 Another study which emphasizes the polymorphic control that can be achieved using 
scCO2 was performed by Padrela et al. in 2017 and features as a foundation for the work 
involved in this thesis.10 In this study, the highly polymorphic drug CBZ was used in a GAS 
method in conjunction with additives to investigate if these additives could provide control 
over the crystalline form in a supercritical antisolvent environment. This study compares the 
GAS method to a conventional solvent evaporation approach and demonstrates that pure 
polymorphs of CBZ can be obtained using the GAS method, a result that is not observed using 
solvent evaporation. The authors of this study use density functional theory to describe the 
interaction between CBZ and various additives that generated pure polymorphic forms. This 
interaction describes the polar and non-polar parts of the CBZ and additive molecules 
influencing the templating of the API molecular structure.10 
 A study which is briefly mentioned in section 1.3.2.1, discusses the works of Bouchard 
et al. which employs the ELAS method to generate different polymorphs of the bulking agent 
glycine.136,137 This study highlighted that operating conditions such as the solution flow rate 
could impact the polymorphic form of glycine (α or β) obtained. Furthermore, increasing the 
ethanol concentration favoured the formation of the metastable β polymorph and when 
employing slow drying conditions, the third polymorphic form, γ could be obtained.  136,137    
 The final role which has not been discussed in this section is when scCO2 acts as a 
solvent. Gosselin et al. discusses how the RESS method could potentially be employed to 
control the crystalline form of CBZ.181 In this study, all four crystalline forms of CBZ can be 
obtained by varying the pressure used and temperature employed. Additionally, the 
crystallinity and quantitative amount of each polymorphic form is determined in this study. 
 In summary, SCF methods can exhibit substantial control over the polymorphic form 
of various pharmaceutical materials through the optimization of processing conditions or 
through the addition of well-established methods, such as additives. This control makes SCF 
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technology an attractive alternative to conventional methods which have been reported to 
adversely affect the final polymorphic form obtained.85 
 
1.3.4.3 Cocrystal Generation by Supercritical Fluids 
Cocrystals are most commonly formed by solution crystallization, slurry crystallization and 
grinding (neat and liquid) methods which can facilitate increased wide-scale screening of APIs 
and coformers.168-169 These conventional methods have many advantages, such as the ability to 
generate single crystal material for identification, a critical characterization method for the 
discovery of novel cocrystals, but some challenges can arise when attempting to scale up these 
methods including the large amount of organic solvents required during processing.168 In order 
to overcome these difficulties, several authors have proposed utilizing alternative approaches 
such as supercritical CO2 methods as a scalable method to generate cocrystals that can reduce 
the number of processing steps as well as the requirement for organic solvent.100-101 The 
different roles of scCO2 (solvent, antisolvent and additive/spray enhancer) have been shown to 
be a viable option for the generation of pharmaceutical cocrystals by different authors with 
additional benefits to conventional methods.103 Beginning with scCO2 being used as a solvent, 
two of the most common methods (RESS and CSS) will be discussed an alternative approach 
to cocrystal generation. The RESS method is described above in section 1.3.1.1 and is used in 
a similar way when processing single component APIs. When attempting to generate cocrystals 
by this method, the API and coformer are dissolved in scCO2 and the resulting solution is 
rapidly expanded to atmospheric conditions and the cocrystal is precipitated. Vemavarapu et 
al. first used this method to generate cocrystals of chlorpropamide and urea in 2002, though 
not the initial aim of this study.170 Since then, other authors have used this method to generate 
different cocrystals of various APIs, investigating the effect of different operating conditions 
on cocrystal purity.103, 171 The benefits of using this method is that organic solvent is not 
required and additional processing steps, such as drying and filtration, are eliminated. 
However, one significant limitation of this method compared to when preparing single entity 
materials is that both API and coformer must be soluble in scCO2 instead of one component, 
meaning that the array of materials that can be selected is significantly reduced based on the 
solubility of many pharmaceutical materials in scCO2.
91 Another method which uses scCO2 as 
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a solvent is the cocrystallization with supercritical solvent (CSS) method which is described in 
section 1.3.1.2. This method, first described by Padrela et al. in 2009100, is predominantly used 
for the cocrystallization of pharmaceutical components. Unlike RESS, both materials do not 
need to be completely soluble in scCO2 as a slurry-like mixture can result in the formation of 
pure cocrystals, thereby increasing the selection of materials available to use.85, 102 This method 
offers a greater degree of control as the use of a co-solvent and extended reaction times have 
been reported to improve the purity of cocrystals generated by CSS.102 Although this method 
has a significant advantage over other methods that use scCO2 as a solvent by not requiring 
complete dissolution of starting materials, practical applications have been scarce. One 
potential reason for this observation is the requirement for high-pressure and high-volume 
equipment in order to process these materials at a suitable scale, which associates significant 
costs and safety concerns to this process.85, 103  
 When scCO2 is used as an antisolvent for cocrystallization, it induces precipitation of 
the API and the coformer by expansion of the organic solvent that they are dissolved in. Two 
of the most common supercritical fluid methods which feature scCO2 as an antisolvent are SAS 
and GAS. The SAS method is based on the relatively low solvent power of scCO2 for APIs and 
coformers and its good miscibility with organic solvent. Several researches have used this 
method to produce pharmaceutical cocrystals based on this methods ability to efficiently 
remove organic solvent and produce narrow size distributions.85, 100, 102, 127 The other 
supercritical antisolvent method (GAS) is typically operated in batch modes of operation and 
its mechanisms are discussed in section 1.3.2.1. This drawback (batch operation modes) may 
introduce greater challenges when attempting to scale up this method, however, it has still been 
investigated by many authors and shown to be a viable method to generate cocrystals with 
efficient removal of organic solvent.85, 103 Neurohr et al. have conducted several 
cocrystallization experiments which demonstrated that cocrystals such as naproxen-
nicotinamide of high purity can be obtained using this method.172-173 The same group were able 
to generate a racemic cocrystal and conglomerate containing both enantiomers for the first 
time.174 The racemic cocrystal was obtained at slow and moderate CO2 feed rates, while a very 
fast introduction of CO2 resulted in the formation of a mixture of chiral cocrystals 
(conglomerate).174 Ober et al. were able to show in 2012 that by employing the GAS method, 
it was possible to obtain cocrystals itraconazole and succinic acid in molar ratios which differed 
from the reported cocrystal stoichiometry.175  
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 Finally, scCO2 can also be used as an additive or spray enhancer to facilitate the 
formation of pharmaceutical cocrystals. Two popular methods, AAS and SEA, explained above 
in sections 1.3.2.3 and 1.3.3.3, respectively, have been presented as alternative approaches for 
the generation of pharmaceutical cocrystals.103 The AAS method utilizes the antisolvent 
capacity of scCO2 as well as its ability to function as a spray enhancer while the SEA method 
relies entirely on scCO2 featuring as a spray enhancer only. Additionally, these methods have 
been shown to be able to generate sub-micron and nano sized cocrystal particles.11, 85, 176 While 
both methods are similar, depending on the level of mixing required between solution 
containing API and coformer and scCO2 antisolvent, AAS or SEA may be chosen. In terms of 
cocrystal generation, the SEA method may be slightly preferable as it is a simple, efficient and 
one-step continuous method to produce cocrystals with very little potential for clogging of the 
nozzle. Additionally, one major advantage of both of these methods (AAS and SEA) is that 
they can be easily adapted to existing conventional spray drying equipment with the exception 
of the high-pressure nozzle, highlighting the applicability of this technology for the 
pharmaceutical sector, particularly in the field of cocrystals which is continuing to grow in 
popularity.103, 141 
Table 3 describes cocrystals that have been generated using the most popular SCF 
methods. 




API-Coformer Used ScCO2 Role 
RESS Cholesterol-caffeine Solvent 
RESS Ibuprofen-nicotinamide Solvent 
RESS Theophylline-caffeine Solvent 
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RESS Chlorpropamide-urea Solvent 
CSS Indomethacin. Theophylline, carbamazepine, caffeine, 
sulfamethazine, acetylsalicylic acid-saccharin 
Solvent 
SAS Indomethacin–saccharin Antisolvent 
SAS Diflunisal–nicotinamide Antisolvent 
SAS Piracetam–salicylic acid Antisolvent 
SAS Paracetamol–dipicolinic acid Antisolvent 
SAS Naproxen–nicotinamide Antisolvent 
SEA Indomethacin. Theophylline, carbamazepine, caffeine, 
sulfamethazine, acetylsalicylic acid-saccharin 
Atomization/Spray 
Enhancer 
SEA Theophylline- Urea, gentistic acid, salicylic acid, 




GAS 4-aminosalicylate, carbamazepine–nicotinamide Antisolvent 
GAS Itraconazole–succinic acid, malic acid Antisolvent 
GAS Naproxen–nicotinamide Antisolvent 
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1.4 Aim of the Project 
The present work focuses on the crystallization of poorly water-soluble APIs (BCS class II) 
using scCO2 technology. Specifically, this thesis investigates the use of SCF methods to control 
the solid state of APIs, such as through the utilization of additives or optimization of processing 
conditions. Despite many publications describing the influence of additives towards the control 
of polymorphism during conventional methods, there is a lack of published data investigating 
additives using methods such as those which employ scCO2. Additionally, the use of scCO2 
methods to generate pharmaceutical cocrystals has only generated interest in the last decade, 
despite significant advantages over conventional crystallization methods.32, 142 As discussed in 
earlier sections of this chapter, scCO2 has three unique roles where it can feature as a solvent, 
antisolvent or spray enhancer which has been shown to provide control over the solid state and 
physical properties of APIs. 
Considering the above, this present work entails the following key challenges: 
 To investigate the effect of additives on the polymorphism of a model system 
(carbamazepine) in scCO2 antisolvent methods. 
 To identify the various processing conditions that influence the solid-state control of 
APIs in methods that employ each of roles (solvent, antisolvent and spray enhancer) 
provided by scCO2. 
 To determine if scCO2 batch methodologies can be converted to a continuous setup 
providing a similar level of solid-state control. 
 To investigate the difference between scCO2 solvent and antisolvent methods for the 
generation of pharmaceutical cocrystals of a model drug (posaconazole) and to develop 
a plausible explanation for the results obtained. 
 
The thesis aims to provide a rational discussion and explanation for the solid state control of 
two model API systems when employing scCO2 methods, building on the available literature 
which acts as the foundation from which this thesis is developed from.17, 22, 101Additionally, 
this thesis aims to showcase the scCO2 methods described herein (GAS, CSS and SASD) as a 
potential alternative method for the generation of pharmaceutical materials. 
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Chapter 2. Materials and Characterization Methods 
 
2.1 Active Pharmaceutical Ingredients 
This thesis describes the solid-state control of two model API systems. Both systems 
(carbamazepine and posaconazole) are highly polymorphic and are capable of producing 
cocrystalline materials as well as hydrates and solvates.3,10 Each of these materials will be 
described in greater details in the sections below.   
 
2.1.1 Carbamazepine (CBZ) 
Carbamazepine was discovered in 1960 and used to treat epilepsy, neuropathic pain and 
schizophrenia. It is generally administered orally and has high intestinal permeability but poor 
solubility in water. It therefore exhibits irregular absorption in the body and is classified as a 
BCS class II drug. There are four anhydrous forms of CBZ which have the following relative 
thermodynamic stabilities (at room temperature): III > I > IV > II.1-3 There is also a dihydrate 
and several solvates of CBZ and the solubilities of these various CBZ forms have been 
examined in gastric fluids and other media such as scCO2. 
4-6 6 The molecular structure of CBZ 
is presented in Figure 1.  
 
Figure 1. Molecular structure of carbamazepine. 
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2.1.2 Posaconazole (PSZ) 
Posaconazole (PSZ) is a BCS class II drug used in the treatment of antifungal infections in 
immunocomprised patients.7 The aqueous solubility of PSZ is < 1 µg/mL and as a result of this 
poor solubility, the current oral formulations exist as a suspension, injection and a delayed-
release tablet.8-9 In addition to its low aqueous solubility, PSZ can be identified by its high 
lipophilicity of LogP 4.6, and high molecular weight of 700.8 g/mol.9  Posaconazole has four 
polymorphic forms with form I being the most stable at ambient conditons.10 The crystal 
structure of this active pharmaceutical ingredient (API), and a methanol solvate was only 
reported in 2019 by McQuiston et al. 10 The molecular structure of PSZ is presented in Figure 
2. 
 
Figure 2. Molecular structure of posaconazole. 
 
2.2 Characterization Techniques 
2.2.1 X-ray Diffraction (XRD) 
Information about the atomic and molecular structure of crystalline materials can be 
determined by X-ray diffraction (XRD). As X-ray have similar wavelengths to distances 
between planes in a crystal lattice, they will cause an incident beam of electrons to diffract at 
certain angles. When X-rays strike electrons within the atomic structure, elastic scattering 
occurs, producing secondary spherical waves.12 A regular array of scattering produces a regular 
array of these secondary spherical waves.13 Constructive inference occurs when the 
experimental conditions satisfy the Bragg equation as shown in Figure 3, which relates the 
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wavelength of the incident X-rays (λ) to the diffraction angle (θ) and the interplanar spacing of 
the crystal (d).14  
 
Figure 3. Diagram showing incident X-rays of n (1, 2 or 3) orders of reflection producing 
constructively interfering scattered waves. Where λ = wavelength of incident X-ray; dhkl = 
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Figure 4 illustrates the basic components of reflection X-ray diffraction. 
 
Figure 4. Schematic of reflection XRD analysis.16 
 
A XRD spectrum is obtained by scanning the sample over a range of pre-determined angles 
(2θ) and detecting the diffracted X-rays at each programmed step count. In a crystalline XRD 
spectrum, the peak positions correspond to the different miller indices of the sample. Every 
crystalline material has a unique set of d-spacings and will generate unique peak positions 
allowing samples to be compared to a standard reference pattern. To generate the X-rays, a 
filament is heated in a cathode ray tube which generates electrons (1 in Figure 4). During 
operation, these electrons are accelerated by a positively charged anode. The X-rays are then 
filtered to produce monochromatic radiation which is then directed towards the sample (2 in 
Figure 4). The sample is placed on a ‘spinner’ attachment which rotates the sample during X-
ray analysis. The detector (3 in Figure 4) measures the intensities of the diffracted rays through 
the specified range of angles. When the angle of incidence satisfied the Bragg equation (nλ = 
2d.Sinθ) for constructive interference, a representative peak will appear on the diffraction 
pattern. 
In this thesis, XRD analysis was performed in reflection mode was performed using an 
Empyrean diffractometer (PANalytical, Phillips) with Cu Kα radiation (λ = 1.5406 Å) at room 
temperature. Samples were lightly ground and pressed on a zero-background plate prior to 
analysis. Data was recorded at a tube voltage of 40 kV and a tube current of 40 mA, with a step 
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size of 0.02° (2θ) and a scan speed of 0.102° (2θ·s–1) in the angular range of 5° to 30° (2θ) 
with 4 RPM. 
 
2.2.2 Scanning Electron Microscopy (SEM) 
A scanning electron microscope (SEM) uses a focused beam of high-energy electrons to 
generate a surface image of the sample. A filament is heated to generate an electron beam 
which is then accelerated onto the sample, allowing for topographical and compositional 
information about the compound. This technique works by detecting the scattering of electrons 
after they interact with the sample which can occur elastically or inelastically.17 The image 
generated by SEM is facilitated through the detection of secondary electrons emitted by atoms 
through inelastic scattering due to ionization of the sample by the primary electron beam. These 
(secondary) electrons are of low energy and are released from the surface of the sample and 
then measured by the detector.18 Figure 5 describes the main components of an SEM including 
the electron gun (source of electrons), the column under vacuum to accelerate electrons and  
focus the beam to generate a clear image and a sample chamber with multiple detectors 
positioned around the sample stage, capable of generating various chemical, topographical and 
compositional information about the material.19 
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Figure 5. Schematic representation of a scanning electron microscope and the critical 
components involved during operation. Adapted from Inkson.19 
 
During operation, the electron beam which is generated thermionically passes down the column 
through a series of lenses and apertures that focus the beam before it interacts with the surface 
of the sample. The x, y scancoils, located at the base of the column raster the beam across the 
sample, which allows for the imaging of a defined area of the sample. In addition to providing 
high-resolution and high-magnification images, SEM techniques can also provide 
compositional information through use of techniques such as energy-dispersive spectroscopy 
(EDS), which will be briefly discussed in the section below. 
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In this thesis, SEM analysis was performed on a Hitachi SU-70 system operating at 3 kV. 
Samples were mounted onto aluminium stubs with double-sided carbon tape. The stubs were 
placed inside a gold sputter coater (Emitech K550X) and coated with a plasma current of 20 
mA for two minutes.  
 
2.2.2.1 Energy Dispersion Spectroscopy (EDS) 
Energy dispersion spectroscopy (EDS) is a technique that can be used in conjunction with SEM 
characterization to analyse or detect the chemical composition of a material. It functions by 
analysing the characteristic X-ray signals emitted by the sample from interacting with the 
electron beam. The electrons (from the sample) become excited to a higher energy state or are 
completely ejected from the atom entirely leaving an electron hole. X-ray signals are released 
due to relaxation of higher state electrons where each element emits a unique signal, allowing 
them to be identified by the detector.20 Quantitative information can be obtained through the 
comparison of the analysed spectra with standard reference materials. This technique can be 
used to estimate the atomic and weight composition of material on the surface of a sample.21 
This technique is utilized in chapter 3 to detect the presence of unique elements (sodium) 
between samples, and provide an indication of the additive location on the surface for certain 
samples. 
 
2.2.3 Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) is a technique in which the mass of a substance is 
monitored as a function of temperature. The mass may increase or decrease when subjected to 
a controlled temperature program in a controlled atmosphere. This technique can provide 
information about a sample including; if a substance is hygroscopic; the stability of a sample 
which can be determined by holding the temperature for a designated period of time; if a sample 
will oxidise indicating its resistance to corrosion, and at what temperatures will a sample 
degrade.22 Figure 6 describes the typical schematic of a standard TGA measurement.  
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Figure 6. Schematic representation of a TGA measurement in operation. Adapted from Ogata 
et al.23 
 
To perform a TGA measurement, typically 3 to 5 mg of a sample is weighed and placed in a 
crucible and placed on the microbalance illustrated in Figure 6. The weight is accurately 
measured and recorded by the equipment. Inert gas (usually nitrogen) is introduced at a 
controlled heating rate while the equipment continues to monitor the weight of the sample. 
In this thesis, TGA measurements were performed using a Perkin Elmer TGA 4000 at 
a constant heating rate of 10 °C/min from 25 to 340 °C under a 50 ml/min flux of nitrogen on 
a sample to determine a suitable range for further analysis.  
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2.2.4 Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) is one of the most commonly used thermal analysis 
techniques in the pharmaceutical industry for providing in-depth thermal information about the 
behaviour of a material. The typical setup for DSC measurements is that a reference sample is 
placed in a controlled atmosphere alongside a sample. Figure 7 shows the typical arrangement 
of a differential scanning calorimeter. This method was first developed in 1962 and functions 
on the principle that when a sample undergoes a physical transformation, such as going from 
amorphous to crystalline or a specific polymorph melting, more or less heat will need to flow 
to the sample than the reference to maintain both at the same temperature.24 The difference in 
heat flow or energy is recorded and is presented as a function of temperature. This technique 
is commonly used for the detection of cocrystal compounds as a sharp peak at one defined 
temperature is typically indicative of a pure sample.25 This technique also can help differentiate 
between different polymorphic melting points or show the glass transition temperature for 
amorphous samples. 
 
Figure 7. Schematic representation of a differential scanning calorimeter. Adapted from 
Beckers.26 
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The DSC characterization performed in Chapter 5 was carried out using sealed aluminium pans 
on a TA Instruments Netzsch Polyma 214 differential scanning calorimeter at a range of 50 to 
275 °C. Temperature calibrations were made using indium as the standard. An empty pan, 
sealed in the same way as the sample, was used as a reference. All the thermogram data was 
collected at a heating/cooling rate of 10 °C/min under a nitrogen purge at a rate of 50 ml/min. 
 
2.2.5 Particle Size Distribution (PSD) Analysis 
Particle size distribution (PSD) analysis is an important characterization technique which is 
frequently used in the study of pharmaceutical materials as particle size is directly linked to 
other critical properties such as dissolution rate and tabletability.  
 There are two common approaches to measuring PSD, one is through dynamic light 
scattering and the other is through static measurements, which is employed in this thesis. In 
this method, a solid powdered sample is dispersed onto a glass plane and detected through an 
automatic optical microscopy lens where filters can be applied such as size and shape. The 
instrument used in this thesis was a Malvern Morphologi G3SE particle characterization system 
(Malvern Instruments, Malvern, UK). Samples were dry dispersed using the systems automated 
sample dispersion unit (5541 mm2 area) onto a glass plate (180 × 110 mm) with an injection 
pressure of 4.0 bar, an injection time of 10 ms and a setting time of 60 s. A range of particle 
size from 0.5 μm to 40 μm were quantified using 50X (Nikon TU plan ELWD) magnification 
optics selection. Figure 8 describes the sample dispersion and PSD analysis completed by the 
Morphologi G3SE. 
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Figure 8. Schematic representation of particle dispersion and measurement of particle size 
distribution completed by the Morphologi G3SE. 
 
2.2.6 Fourier Transform Infrared Spectroscopy (FTIR) 
Fourier-transform infrared (FTIR) spectroscopy is a characterization technique used to obtain 
the infrared spectrum of a sample. In order to measure the FTIR spectrum of a sample, infrared 
radiation is passed through the material, which can be a solid, liquid or gas.28 A typical FTIR 
spectrometer, described in Figure 9 consists of a source, interferometer (beam splitter), sample 
stage, detector and a series of mirrors. In operation, IR radiation is generated from the source 
and is then split by an interferometer so that the path of both beams is different. The beams 
pass through a series of static and stationary mirrors then interact with the sample where sample 
molecules absorb some radiation of different wavelengths while the unabsorbed radiation 
continues to the detector which uses an interferogram to translate the signal to a spectrum.29  
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Figure 9. Schematic representation of a typical FTIR spectrometer. 
 
In this thesis, the FTIR characterization of the samples was measured at an ambient temperature 
using a Perkin-Elmer Spectrum 100 FTIR spectrometer. The spectrum was collected at 
wavelengths of 4000–650 cm−1 using an attenuated total reflection accessory with a ZnSe 
crystal. Samples were uniformly spread on the crystal with a pushing arm and 50 scans were 
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Chapter 3. Investigating Process Variables and Additive 
Selection to Optimize Polymorphic Control of 
Carbamazepine in a CO2 Antisolvent Crystallization 
Process 




The ability of an active pharmaceutical ingredient (API) to crystallize in different structural 
arrangements, named polymorphs, has generated significant attention from the pharmaceutical 
industry over the last 20 years. Pharmaceutical polymorphism is a critical control objective in 
crystallization processes which is known to play a major role in determining drug product 
attributes including solubility, stability and rheological behaviour during downstream 
processing.1-2  
 There is currently an urgency among the pharmaceutical industry to develop novel 
approaches to address the worsening issue of poor drug solubility.3-6 The ability to control the 
polymorphism of an API represents a potential solution to address the concerning issue of 
poorly soluble polymorphic APIs, as metastable forms typically demonstrate a higher solubility 
profile than stable forms. This is discussed in greater detail in Chapter 1 of this thesis. The 
crystalline form of an API obtained from a pharmaceutical crystallization process can be 
affected by several processing parameters such as temperature, pressure, supersaturation, type 
of solvent and presence of molecular additives.7-9 Additives have been shown to affect the 
crystallization kinetics, namely, the growth of polymorphic materials.10-14 In these cases, 
additives incorporate themselves, stereoselectively, into growing faces of crystals, thereby 
inhibiting further growth of these faces, promoting the appearance/growth of other 
polymorphic forms.14-15 To date, the detailed mechanisms involved in additive-mediated 
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pharmaceutical crystallization methods are still unknown in many instances but potentially 
provide the opportunity to combat the poor API solubility concerns present in the 
pharmaceutical industry.16  
 The properties of supercritical fluids (SCF) have been investigated by many authors 
with a perspective towards solid-state control and particle engineering of pharmaceutical 
compounds.16-22 Supercritical CO2 (scCO2) has many unique properties which makes it unique 
to API processing..23-24 Additionally, scCO2 is non-toxic and can be considered to be a greener 
method of producing drugs, relative to conventional methods as the CO2 gas is able to be 
recycled in large scale processes.19, 25-26 Supercritical CO2 has three unique roles that make it 
suitable for pharmaceutical processing.20 The role, which will be discussed in this chapter and 
is the most commonly reported, relates to the antisolvent capacity of scCO2.
16, 24, 27-31 The 
decision on which scCO2 role to select can depend on various factors but is heavily influenced 
by the solubility of the organic solvent and API in scCO2. 
 Carbamazepine, a BCS class II drug discovered in 1960 exists in four anhydrous forms 
that are discussed in greater detail, such as their respective thermodynamic stabilities, in 
Chapter 2, section 2.1.1.32, 33-35 An enantiotropic relationship between CBZ forms I and III has 
been determined, alongside a transition temperature of 71 °C between these two polymorphs.36 
The solubility of these two polymorphs in simulated gastric fluids and particularly scCO2 has 
been reported by Kalikin et al. and Bettini et al, respectively.37-39 Bettini et al. demonstrated 
that at pressures below 150 bar, both polymorphs show a similar solubility in scCO2 at 40 °C 
and 55 °C; and it is not until 300 bar at increased temperatures (55 °C) that there is a significant 
difference in solubilities observed.38  Due to the quick transformation of other metastable 
forms, such as CBZ form II, it is not possible to determine its thermodynamic relationship to 
other CBZ polymorphs.40 With great emphasis being placed on polymorphic monitoring and 
control of APIs by the pharmaceutical industry, numerous studies have been conducted to 
attempt to identify timeframes when polymorphic transformation will occur under the influence 
of various processing conditions.41-43 
 In this work, a gas antisolvent (GAS) crystallization method is used to crystallize 
distinct CBZ polymorphic forms from methanol solutions containing molecular additives. This 
method (GAS) is typically employed when an API has a low solubility in scCO2 and the organic 
solvent is readily miscible with scCO2.
16, 19-20, 29, 38, 44-45 In 2017, Padrela et al. reported the 
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polymorphic control of CBZ through the use of anionic additives in a supercritical antisolvent 
crystallization method at specific operating conditions.16 This control was achieved by using 
the GAS method and demonstrated that both stable and metastable forms of CBZ could be 
obtained when using distinct molecular additives such as sodium dodecyl sulfate (SDS) and 
sodium stearate (SS), respectively. This work also included molecular modelling using density 
functional theory (DFT) to gain insight into the molecular mechanisms by which the additives 
governed the polymorphic outcome of CBZ.16 It was suggested that CBZ molecules arrange 
themselves (during a pre-nucleation stage) in different formations depending on the additive 
selected, and template the crystallization of distinct polymorphic forms.16  
 This chapter aims to investigate how robust the polymorphic control of CBZ, exhibited 
by anionic additives (SS and SDS), can be across a range of distinct operating variables. The 
processing variables that were selected for this study include temperature, pressure and scCO2 
addition rate. The polymorphic stability of precipitated CBZ particles while immersed in scCO2 
for an extended period is also investigated in this study to determine the degree of control 
achievable using these additives, SS and SDS. 
 
3.2 Experimental Section 
3.2.1 Materials 
Carbamazepine (verified to be Form III by reflection powder X-ray diffraction), sodium 
stearate, sodium dodecyl sulfate, ethyl cellulose and methanol were purchased from Sigma 
Aldrich and used without further purification (purity was >99.9%). Carbon dioxide (99.98%) 
was supplied by BOC (Ireland). 
 
3.2.2 Solution Preparation 
Carbamazepine with/without additives was dissolved in methanol (70.0 mg in 1 mL of 
methanol). The sample was placed in an ultrasonic water bath for 5 minutes to ensure complete 
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dissolution of solid material. When additives were selected for the preparation of the CBZ 
solutions, 5% w/w (3.5 mg) of each additive were added to the CBZ solutions. Each solution 
was then filtered through a 0.2 μm pore size nylon filter (Whatman Inc.) to remove any 
undissolved material.  
 
3.2.3 Gas Antisolvent (GAS) Crystallization 
Figure 1 presents a schematic diagram of a custom-designed batch GAS apparatus. 
 
Figure 1. Schematic diagram of the GAS apparatus. 1, CO2 cylinder; 2, gas compressor; 3, 
temperature-controlled air chamber; 4, stainless steel storage cylinder; 5, pressure transducer; 
6, high-pressure vessel; 7, magnetic stirrer plate; 8, exit valve.  
 
The GAS apparatus presented in Figure 1 comprises of a 100 cm3 stainless steel storage vessel 
and a 10 cm3 stainless steel high-pressure reaction vessel (where crystallization occurs) with 
monitored temperature and pressure using a T-type thermocouple and a pressure transducer 
(Omega model PX603), respectively. These vessels were placed inside a temperature-
controlled air chamber to maintain the scCO2 properties and ongoing reaction at the desired 
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temperature. A borosilicate window was fitted on the top of the high-pressure vessel for 
visualization purposes during the experiments.  
 
A Teledyne ISCO 260D pump was used to compress the CO2 before discharging it into the 
storage vessel and allowing it to remain in this vessel for a short period of time (~10 minutes) 
until it reached the desired temperature. A solution containing 70 mg of CBZ dissolved in 1mL 
of methanol with/without additive was placed inside the high-pressure reaction vessel and 
sealed.  Previous studies have demonstrated that precipitation of this API (CBZ) using the GAS 
method can be achieved at lower concentrations (50 mg/ml). The work in this manuscript will 
be conducted at a higher temperature than the study referenced16, therefore higher pressures 
may be required to induce precipitation and, in order to avoid exceeding the maximum 
allowable pressure value (200 bar), a higher initial concentration was selected for this study to 
achieve supersaturation and, thus, antisolvent precipitation inside the vessel.  Supercritical CO2 
was then allowed to flow into the high-pressure vessel at a pre-determined addition rate (0.01-
1.52 g/s) until the desired pressure was reached, so that antisolvent crystallization could occur. 
As scCO2 entered the vessel, the solutions were subjected to magnetic stirring at 600 rpm to 
ensure appropriate miscibility between the antisolvent (scCO2) and the API solution occurs. 
When supersaturation was reached, and precipitation of the API had occurred, magnetic stirring 
was turned off and the exit valve (number 8 in Figure 1) was opened to continuously flush 
scCO2 through the high-pressure vessel, thereby allowing methanol to evaporate into the scCO2 
and be removed from the vessel. The scCO2 was passed through the reaction vessel over a 1-
hour time frame at a flowrate of approximately 5 g/min (dependent on the pressure and 
temperature value). After the solvent flushing had concluded, the high-pressure vessel was 
slowly depressurized, and the resulting material was collected. 
The samples obtained from the GAS experiments were stored in a desiccator prior to their 
characterization. Table 1 presents the experimental conditions used in the preparation of the 
CBZ solutions prior to being processed by the GAS method. 
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3.2.4 Design of Experiments (DoE)  
A study using 3-factor 2-level full factorial DoE with centre points was performed to 
investigate the influence of the variable GAS processing variables (pressure, temperature and 
CO2 antisolvent addition rate) and solution properties (with/without additive) on the 
polymorphism of CBZ crystals. A DoE without the use of additives was first performed before 
investigating the impact of additives (Tables 1 and 2; Figure 3). Sodium stearate and SDS were 
the additives used in the DoE study (Tables 1 and 2; Figures 4 and 5), as it has been reported 
recently that these additives promote the formation of CBZ forms II and III, respectively at 
specific conditions.16  
 
Table 1. Experimental Conditions Used in GAS Experiments for the Crystallization of 








P       
(bar) 




DoE Point 1 No Additive - 90 40 0.01 
DoE Point 2 No Additive - 170 40 0.01 
DoE Point 3 No Additive - 170 40 1.52 
DoE Point 4 No Additive - 90 40 1.52 
DoE Point 5 No Additive - 130 55 0.77 
DoE Point 6 No Additive - 90 70 0.01 
DoE Point 7 No Additive - 170 70 0.01 
DoE Point 8 No Additive - 170 70 1.52 
DoE Point 9 No Additive - 90 70 1.52 
DoE Point 10 SS 5 90 40 0.01 
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DoE Point 11 SS 5 170 40 0.01 
DoE Point 12 SS 5 170 40 1.52 
DoE Point 13 SS 5 90 40 1.52 
DoE Point 14 SS 5 130 55 0.77 
DoE Point 15 SS 5 90 70 0.01 
DoE Point 16 SS 5 170 70 0.01 
DoE Point 17 SS 5 170 70 1.52 
DoE Point 18 SS 5 90 70 1.52 
DoE Point 19 SDS 5 90 40 0.01 
DoE Point 20 SDS 5 170 40 0.01 
DoE Point 21 SDS 5 170 40 1.52 
DoE Point 22 SDS 5 90 40 1.52 
DoE Point 23 SDS 5 130 55 0.77 
DoE Point 24 SDS 5 90 70 0.01 
DoE Point 25 SDS 5 170 70 0.01 
DoE Point 26 SDS 5 170 70 1.52 
DoE Point 27 SDS 5 90 70 1.52 
aCAdditive: proportion of additive used; P: pressure; T: temperature; RAddition Rate: addition rate of 
scCO2 into the high-pressure vessel; SS: Sodium Stearate; SDS: Sodium dodecyl sulfate. For 
all DoE points, concentration of CBZ in methanol was 70 mg/ml and stirring rate was 600 
RPM. Once antisolvent crystallization occurred, scCO2 was immediately flushed through the 
reactor for 1 hour at a rate of approximately 5 g/min (10 ml/min). 
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An additional study to monitor the polymorphic form obtained over a longer period was also 
undertaken. In these experiments (described in Table 2), once anti-solvent crystallization 
occurred and the CBZ particles precipitated, the high-pressure vessel remained pressurized 
with the drug suspension immersed in scCO2 for an additional sixty hours. Upon completion 
of this period, the solvent was removed with continuous scCO2 flushing as described 
previously. 
 
Table 2. Experimental Conditions Used in GAS Experiments for the Crystallization of 







P         
(bar) 




DoE Point 28 No Additive - 90 40 0.01 
DoE Point 29 No Additive - 170 40 0.01 
DoE Point 30 No Additive - 170 40 1.52 
DoE Point 31 No Additive - 90 40 1.52 
DoE Point 32 No Additive - 130 55 0.77 
DoE Point 33 No Additive - 90 70 0.01 
DoE Point 34 No Additive - 170 70 0.01 
DoE Point 35 No Additive - 170 70 1.52 
DoE Point 36 No Additive - 90 70 1.52 
DoE Point 37 SS 5 90 40 0.01 
DoE Point 38 SS 5 170 40 0.01 
DoE Point 39 SS 5 170 40 1.52 
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DoE Point 40 SS 5 90 40 1.52 
DoE Point 41 SS 5 130 55 0.77 
DoE Point 42 SS 5 90 70 0.01 
DoE Point 43 SS 5 170 70 0.01 
DoE Point 44 SS 5 170 70 1.52 
DoE Point 45 SS 5 90 70 1.52 
DoE Point 46 SDS 5 90 40 0.01 
DoE Point 47 SDS 5 170 40 0.01 
DoE Point 48 SDS 5 170 40 1.52 
DoE Point 49 SDS 5 90 40 1.52 
DoE Point 50 SDS 5 130 55 0.77 
DoE Point 51 SDS 5 90 70 0.01 
DoE Point 52 SDS 5 170 70 0.01 
DoE Point 53 SDS 5 170 70 1.52 
DoE Point 54 SDS 5 90 70 1.52 
bCAdditive: proportion of additive used; P: pressure; T: temperature; RAddition Rate: addition rate of 
scCO2 into the high-pressure vessel; SS: Sodium Stearate; SDS: Sodium dodecyl sulfate. For 
all DoE points, concentration of CBZ in methanol was 70 mg/ml and stirring rate was 600 
RPM. Once antisolvent crystallization occurred, scCO2 and the drug suspension remained in 
the high-pressure vessel for a period of sixty hours, after which scCO2 was flushed through the 
reactor for 1 hour at a rate of approximately 5 g/min (10 ml/min). 
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3.3 Results and Discussion 
3.3.1 Design of Experiments (DoE) 
The GAS process variables investigated in this study were temperature, pressure and scCO2 
addition rate. These factors were selected for the DoE as they typically represent critical 
operating conditions that influence crystal growth and polymorphism. Pressure and 
temperature can affect the density of CO2, thereby influencing its solvating power/miscibility 
in the organic solvent and consequently impacting supersaturation levels of the API solutions. 
As a result of the transition temperature (71 °C) between form I and III31, a maximum operating 
temperature of 70 °C was chosen for the DoEs studied in this work (see Figure 2). As the 
critical temperature of CO2 is 31.1 °C, a minimum working temperature of 40 °C was selected 
to ensure that the CO2 remains in a supercritical state. 
The maximum pressure for this study was determined by the pressure rating of the high-
pressure vessel (200 bar); therefore, 170 bar was selected as the maximum working pressure in 
the event of a pressure increase by external factors (e.g. temperature). The maximum pressure 
determination was also chosen to understand the influence of increased supersaturation on the 
polymorphic form of precipitated CBZ particles. The minimum operating pressure was decided 
based on the previous work by Padrela et al. in 2017, which reported that CBZ precipitates 
from methanol solutions when operating pressures of 90 bar and above are used in the GAS 
method.16 Although precipitation was reported to occur at pressures below 90 bar, this value 
was selected to ensure that all CBZ samples would effectively precipitate and particles would 
be collected at the end of each experiment. Additionally, the critical pressure for CO2 (74.8 
bar) also influenced our selection of the minimum operating pressure, to ensure that we are 
using CO2 in the supercritical state.  
The final variable chosen for this study was the antisolvent (scCO2) addition rate.  Antisolvent 
addition rate has been reported in the literature to impact the final particle size of APIs,46 
however this paper aims to investigate if this variable has an impact on the final polymorphic 
form of CBZ obtained in a GAS method. This variable influences the crystallization kinetics, 
as supersaturation will be achieved faster at higher antisolvent addition rates.  
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Padrela et al. reported that when using supercritical antisolvent methods such as GAS, 
in combination with anionic additives, it is possible to accurately control the polymorphism of 
CBZ at specific conditions (90 bar, 40 °C, 70 mg/ml).16 The study presented herein investigates 
if this control can be extended over a wide range of critical operating variables compared to 
the specific conditions reported previously. Additionally, this paper investigates if polymorphic 
transformations are likely to occur for CBZ after it has crystallized by GAS, while immersed 
in scCO2-methanol mixtures over an extended period of time.  
At certain conditions (70 °C, 90 bar, described in Tables 1 and 2), antisolvent 
supersaturation did not immediately occur as there was an insufficient amount of CO2 to induce 
precipitation. However, upon flushing scCO2 through the vessel for a period of time (~2 
minutes) and allowing methanol to evaporate and be removed, precipitation, caused by a 
combination of the antisolvent effect and evaporation could be observed. 
 
Figure 2 presents the DoE approach undertaken for this study using the previously mentioned 
operating process variables (temperature, pressure and CO2 antisolvent addition rate). An initial 
DoE was completed without the use of additives to determine a control result for the polymorph 
of CBZ generated.  
 
Figure 2. Design of experiments schematic investigating the effect of temperature, pressure 
and CO2 addition rate on the polymorphic form of CBZ with/without using anionic additives 
(SS and SDS). 
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The results from this DoE, shown in Figure 3, emphasize that very little systematic control can 
be achieved in this system (CBZ and methanol) across a wide range of operating conditions, 
when additives are not used.  
 
Figure 3. a) Design of experiments schematic to investigate the polymorphic outcome of CBZ 
in a GAS method without the use of additives, using pressure, temperature and antisolvent 
addition rate as the process variables. b) Powder X-ray diffraction patterns of theoretical CBZ 
polymorphic forms (I, II, and III) from the Cambridge Structural Database and CBZ samples 
processed (without additives) by the GAS method. Experimental conditions as described in 
Table 1 (DoE Points 1-9). 
 
The introduction of form I at DoE Point 6 at 70 °C is likely due to the proximity of this value 
to the reported transition temperature between CBZ form I and form III. Although form III is 
present in all samples, either as a PXRD-pure form or an impurity, no clear trend can be 
observed to determine what polymorphic form will be produced at each condition. Statistical 
analysis of this DoE is discussed in the supporting information. A similar DoE approach to 
examine the polymorphic control of CBZ, provided by anionic additives, is investigated below.  
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Figure 4 describes the results of another DoE which explores the GAS process variables 
(pressure, temperature and CO2 antisolvent addition rate) over a wide range of conditions using 
the anionic additive SS. This additive has previously been shown to control the polymorphism 
of CBZ in both batch (GAS) and continuous (SASD) supercritical antisolvent processes, at 
specific processing conditions.16, 47  
 
Figure 4. a) Design of experiments schematic to investigate the polymorphic outcome of CBZ 
in a GAS method using sodium stearate as the additive and using pressure, temperature and 
antisolvent addition rate as the process variables. b) Powder X-ray diffraction patterns of 
theoretical CBZ polymorphic forms (I, II, and III) from the Cambridge Structural Database, SS 
and CBZ samples processed by the GAS method using SS as the additive. Experimental 
conditions as described in Table 1 (DoE Points 10-18). 
 
The mechanistic details of the role of these additives on the polymorphic control of CBZ have 
already been proposed by Padrela et al., however, exploring how robust this control is across a 
range of process conditions in the GAS method has not yet been addressed. The results of this 
DoE confirm that SS generates CBZ form II in a GAS method across a wide range of 
temperatures, pressures and antisolvent addition rates. From the patterns in Figure 4 (b), we 
observe PXRD-pure form II at each condition explored. These results indicate that the 
templating of CBZ molecules by SS, during the pre-nucleation stage in a CO2 antisolvent 
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method such as GAS, occurs across the wide range of critical operating conditions selected in 
this study. 
 
In Figure 5, SDS was selected as an additive to investigate if the stable form of CBZ (form III) 
could be obtained across the same operating conditions as described previously in Figures 3 
and 4. This additive has previously been shown to control the polymorphic form of CBZ in 
GAS and SASD methods. 
 
 
Figure 5. a) Design of experiments schematic to investigate the polymorphic outcome of CBZ 
in a GAS method using SDS and using pressure, temperature and antisolvent addition rate as 
the process variables. b) Powder X-ray diffraction patterns of theoretical CBZ polymorphic 
forms (I, II, and III) from the Cambridge Structural Database, SDS and CBZ samples processed 
by the GAS method with SDS as the additive. Experimental conditions as described in Table 
1 (DoE Points 19-27). 
 
These results highlight the high degree of control achieved on the polymorphism of CBZ when 
using SDS as the additive at 5% w/w. The stable form III is obtained for almost every point on 
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the DoE in Figure 5. The only exception is for DoE Point 24 where the presence of small 
diffraction peaks from the metastable form II at 5 ° and 9 ° (2 Theta) can be observed. The 
presence of peaks (at ~ 6 and 7.5 ° 2 Theta) at DoE Points 20 and 21 appear to correspond to 
the molecular additive (SDS) used for this study. As this value is close to the transition 
temperature between form I and form III at 70 °C, we propose that the change in stability of 
form III provides an opportunity for metastable polymorphs, such as CBZ form II, to appear in 
the sample. Despite these stability differences at this temperature (70 °C), DoE Point 24 is the 
only experiment where we have observed the presence of minor impurities from other 
polymorphic forms in the final sample. 
 
3.3.2 Particle Shape of CBZ Crystals Produced by GAS Using Anionic 
Additives 
Figure 6 depicts SEM images of a specific CBZ form II sample (DoE Point 14) produced by 
the GAS method using sodium stearate as the additive (conditions as described in Table 1).  
 
Figure 6. Scanning electron microscopy images of CBZ particles produced by the GAS method 
using SS as the additive (DoE Point 14): a) CBZ form II (x450); b) CBZ form II (x1000); c) 
CBZ form II (x4500) and d) CBZ form II (x8000). 
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The shape of these CBZ particles can be described as needle-like, which corresponds well with 
existing literature for the crystal shape of CBZ form II.48 The average size of these particles 
varies as larger needles can be observed in most samples but typically range from about 1-10 
µm in width and approximately 5-500 µm in length. The presence of smaller rod-shaped 
particles on the crystal surface (particularly visible in Figure 6 (c) and (d)), produce an 
increased level of elemental sodium (the only element unique to SS) detected by EDS analysis 
at these localized areas. Based on the findings of the 2017 from Padrela et al. study which 
employs DFT modelling to propose the interaction between the additive molecules (sodium 
stearate and SDS) and CBZ, the sodium stearate molecules are suggested to sit in the channels 
of templated CBZ form II molecular arrangements. The presence of sodium detected on the 
surface of CBZ particles may indicate that upon crystallization, the additive (sodium stearate) 
exits the channels from where the DFT model suggests it sits during nucleation. However, this 
claim is difficult to verify without the use of DFT modelling which is beyond the scope of this 
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Figure 7 depicts SEM images of DoE Point 23, produced using 5% w/w SDS by the GAS 
method (conditions as described in Table 1).  
 
Figure 7. Scanning electron microscopy images of CBZ particles produced by the GAS method 
using SDS as the additive (DoE Point 23): a) CBZ form III (x100); b) CBZ form III (x500); c) 
CBZ form III (x1000) and d) CBZ form III (x4000). 
 
These CBZ particles are block-shaped which corresponds well to the reported shape for this 
polymorph (form III).49 These CBZ form III crystals appear to have greater uniformity, when 
compared to the particles in Figure 6. However, this may be influenced by the high probability 
of breakages that is frequently observed for needle-like API particles as studied by Hua et al.50 
The average particle size in this sample (DoE Point 23) is approximately between 20-25 µm. 
Unlike Figure 6, the presence of smaller additive particles is not observed in this sample. As 
smaller additive particles were not observed but, based on the EDS analysis, elemental sodium 
was detected, this result may indicate that SDS does not absorb to the surface and cannot 
prevent the transformation from metastable polymorphic forms to the stable CBZ form III, 
unlike SS. However, similar to the comments below Figure 6, it is difficult to verify these 
claims without the use of DFT modelling. Although this falls beyond the scope of this thesis, 
the use of modelling to investigate the location of the additive once crystallization has occurred 
is a topic worth further exploration. 
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3.3.3 Stability of CBZ Particles Precipitated by GAS Immersed in scCO2-
Methanol Mixtures 
An investigation into the thermodynamic stability of precipitated CBZ particles was performed 
to determine the extent of the polymorphic control exhibited by anionic additives (SS and 
SDS). To perform this, the drug suspension (CBZ, additive and methanol) remained immersed 
in scCO2 for a period of sixty hours. Understanding the extent of this polymorphic control 
exhibited by anionic additives may be crucial for API processing with the prospect that the 
drug may be suspended in a reactor for a longer time than scheduled due to unforeseen 
circumstances in manufacturing environments. This period (sixty hours) was deemed adequate 
to investigate if polymorphic transformation would occur in supercritical media as it is unlikely 
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Figure 8 shows a long-hold DoE study without the use of additives. The results of this DoE 
compared to Figure 8 (short hold DoE) indicate that polymorphic conversions of CBZ in 
mixtures of methanol and CO2 are likely to occur depending on the amount of time immersed 
in scCO2.  
 
Figure 8. a) Design of Experiments schematic to investigate the polymorphic conversion of 
CBZ in scCO2-methanol mixtures without using additives, using pressure, temperature and 
antisolvent addition rate as the GAS process variables over an extended period (sixty hours). 
b) Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms from the 
Cambridge Structural Database and CBZ samples processed (without additives) by the GAS 
method. Experimental conditions as described in Table 2 (DoE Point 28-36). Short hold DoE 
(Figure 3) included for comparison. 
 
These results show that some CBZ samples from the DoE points presented in Figure 8 begin 
to convert from impure polymorphic mixtures (DoE points 3, 4 and 5 from Figure 3) to PXRD-
pure form III (DoE points 30, 31 and 32 from Figure 8), which is the stable form at this 
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temperature. Interestingly, two DoE Points (33 and 36) which lie close to the transition 
temperature between form I and III are the only values in this DoE that show no evidence of 
form III. The conversion of PXRD-pure form III to a mixture of forms I and II, observed for 
DoE point 36, is an unexpected result. This result (conversion from CBZ form III to CBZ forms 
I and II) may be explained by the close proximity to the reported transition temperature between 
CBZ forms I and III. This presence of another metastable form (CBZ form II) requires further 
investigation to understand why the introduction of this form occurs during a long hold study.  
The reduced stability of form III at this temperature likely explains the presence of form I, but 
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Figure 9 investigates the effect that an increased hold-time of CBZ in scCO2-methanol mixtures 
has on the polymorphic outcome of CBZ obtained when SS is used as an additive at 5% w/w.  
 
Figure 9. a) Design of experiments schematic to investigate the polymorphic conversion of 
CBZ in in scCO2-methanol mixtures using the anionic additive SS, using pressure, temperature 
and antisolvent addition rate as the GAS process variables over an extended period (sixty 
hours). b) Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, and 
III) from the Cambridge Structural Database and CBZ samples processed (with SS) through 
the GAS method. Experimental conditions as described in Table 2 (DoE Points 37-45). Short 
hold DoE (Figure 4) included for comparison. 
 
The results show that at lower temperatures (40° C), the metastable form II begins to convert 
to the stable form III (DoE Points 37-40), resulting in PXRD-pure form III at higher pressures 
(170 bar) and a mixture of forms II and III at lower pressures (90 bar). Denser scCO2 (CO2 at 
higher pressures) has been shown to promote crystallization reactions when compared to CO2 
at lower pressures.19 This may provide an explanation to why complete polymorphic 
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transformations are observed at higher pressures, while partial transformations are observed at 
lower pressures.   
 
The final DoE (Figure 10) investigates the effect that hold-time of CBZ in scCO2-methanol 
mixtures has on the polymorphic outcome of CBZ obtained when sodium dodecyl sulfate 
(SDS) is used as an additive at 5% w/w. The DoE in Figure 11 shows minimal conversion of 
CBZ form III when compared to the short hold DoE in Figure 5.  
 
Figure 10. a) Design of experiments schematic to investigate the polymorphic conversion of 
CBZ immersed in scCO2-methanol mixtures using the anionic additive SDS, using pressure, 
temperature and antisolvent addition rate as the GAS process variables over an extended period 
(sixty hours). b) Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, 
II, and III) from the Cambridge Structural Database and CBZ samples processed (with SDS) 
through the GAS method. Experimental conditions as described in Table 2 (DoE Point 46-54). 
Short hold DoE (Figure 5) included for comparison. 
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This result was expected, as it is unlikely to observe significant polymorphic conversions when 
the initial polymorph obtained (figure 5) is the stable form (at room temperature). From the 
short hold DoE in Figure 5, only one sample (DoE point 24) contained a mixture of two 
polymorphic forms (II and III). When the CBZ in scCO2-methanol mixture was allowed to 
remain in the reactor for an extended period, PXRD-pure form III was produced. The presence 
of form III crystals at short hold points (DoE point 24) may have acted as a seed to promote 
the conversion of CBZ from forms II and III to PXRD-pure form III in the long hold study, 
despite the reduced stability. In the DoE presented in Figure 10, point 54 converts from PXRD-
pure form III (point 27 in Figure 5) to a mixture of forms I and III. Unsurprisingly, this point 
(DoE Point 54) occurs at 70 °C, close to the transition temperature between these polymorphs, 
which may explain why this mixture was observed. The minimal polymorphic transformations 
that occur between Figures 5 and 10 highlight the control provided by SDS as well as the 
thermodynamics of the CBZ system. Similarly to the PXRD observed in the short hold-time 
DoE using SDS (Figure 5), PXRD peaks from the additive used (SDS) can be observed in 
several diffraction patterns of CBZ samples from the long hold DoE (DoE Points 47, 48, 49 
and 53) from Figure 10. 
An additional study, which investigates the impact that the quantity of a different additive 
(ethyl cellulose) has on the polymorphic form of CBZ obtained by GAS methods is presented 
and discussed in the supporting information. In 2017, Padrela et al. proposed the mechanistic 
details that gave rise to the formation of CBZ form II when using SS, and to the formation of 
CBZ form III when using SDS.16 Those models, generated using density functional theory 
calculations, described the interaction between CBZ and additive molecules at a ‘pre-
nucleation’ stage, which led to the selective formation of either CBZ form II or III. We propose 
that the mechanisms described by Padrela et al. in 201716 appear to be upheld for, not only a 
specific set of conditions but also a wide range of critical processing variables. This observation 
is based on the results obtained from figures 4 and 5 as well as the minimal polymorphic 
conversions taking place in Figures 9 and 10 (long hold DoEs with the additives SS and SDS, 
respectively) compared to Figure 8 (DoE without additives). 
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3.4 Conclusions 
This manuscript demonstrates that process variables such as temperature and antisolvent 
addition rate can influence the polymorphism of CBZ in a GAS method when additives are not 
selected. This study was performed using a DoE approach in conjunction with statistical 
analysis. Both approaches indicated that when additives were not used, the combination of 
temperature and antisolvent addition rate were major influencing factors (p < 0.05) with respect 
to polymorphism (see supporting information).  However, when two anionic additives (SS or 
SDS) were added in 5% w/w amounts, polymorphic control of CBZ across a wide range of 
processing variables was achieved.   
Samples that were observed to contain mixtures of two or more polymorphic forms of CBZ 
primarily occurred at the higher temperature range (70 °C). Interestingly, this temperature 
value is close to the transition temperature between forms I and III (~ 71 °C). The reduced 
stability of form III at this temperature may allow for the introduction of impurities from other 
polymorphic forms to emerge in the final CBZ samples.  
An investigation into the stability of precipitated CBZ particles was also performed where the 
crystallized drug suspension would remain immersed in scCO2 for a period of sixty hours. At 
low temperatures without additives it was observed that CBZ form III (the stable form at room 
temperature) became the dominant polymorph produced. Even when sodium stearate (which 
promotes the formation of CBZ form II) was used, partial to complete conversions at low 
temperatures (40° C) from form II to form III were observed after sixty hours. Sodium dodecyl 
sulfate promoted the formation of form III during short-hold processing and, as a result, 
minimal polymorphic conversions were observed during longer hold times. Long hold DoEs 
that employ additives highlight that control over polymorphism can still be achieved during 
extended periods. However, this control is not as comprehensive as observed with shorter hold 
times. 
Overall, CBZ forms II and III can be readily produced using a GAS method by using anionic 
additives, regardless of the processing conditions used (pressure, temperature and CO2 addition 
rate). These additives (SS and SDS) influence the final polymorphic form obtained at both 
short and long hold times. Statistical analysis is used in this study to demonstrate that this 
control is not achieved comprehensively in the absence of anionic additives, SS and SDS.  
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3.5 Supporting Information 
3.5.1 Additive Location during GAS Processing 
This work investigates the final location of additive particles once antisolvent crystallization 
of CBZ and flushing of solvent has occurred in the reaction vessel. This work was completed 
using SEM-EDS analysis to detect the content of sodium (the only element unique to each 
additive) relative to nitrogen and oxygen (see Figure SI1). Carbon was excluded from 
elemental analysis, as the element which is the focus of this study (sodium) would have an, 
almost, insignificant value relative to carbon. Figure SI2 depicts SEM images of a CBZ form 
II sample (DoE Point 14) produced by the GAS method using sodium stearate as the additive 
(conditions as described in Table 1). The shape of these CBZ particles is further presented in 
Figure 6 and discussed in the Results and Discussion section of the manuscript. 
 
 
Figure SI1. Molecular structure of a) CBZ, b) SS and c) SDS. 
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Figure SI2. Scanning electron microscopy images of CBZ particles produced by the GAS 
method using sodium stearate as the additive (DoE Point 14) using different magnifications 
and EDS mapping: a) CBZ form II (x1000); b) CBZ form II (x8000); c) EDS point scan and 
mapping of CBZ sample (b); d) EDS point scan of elemental composition of nitrogen, oxygen 
and sodium of DoE Point 14. 
 
The presence of small (< 1 μm) rod-shaped particles on the surface of the CBZ form II needles 
were investigated for the presence of sodium by multiple point scans and elemental mapping 
as evidence of SS settling on the surface of the larger CBZ crystals. Point 1 in the EDS scan in 
Figure SI2 (c) was selected to be a flat surface with no visible indication of the small rods. 
Point 2 in the same image was selected in the centre of these rod-shaped particles and point 3 
was chosen to be near, but not on these rods. The EDS points show the highest content of 
sodium is located in the centre (point 2) of the rod-shaped particles while the lowest is on the 
flat crystal surface with no rod-shaped particles in proximity, suggesting that these rods are in 
fact, sodium stearate particles. Padrela et al. proposed in 2017 that, during a ‘pre-nucleation 
stage’, sodium stearate templates the formation of CBZ form II by promoting CBZ molecules 
to form columnar channels, which is characteristic of the crystalline structure of CBZ form II, 
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which are filled by sodium stearate molecules.14 The results from Figure SI2 suggest that the 
additive (SS) does not remain in these channels after the nucleation event, but rather settle on 
the surface of the CBZ crystal face. Elemental mapping, as well as point scans of the image 
was also performed in Figure SI2 (c), which displays denser measurements of sodium around 
the rod-shaped particles than around the flat surface of the CBZ crystal.  
 
Figure SI3 describes the SEM images and EDS analysis of DoE Point 23, produced using 5% 
w/w SDS by the GAS method (conditions as described in Table 1).  
 
Figure SI3. Scanning electron microscopy images of CBZ samples produced by the GAS 
method using SDS as the additive (DoE Point 23) using different magnifications and EDS 
mapping: a) CBZ form III (x300); b) CBZ form III (x800); c) EDS point scan and mapping of 
CBZ sample; d) EDS point scan of elemental composition of nitrogen, oxygen and sodium of 
DoE Point 23. 
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The shape of these particles are discussed in the manuscript. Unlike the SEM images of CBZ 
particles produced with SS (Figure SI2), there is no evidence of rods or any other smaller 
particles located on the surface of the form III CBZ crystals. An EDS point scan and elemental 
mapping (Figure SI3) were also performed to investigate if sodium could be detected despite 
no visible presence of additive particles. The point scan results in Figure SI3 (d) indicate that 
an even quantity of sodium exists (relative to nitrogen and oxygen) at each point. This result 
suggests that there are no zones of the additive (SDS) localized at specific areas, as seen in 
Figure SI2, but, instead, an even distribution of the additive throughout the CBZ form III 
particles can be observed. A large proportion of oxygen (relative to nitrogen and sodium) is 
detected for this sample, compared to Figure SI2. This difference is likely explained by the 
greater amount of oxygen molecules present in sodium stearate compared to SDS (two and four 
atoms, respectively). The results of the point scans in Figure SI3 (c) are further supported by 
elemental mapping of sodium which shows there are no areas of high or low sodium density, 
rather an evenly dispersed quantity throughout the SEM image. Based on the even dispersion 
of sodium detected throughout the sample using SDS (Figure SI3) compared to the localized 
detection using SS (Figure SI2), we suggest that SS particles are located on the surface of CBZ 
particles while SDS particles may be on the surface or embedded (based on penetration depth 
of EDS analysis) in the CBZ crystals. 
 
3.5.2 Statistical Analysis 
JMP Pro statistical analysis software (version 14.3.0) was used to prepare the DoE and perform 
statistical analysis of the results. The statistical analysis of the experimental data was performed 
by running a nominal logistics model. A p-value < 0.05 was considered statistically significant. 
Table SI1 investigates the effect of operating variables on the final polymorphic form obtained 
from a statistical perspective without using additives (Figure 3) during short hold experiments. 
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Table SI1. Statistical Analysis of Processing Variables from the Short Hold DoE Without 




Antisolvent Addition Rate 0.999 
Pressure*Temperature 1.000 
Pressure*Antisolvent Addition Rate 1.000 
Temperature*Antisolvent Addition Rate 0.044 
Pressure*Temperature*Antisolvent Addition Rate 1.000 
aEach variable (pressure, temperature and antisolvent addition rate) was investigated 
individually before analysing the effects of these conditions combined. 
 
The results from this statistical analysis from table SI1 shows that the combination of 
temperature and CO2 antisolvent addition rate are statistically significant (p < 0.05) with 
respect to the polymorphism of CBZ. Statistical analysis was not completed for DoEs for 
Figure 4 and 5 (using SS and SDS) as all DoE points excluding one showed PXRD-pure 
polymorphs and demonstrated that processing variables had no impact on the final polymorph 
obtained. 
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Statistical analysis was also performed on the processing variables for the long hold DoE when 
no additives (Figure 8) were added to the solution. This study involved allowing the drug 
suspension (CBZ and methanol) to remain immersed in scCO2 for a period of sixty hours as 
described in the manuscript. 
 
This outcome of this analysis was that no original operating variable (pressure, temperature or 
antisolvent addition rate) had statistical significance (p < 0.05). We can interpret from these 
results that the increased time CBZ spent immersed in the scCO2-methanol mixture contributed 
to the polymorphic conversions observed. The model used for the statistical analysis reported 
in Table SI1 and preformed for the long hold DoE was:  
Fit Model( 
 Y( :Polymorph Obtained ), 
 Effects( 
  :Name( "Antisolvent Addition Rate (g/s)" ), 
  :Name( "Temperature (Deg C)" ), 
  :Name( "Pressure (Bar)" ), 
  :Name( "Pressure (Bar)" ) * :Name( "Temperature (Deg C)" ), 
  :Name( "Temperature (Deg C)" ) * :Name( "Antisolvent Addition 
Rate (g/s)" ), 
  :Name( "Pressure (Bar)" ) * :Name( "Antisolvent Addition Rate 
(g/s)" ), 
  :Name( "Pressure (Bar)" ) * :Name( "Temperature (Deg C)" ) * 
  :Name( "Antisolvent Addition Rate (g/s)" ) 
 ), 
 Personality( "Nominal Logistic" ), 
 Run( Likelihood Ratio Tests( 1 ), Wald Tests( 0 ) ) 
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3.5.3 Design of Experiment Approach using Ethyl Cellulose 
An additional investigation was taken to understand if an additive that did not fall under the 
categorical assignment of ‘anionic additives’ would impact the polymorphic form of CBZ 
across a similar range of processing conditions described in the manuscript. Ethyl cellulose 
was selected for this study as it was previously reported by Padrela et al. to generate the stable 
CBZ form III by batch CO2 antisolvent methods. However, that study was performed at a 
standard set of conditions (90 bar, 40 °C and 5% w/w additive) and did not explore if ethyl 
cellulose would continue to promote the formation of this form when those critical parameters 
are varied. 
One variable, which differs from the DoE preformed in this manuscript, involves the proportion 
of additive added to the initial drug solution. This variable was selected to develop a better 
understanding if a minimum and maximum effective threshold existed for polymorphic control 
of CBZ using this additive. Instead of using 5% w/w additive, minimum and maximum limits 
of 1% and 10% w/w, respectively, were selected. The values for other variables selected for 
this DoE (pressure, temperature and CO2 addition rate) were kept the same for all DoEs 
completed with anionic additives. Table SI2 describes the operating conditions used for each 
of these DoEs. 
 
Table SI2. Experimental Conditions Used in GAS Experiments for the Crystallization of 






P       
(bar) 






DoE Point 55 1 90 40 0.01 III 
DoE Point 56 1 170 40 0.01 III 
DoE Point 57 1 170 40 1.52 II and III 
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DoE Point 58 1 90 40 1.52 III 
DoE Point 59 1 130 55 0.77 II and III 
DoE Point 60 1 90 70 0.01 II 
DoE Point 61 1 170 70 0.01 II and III 
DoE Point 62 1 170 70 1.52 III 
DoE Point 63 1 90 70 1.52 II  
DoE Point 64 10 90 40 0.01 III 
DoE Point 65 10 170 40 0.01 II and III 
DoE Point 66 10 170 40 1.52 II and III 
DoE Point 67 10 90 40 1.52 II and III 
DoE Point 68 10 130 55 0.77 II and III 
DoE Point 69 10 90 70 0.01 II and IV 
DoE Point 70 10 170 70 0.01 II 
DoE Point 71 10 170 70 1.52 I, II and III 
DoE Point 72 10 90 70 1.52 II 
cCAdditive: proportion of additive; P: pressure; T: temperature; RAddition Rate: addition rate of scCO2 
into the high-pressure vessel. For all DoE points, concentration of CBZ in methanol was 70 
mg/ml and the stirring rate was 600 RPM. Once antisolvent crystallization occurred, scCO2 




- 109 - 
 
Figure SI4 presents the graphical DoE results of processing using ethyl cellulose at (a) 1% w/w 
and (b) 10% w/w. These results appear to indicate that ethyl cellulose does not provide control 
over the polymorphism of CBZ and are discussed in detail below. These results serve to further 
emphasize the enhanced control over the polymorphism of CBZ that can be obtained in CO2 
antisolvent crystallization using anionic additives (SS or SDS). 
 
Figure SI4. Design of experiments schematic to investigate the polymorphic outcome of CBZ 
in a GAS method using ethyl cellulose as additive at (a) 1% w/w and (b) 10% w/w. Pressure, 
temperature and antisolvent addition rate used as process variables 
 
Figures SI5 and SI6 present the analytical PXRD data of the CBZ samples obtained from the 
DoEs in Figure SI4 (a) and (b), respectively. This data is compared to the reported literature 
values, obtained from the Cambridge Structural Database (CSD) and it is how the polymorphic 
assignments in Figure SI4 were determined. The stability of these samples in supercritical CO2 
over an extended period was not investigated due to the poor levels of polymorphic control 
achieved during short hold processing. 
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Figure SI5. a) Design of experiments schematic to investigate the polymorphic outcome of 
CBZ in a GAS method using Ethyl Cellulose as the additive (1% w/w) and using pressure, 
temperature and antisolvent addition rate as the process variables. b) Powder X-ray diffraction 
patterns of theoretical CBZ polymorphic forms (I, II, III and IV) from the CSD and CBZ 
samples processed by the GAS method with ethyl cellulose as the additive. Experimental 
conditions as described in Table SI1 (DoE Points 55-63). 
 
The results of the DoE presented in Figure SI5 suggest that very little control over the final 
polymorphic form of CBZ is attainable using ethyl cellulose at 1% w/w. At low temperatures, 
three out of a possible four DoE values show CBZ form III. An initial investigation into the 
role of additives in GAS processing by Padrela et al. demonstrated how form III was produced 
at 40 °C and 90 bar using this additive (ethyl cellulose) at 5% w/w.14  However, as the 
temperature increases, the introduction of a metastable polymorph (CBZ form II) appears as 
both PXRD-pure forms and polymorphic impurities. The presence of metastable forms at 
higher temperatures is addressed in the manuscript and is likely due to the reduced stability of 
form III at temperatures that are close to the transition point between form I and III.  
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Figure SI6 investigates the impact of using a higher amount (10% w/w) of ethyl cellulose as 
additive on the polymorphic form obtained for CBZ.  
 
Figure SI6. a) Design of experiments schematic to investigate the polymorphic outcome of 
CBZ in a GAS method using Ethyl Cellulose as the additive (10% w/w) and using pressure, 
temperature and antisolvent addition rate as the process variables. b) Powder X-ray diffraction 
patterns of theoretical CBZ polymorphic forms (I, II, III and IV) from the CSD and CBZ 
samples processed by the GAS method with ethyl cellulose as the additive. Experimental 
conditions as described in Table SI1 (DoE Points 64-72). 
 
Figure SI6 shows that higher amounts (10 % rather than 1 % w/w) of the additive ethyl cellulose 
demonstrate even less control over the polymorphic form when compared to Figure SI6. The 
results from this DoE show that the metastable form II is obtained at every DoE value except 
for Point 64 (PXRD-pure form III was obtained). This form (CBZ form II) appears as a PXRD-
pure form for DoE points 70 and 72, and as impurities for all other DoE points. These results 
may suggest that higher additive quantities (10% w/w) may affect the stability of CBZ 
polymorphs as a higher proportion of metastable polymorphs are observed when compared to 
Figure 3 (DoE without additives). The introduction of other metastable forms (form I and IV) 
is also observed at high temperatures (70 °C) which is not seen when using low additive 
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amounts (1% w/w). The presence of these polymorphs further supports our suggestion that the 
reduced stability of CBZ form III at higher temperatures is the reason for these new impurities.  
 
Table SI3 provides the results from statistical analysis to investigate the impact of GAS 
processing variables on the DoE using 1% w/w ethyl cellulose (Figure SI5) with respect to the 
polymorphism of CBZ. The results of this table are discussed below. 
Table SI3. Statistical Analysis of Processing Variables from DoE Using 1% w/w Ethyl 




Antisolvent Addition Rate 1.000 
Pressure*Temperature 1.000 
Pressure*Antisolvent Addition Rate 1.000 
Temperature*Antisolvent Addition Rate 1.000 
Pressure*Temperature*Antisolvent Addition Rate 0.002 
dEach variable (pressure, temperature and antisolvent addition rate) was investigated 
individually before analysing the effects of these conditions combined. 
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This table shows that a combination of all operating variables (pressure, temperature and 
antisolvent addition rate) had a statistically significant impact (p < 0.05) on the final 
polymorphic form of CBZ obtained. These results imply that the polymorphic form cannot be 
impacted by these variables individually and that the additive used (ethyl cellulose) does not 
provide any comprehensive control over the polymorphism of CBZ. Due to the low quantity 
of additive used (1% w/w), the effect of the additive may have not been realised. Thus, 
statistical analysis was also completed for Figure SI6, which used a larger quantity (10% w/w) 
of ethyl cellulose. The results of this analysis suggest that no operating variable significantly 
influenced the polymorphism of CBZ (p < 0.05). Although a preliminary visual analysis on the 
DoE results suggested that temperature appeared to have some impact on the polymorphism of 
CBZ, it is not considered to be statistically significant with a p value of 0.096. The results from 
this analysis and Table SI3 provides sufficient statistical evidence to suggest that ethyl cellulose 
does not significantly influence the final polymorphic form of CBZ, regardless of the quantity 
used. The model used for the statistical analysis reported is provided below:  
Fit Model( 
 Y( :Polymorph Obtained ), 
 Effects( 
  :Name( "Pressure (bar)" ), 
  :Name( "Temperature (Deg C)" ), 
  :Name( "Antisolvent Addition Rate (g/s)" ), 
  :Name( "Pressure (bar)" ) * :Name( "Temperature (Deg C)" ), 
  :Name( "Pressure (bar)" ) * :Name( "Antisolvent Addition Rate 
(g/s)" ), 
  :Name( "Temperature (Deg C)" ) * :Name( "Antisolvent Addition 
Rate (g/s)" ), 
  :Name( "Pressure (bar)" ) * :Name( "Temperature (Deg C)" ) * 
  :Name( "Antisolvent Addition Rate (g/s)" ) 
 ), 
 Personality( "Nominal Logistic" ), 
 Run( Likelihood Ratio Tests( 1 ), Wald Tests( 0 ) ) 
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In summary, the location of the additive post-crystallization was investigated in this work. 
From the SEM images and EDS analysis, it was observed that when using SS, small (< 1 µm) 
rod-shaped particles appeared to be located on the surface of the CBZ crystals. Elemental 
mapping suggested that these rod-shaped particles located on the surface of CBZ crystals 
appeared to be the additive used in the study. Unlike SS, when SDS was selected, additive 
particles were not visible through the SEM images. Elemental mapping detected a uniform 
density of sodium (the only element unique to each additive) throughout the CBZ form III 
particles, indicating that the SDS is well dispersed throughout and may be embedded or located 
on the crystal surface. 
Overall, the DoEs reported in Figures SI3 and SI4 demonstrate that ethyl cellulose does not 
appear to provide significant control over the polymorphic form of CBZ obtained using the 
GAS method, confirmed by statistical analysis. The results discussed in the manuscript 
involving anionic additives cannot be replicated using other additives such as ethyl cellulose 










- 115 - 
 
3.6 References 
1. Brittain, H. G.; Grant, D. J.; Myrdal, P. B., Effects of polymorphism and solid-state 
solvation on solubility and dissolution rate. Polymorphism in pharmaceutical solids 1999, 95, 
279-330. 
2. Snider, D. A.; Addicks, W.; Owens, W., Polymorphism in generic drug product 
development. Adv. Drug Delivery Rev. 2004, 56 (3), 391-395. 
3. Loftsson, T.; Brewster, M. E., Pharmaceutical applications of cyclodextrins: 
basicscience and product development. J. Pharm. Pharmacol. 2010, 62 (11), 1607-1621. 
4. Rodriguez-Aller, M.; Guillarme, D.; Veuthey, J.-L.; Gurny, R., Strategies for 
formulating and delivering poorly water-soluble drugs. J. Drug Delivery Sci. Technol. 2015, 
30, 342-351. 
5. Ross, A. M.; Mc Nulty, D.; O'Dwyer, C.; Grabrucker, A. M.; Cronin, P.; Mulvihill, J. 
J. E., Standardization of research methods employed in assessing the interaction between 
metallic-based nanoparticles and the blood-brain barrier: Present and future perspectives. J. 
Control. Release 2019, 296, 202-224. 
6. Lim, S. B.; Banerjee, A.; Önyüksel, H., Improvement of drug safety by the use of lipid-
based nanocarriers. J. Control. Release 2012, 163 (1), 34-45. 
7. Llinàs, A.; Goodman, J. M., Polymorph control: past, present and future. Drug Discov. 
2008, 13 (5), 198-210. 
8. Lai, T.-T. C.; Cornevin, J.; Ferguson, S.; Li, N.; Trout, B. L.; Myerson, A. S., Control 
of Polymorphism in Continuous Crystallization via Mixed Suspension Mixed Product Removal 
Systems Cascade Design. Cryst. Growth Des. 2015, 15 (7), 3374-3382. 
9. Sypek, K.; Burns, I. S.; Florence, A. J.; Sefcik, J., In Situ Monitoring of Stirring Effects 
on Polymorphic Transformations during Cooling Crystallization of Carbamazepine. Cryst. 
Growth Des. 2012, 12 (10), 4821-4828. 
10. Kitamura, M., Controlling factor of polymorphism in crystallization process. J. Cryst. 
Growth 2002, 237-239, 2205-2214. 
11. Kitamura, M.; Ishizu, T., Kinetic effect of L-phenylalanine on growth process of L-
glutamic acid polymorph. J. Cryst. Growth 1998, 192 (1), 225-235. 
12. Poornachary, S. K.; Han, G.; Kwek, J. W.; Chow, P. S.; Tan, R. B. H., Crystallizing 
Micronized Particles of a Poorly Water-Soluble Active Pharmaceutical Ingredient: Nucleation 
Enhancement by Polymeric Additives. Cryst. Growth Des. 2016, 16 (2), 749-758. 
13. Klapwijk, A. R.; Simone, E.; Nagy, Z. K.; Wilson, C. C., Tuning Crystal Morphology 
of Succinic Acid Using a Polymer Additive. Cryst. Growth Des. 2016, 16 (8), 4349-4359. 
14. Black, S. N.; Davey, R. J.; Halcrow, M., The kinetics of crystal growth in the presence 
of tailor-made additives. J. Cryst. Growth 1986, 79 (1, Part 2), 765-774. 
- 116 - 
 
15. Van Rosmalen, G. M.; Bennema, P., Characterization of additive performance on 
crystallization: Habit modification. J. Cryst. Growth 1990, 99 (1, Part 2), 1053-1060. 
16. Padrela, L.; Zeglinski, J.; Ryan, K. M., Insight into the Role of Additives in Controlling 
Polymorphic Outcome: A CO2-Antisolvent Crystallization Process of Carbamazepine. Cryst. 
Growth Des. 2017, 17 (9), 4544-4553. 
17. Padrela, L.; Rodrigues, M. A.; Velaga, S. P.; Matos, H. A.; de Azevedo, E. G., 
Formation of indomethacin–saccharin cocrystals using supercritical fluid technology. Eur. J. 
Pharm. Sci. 2009, 38 (1), 9-17. 
18. Padrela, L.; Rodrigues, M. A.; Velaga, S. P.; Fernandes, A. C.; Matos, H. A.; de 
Azevedo, E. G., Screening for pharmaceutical cocrystals using the supercritical fluid enhanced 
atomization process. J. Supercrit. Fluids  2010, 53 (1), 156-164. 
19. Padrela, L.; Rodrigues, M. A.; Tiago, J.; Velaga, S. P.; Matos, H. A.; de Azevedo, E. 
G., Insight into the Mechanisms of Cocrystallization of Pharmaceuticals in Supercritical 
Solvents. Cryst. Growth Des. 2015, 15 (7), 3175-3181. 
20. Padrela, L.; Rodrigues, M. A.; Duarte, A.; Dias, A. M. A.; Braga, M. E. M.; de Sousa, 
H. C., Supercritical carbon dioxide-based technologies for the production of drug 
nanoparticles/nanocrystals – A comprehensive review. Adv. Drug Delivery Rev. 2018, 131, 22-
78. 
21. Rodrigues, M. A.; Tiago, J. M.; Padrela, L.; Matos, H. A.; Nunes, T. G.; Pinheiro, L.; 
Almeida, A. J.; de Azevedo, E. G., New Thermoresistant Polymorph from CO2 
Recrystallization of Minocycline Hydrochloride. Pharm. Res. 2014, 31 (11), 3136-3149. 
22. Long, B.; Ryan, K. M.; Padrela, L., From batch to continuous — New opportunities for 
supercritical CO2 technology in pharmaceutical manufacturing. Eur. J. Pharm. Sci. 2019, 137, 
104971. 
23. Abuzar, S. M.; Hyun, S.-M.; Kim, J.-H.; Park, H. J.; Kim, M.-S.; Park, J.-S.; Hwang, 
S.-J., Enhancing the solubility and bioavailability of poorly water-soluble drugs using 
supercritical antisolvent (SAS) process. Int. J. Pharm. 2018, 538 (1-2), 1-13. 
24. Jung, J.; Perrut, M., Particle design using supercritical fluids: literature and patent 
survey. J. Supercrit. Fluids  2001, 20 (3), 179-219. 
25. Subramaniam, B.; Rajewski, R. A.; Snavely, K., Pharmaceutical Processing with 
Supercritical Carbon Dioxide. J. Pharm. Sci. 1997, 86 (8), 885-890. 
26. Uchida, H.; Manaka, A.; Matsuoka, M.; Takiyama, H., Growth Phenomena of Single 
Crystals of Naphthalene in Supercritical Carbon Dioxide. Cryst. Growth Des. 2004, 4 (5), 937-
942. 
27. Matson, D. W.; Fulton, J. L.; Petersen, R. C.; Smith, R. D., Rapid expansion of 
supercritical fluid solutions: solute formation of powders, thin films, and fibers. Ind. Eng. 
Chem. Res. 1987, 26 (11), 2298-2306. 
- 117 - 
 
28. Matson, D. W.; Petersen, R. C.; Smith, R. D., Production of powders and films by the 
rapid expansion of supercritical solutions. J. Mater. Sci. 1987, 22 (6), 1919-1928. 
29. Gallagher, P. M.; Coffey, M. P.; Krukonis, V. J.; Klasutis, N., Gas Antisolvent 
Recrystallization: New Process To Recrystallize Compounds Insoluble in Supercritical Fluids. 
In Supercritical Fluid Science and Technology, American Chemical Society: 1989; Vol. 406, 
pp 334-354. 
30. Chen, W.; Hu, X.; Hong, Y.; Su, Y.; Wang, H.; Li, J., Ibuprofen nanoparticles prepared 
by a PGSS™-based method. Powder Technol. 2013, 245, 241-250. 
31. Reverchon, E., Supercritical-Assisted Atomization To Produce Micro- and/or 
Nanoparticles of Controlled Size and Distribution. Ind. Eng. Chem. Res. 2002, 41 (10), 2405-
2411. 
32. Schindler, W. New N-heterocyclic compounds. 1960. 
33. Grzesiak, A. L.; Lang, M.; Kim, K.; Matzger, A. J., Comparison of the Four Anhydrous 
Polymorphs of Carbamazepine and the Crystal Structure of Form I**Supplementary material: 
X‐ray crystallographic information file (CIF) of triclinic CBZ (form I) is available. J. Pharm. 
Sci. 2003, 92 (11), 2260-2271. 
34. Czernicki, W.; Baranska, M., Carbamazepine polymorphs: Theoretical and 
experimental vibrational spectroscopy studies. Vib. Spectrosc. 2013, 65, 12-23. 
35. Hu, C.; Testa, C. J.; Shores, B. T.; Wu, W.; Shvedova, K.; Born, S. C.; Chattopadhyay, 
S.; Takizawa, B.; Mascia, S., An experimental study on polymorph control and continuous 
heterogeneous crystallization of carbamazepine. CrystEngComm 2019, 21 (34), 5076-5083. 
36. Behme, R. J.; Brooke, D., Heat of Fusion Measurement of a Low Melting Polymorph 
of Carbamazepine That Undergoes Multiple-Phase Changes During Differential Scanning 
Calorimetry Analysis. J. Pharm. Sci. 1991, 80 (10), 986-990. 
37. Kobayashi, Y.; Ito, S.; Itai, S.; Yamamoto, K., Physicochemical properties and 
bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 2000, 193 (2), 137-
146. 
38. Bettini, R.; Bonassi, L.; Castoro, V.; Rossi, A.; Zema, L.; Gazzaniga, A.; Giordano, F., 
Solubility and conversion of carbamazepine polymorphs in supercritical carbon dioxide. Eur. 
J. Pharm. Sci. 2001, 13 (3), 281-286. 
39. Kalikin, N.; Kurskaya, M.; Ivlev, D.; Krestyaninov, M.; Oparin, R.; Kolesnikov, A.; 
Budkov, Y.; Idrissi, A.; Kiselev, M., Carbamazepine solubility in supercritical CO $ _2 $: a 
comprehensive study. arXiv 2020. 
40. Harris, R. K.; Ghi, P. Y.; Puschmann, H.; Apperley, D. C.; Griesser, U. J.; Hammond, 
R. B.; Ma, C.; Roberts, K. J.; Pearce, G. J.; Yates, J. R., Structural studies of the polymorphs 
of carbamazepine, its dihydrate, and two solvates. Org. Process Res. Dev.  2005, 9 (6), 902-
910. 
- 118 - 
 
41. Zhu, M.; Wang, Y.; Li, F.; Bao, Y.; Huang, X.; Shi, H.; Hao, H., Theoretical model and 
experimental investigations on solution-mediated polymorphic transformation of theophylline: 
From polymorph I to polymorph II. Crystals 2019, 9 (5), 260. 
42. Hilfiker, R.; De Paul, S. M.; Szelagiewicz, M., Approaches to Polymorphism 
Screening. In Polymorphism in the Pharmaceutical Industry, Hilfiker, R., Ed. Wiley-VCH: 
2006; pp 287-308. 
43. Guthrie, S. M.; Smilgies, D.-M.; Giri, G., Controlling Polymorphism in Pharmaceutical 
Compounds Using Solution Shearing. Cryst. Growth Des. 2018, 18 (2), 602-606. 
44. Esfandiari, N.; Ghoreishi, S. M., Ampicillin Nanoparticles Production via Supercritical 
CO2 Gas Antisolvent Process. AAPS PharmSciTech 2015, 16 (6), 1263-1269. 
45. Esfandiari, N.; Ghoreishi, S. M., Kinetics modeling of ampicillin nanoparticles 
synthesis via supercritical gas antisolvent process. J. Supercrit. Fluids  2013, 81, 119-
127. 
46. Fusaro, F.; Mazzotti, M.; Muhrer, G., Gas Antisolvent Recrystallization of Paracetamol 
from Acetone Using Compressed Carbon Dioxide as Antisolvent. Cryst. Growth Des. 2004, 4 
(5), 881-889. 
47. Long, B.; Walker, G. M.; Ryan, K. M.; Padrela, L., Controlling Polymorphism of 
Carbamazepine Nanoparticles in a Continuous Supercritical-CO2-Assisted Spray Drying 
Process. Cryst. Growth Des. 2019. 
48. Cruz Cabeza, A. J.; Day, G. M.; Motherwell, W. D. S.; Jones, W., Solvent inclusion in 
form II carbamazepine. Chem. Commun. 2007,  (16), 1600-1602. 
49. O’Mahony, M. A.; Seaton, C. C.; Croker, D. M.; Veesler, S.; Rasmuson, Å. C.; Hodnett, 
B. K., Investigation into the Mechanism of Solution-Mediated Transformation from FI to FIII 
Carbamazepine: The Role of Dissolution and the Interaction between Polymorph Surfaces. 
Cryst. Growth Des. 2013, 13 (5), 1861-1871. 
50.  Hua, X.; Curtis, J.; Guo, Y.; Hancock, B.; Ketterhagen, W.; Wassgren, C. The Internal 
Loads, Moments, And Stresses In Rod-Like Particles In A Low-Speed, Vertical Axis Mixer. 




- 119 - 
 
Chapter 4. Controlling Polymorphism of Carbamazepine 
in a Continuous Supercritical CO2-Assisted Spray Drying 
Process  
The contents of this chapter appear in Crystal Growth & Design, 2019, 19 (7), 3755-3767. 
 
4.1 Introduction 
The transition from batch to continuous processing is beginning to gain momentum in the 
pharmaceutical industry in an attempt to achieve greater control over the physical properties of 
poorly soluble APIs which are set to dominate the market in upcoming years. 1-2 
The API selected for this chapter is the same compounds that was reported in Chapter 3, 
carbamazepine (CBZ), a BCS class II drug.3 Carbamazepine was considered a suitable model 
candidate to study polymorphism in crystallization processes as it exists in at least four 
anhydrous polymorphs, discussed in earlier chapters, and was the compound selected for batch 
scCO2 processing.
4-5 To overcome the concerns of poor solubility in APIs, two popular 
approaches that have been successfully implemented include (1) generating amorphous or 
metastable forms of the drug and (2) reducing the particle size.6-9  
It is estimated that more than 50% of active pharmaceutical ingredients have more than one 
polymorphic form.10-11 Isolating pure polymorphic forms has proven to be a challenging task, 
despite many different methods employed to achieve this.12-14 Impurities, in the form of various 
other polymorphic forms, are one of the most common obstacles that the pharmaceutical 
industry face during the manufacture of an API.15-17Although continuous crystallization boasts 
higher levels of control over some process variables when compared to batch methods, 
approaches which control polymorphism of continuous crystallization methods have yet to be 
comprehensively achieved. Only recently have researchers attempted to address the complexity 
of controlling polymorphism in continuous crystallization methods.18-20 As a result of this, the 
pharmaceutical industry have placed their focus on polymorphic studies to avoid adverse 
effects such as spontaneous conversion between different crystalline phases and to take 
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advantage of beneficial effects such as improved physicochemical properties and patent life 
extensions.15, 21-2223-24 As described in section 1.2.4, polymorphism can be affected by various 
processing conditions in pharmaceutical crystallization such as the type of solvent, 
temperature, antisolvent,  the use of additives or surfactants and, specifically, the crystallization 
mode used (batch versus continuous).18, 25-30  
The use of additives to control polymorphism has been explored in Chapter 3 and by many 
researchers in an attempt to isolate pure forms of both stable and metastable polymorphs of 
various compounds. 26, 31-35 Davey et al. have studied the effect of additives on generating and 
isolating metastable polymorphs or various compounds.32-33 In many cases when additives are 
selected for this purpose, they have been shown to incorporate themselves, stereoselectively, 
into growing faces thereby inhibiting further growth of these faces, promoting alternative 
polymorphic forms. 32-33, 36-37 Another method that may also be utilized to control the 
polymorphism of different compounds includes the confinement of crystallization habitats.38-
39 It has been reported that the size constraint imposed by nano- and submicron- scale pores 
during crystallization can influence the final polymorphic form obtained. 39-41 The confinement 
can cause the relative free-energy values for various polymorphs to become almost equivalent, 
thereby reducing the preference for one polymorphic form to crystallize over another.40-42 
This study reports the transition of a supercritical antisolvent crystallization method from the 
batch method (GAS) presented in Chapter 3 to a continuous method, a trend that is encouraged 
by most regulatory bodies for pharmaceutical manufacturing processes.43-44  Currently, 
pharmaceutical companies are reluctant to make the switch as designing a continuous 
manufacturing process typically requires a higher level of process control and monitoring than 
batch manufacturing processes in addition to further investment in the facilities.44-46 However, 
scaling up represents itself as one of the major obstacles that limits pharmaceutical processing 
due to difficulties arising from the prediction of lab-scale to industrial-scale evolutions.45 One 
of the selling points for continuous manufacturing is that the requirement for scaling up is 
removed as emphasis is shifted to scaling down and out instead. Evidence shows that making 
the switch could prove worthwhile in the long term as continuous manufacturing provides: 47-
48 
 Fewer steps in the process, resulting in faster production times. 
 Lower costs. 
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 Real time in-line monitoring of experimental runs using quality-by-design approaches.  
 Possibility of scaling-down instead of scaling-up. 
 
Continuous processing features heavily in most fields of research as it is expected that these 
methods will dominate the first-choice crystallization mode for the pharmaceutical industry in 
the near future. Continuous methods such as plug flow crystallization, milling, high-pressure 
homogenization and antisolvent methods have recently become a popular and effective method 
to control particle size, shape and polymorphic form of APIs.49-53 Supercritical fluid (SCF) 
approaches have also emerged as methods which can be employed in batch, semi-continuous 
and, more recently, in continuous modes (in spray drying methods which use CO2 as the 
atomizing fluid) to generate unique polymorphic forms of APIs which are not reproducible by 
other methods.54 Supercritical fluid methods provide advantages over conventional 
precipitation methods with respect to generating high levels of supersaturation, polymorphic 
control, particle size control as well as providing low levels of residual solvent in the final 
product.55-59 Carbon dioxide is employed in this study to feature as an antisolvent as well as a 
spray enhancer based on its favourable physical properties.26, 59 59-60 Supercritical CO2 (scCO2) 
has a low viscosity and a high diffusivity coefficient making it a viable candidate for antisolvent 
processing and allows the CO2 to be easily atomized.
59, 61Additionally, scCO2 demonstrates a 
high miscibility with the organic solvent employed in this study (methanol), relative to CBZ. 
71, 72 An additional benefit of using scCO2 as an antisolvent is that there is less risk of a hydrate 
forming during processing as would be a concern when using water, a common antisolvent in 
pharmaceutical crystallization.62 Additionally, when using water, CBZ can spontaneously 
absorb water and convert to a dihydrate crystalline structure that demonstrates a lower 
dissolution rate than other CBZ polymorphs.69 Carbamazepine can also form agglomerates 
when placed directly in water without the use of surfactants.70  
In the scCO2 antisolvent-assisted nano spray drying method (SASD) discussed, scCO2 mixes 
with the solution containing the drug and additives in a small volume high pressure co-axial 
nozzle. Supersaturation is induced in the nozzle and nucleation follows. Unlike other methods 
such as the gas antisolvent (GAS) crystallization method presented in Chapter 3, atomization 
is employed by the SASD method which results in the generation of a spray of ultra-fine 
droplets in which the solvent is removed by thermal means. This process is an attractive method 
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for the pharmaceutical industry as it can be easily adapted to existing conventional spray dryers. 
As the region of high pressure is concentrated to the small volume mixing chamber (nozzle), 
there is little requirement for specialist high-pressure equipment.  
This study builds on a foundation generated from two previous studies. The first is by Padrela 
et al. demonstrated that the use of additives provides control over the molecular packing of 
CBZ molecules at the pre-nucleation stage using the GAS method, resulting in the production 
of specific polymorphic forms of CBZ.26 In this work, density functional theory modelling 
predicts that nonpolar parts of CBZ molecules interact with the nonpolar tails of the anionic 
additive, sodium stearate (SS), resulting in the templating of empty columnar channels which 
SS can interact with for the generation of CBZ form II. The absence of these channels is 
observed when sodium dodecyl sulfate is selected, which causes templating of CBZ to 
represent form III.26 The second is presented in Chapter 3 and demonstrates that these anionic 
additives (SS and SDS) can provide polymorphic control over a far greater range of processing 
conditions using a GAS method than what was first described by Padrela et al. in 2017.  
The objective of the work presented in this chapter is to investigate if this effect can be 
replicated in a continuous SASD method, as the kinetics and mechanisms for crystallization in 
each of these methods (batch versus continuous) are expected to be different. Supercritical CO2 
nano spray drying and related supercritical antisolvent methods typically promote the 
formation of metastable crystalline forms of APIs by generating high levels of supersaturation 
in the mixing region (nozzle) and prevent further conversion to more stable forms due to their 
fast crystallization and drying steps.57, 63 However, our novel methodology presented herein 
uses molecular additives in an SASD method to enable control over the final API polymorphic 
form generated (exemplified for CBZ as our model system). This approach consists of 
continuously templating the desired polymorphic form of CBZ in the nozzle (where scCO2 
antisolvent mixes with the solution containing the drug and the additive) by using specific 
additives before crystallization takes place (which will mostly occur after the nozzle exit during 
the spray drying step).  
In this work, a supercritical antisolvent method (GAS), identical to that discussed in Chapter 3 
was employed for the production of distinct polymorphic forms of CBZ microparticles, is 
converted into a continuous SASD method for the production of distinct polymorphic forms of 
CBZ particles. A design of experiments (DoE) methodology was applied to study the influence 
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of selected process parameters (solution feed rate and additive quantity) on the polymorphic 
outcome of CBZ produced by the SASD method. The mass ratio of scCO2 and methanol 
required to achieve supersaturation and consequently precipitation of CBZ was determined 
using a batch supercritical antisolvent method, and this information was used to select the 
required processing conditions in SASD to ensure that supersaturation is achieved. This paper 
also aims to clarify if the influence of additives on the polymorphism of CBZ is only caused 
by the antisolvent effect of CO2 in the SASD nozzle or if it can also be achieved using lower 
supersaturation levels or by conventional spray drying. 
 
4.2 Experimental  
4.2.1 Materials 
Carbamazepine (form III) was purchased from Kemprotec. Maltitol, sodium stearate (SS), 
ethyl cellulose, sodium dodecyl sulfate (SDS), sodium deoxycholate and pluronic F-127 were 
purchased from Sigma Aldrich and used without further purification (purity was >99.9%). 
Eudragit L-100-55 was a gift from Evonik Industries. Carbon dioxide (99.98%) was supplied 
by BOC (Ireland). Table 1 summarizes the different types of additives used in this work. These 
additives were selected from a study by Padrela et al. where they were shown to produce 
different polymorphic forms of carbamazepine in a batch supercritical antisolvent (GAS) 
method.26 
 
Table 1. Type of Additives Used in the Preparation of Carbamazepine Solutions in 





Anionic polymers Non-ionic polymers 
Sodium stearate Maltitol Eudragit L-100-55 
Ethyl cellulose 











4.2.2 Solution Preparation 
For the precipitation experiments involving CBZ and using the GAS method, 50 mg of CBZ 
was dissolved in 1 ml of methanol and placed in an ultrasonic bath until the solids were 
completely dissolved (~5 minutes). This concentration (50 mg/ml) is below the maximum 
solubility of CBZ in methanol at room temperature (80 mg/ml) to avoid crystallization which 
may lead to blockages inside the nozzle during SASD processing. For the production of 
carbamazepine particles using the SASD method, CBZ with/without additives was dissolved 
in 20 ml of methanol (50.0 mg/ml) and placed in an ultrasonic bath for a similar period of time 
as mentioned above. When using additives for the preparation of a 50 mg/ml CBZ solution in 
methanol, 5% w/w (2.5 mg/ml) of each additive was dissolved in the CBZ solutions. When low 
concentration experimental runs (SASD 20, 21 and 22) were completed, the concentration of 
CBZ was reduced to 17.0 mg/ml and 5% w/w of specific additives (0.8 mg/ml) were added. 
The solutions were then filtered through a 0.2µm pore size nylon filter (Whatman Inc., Florham 
Park, NJ) to remove any undissolved material.  
 
4.2.3 Precipitation of CBZ in a Batch Supercritical Antisolvent Method 
In order to determine the pressures and the mass ratios of solution to scCO2 at which 
supersaturation would occur in the SASD nozzle, precipitation of CBZ was performed using a 
batch supercritical antisolvent method. This apparatus consisted of a 10 cm3 stainless steel 
high-pressure vessel shown in Figure 1 and as described elsewhere.26 The pressure was 
determined using a pressure transducer (Omega model PX603). A high-pressure stainless steel 
storage vessel was used to store the CO2 to allow it to reach the set temperature inside a 
temperature-controlled (monitored by a T-type thermocouple) air chamber. A solution 
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containing 50 mg of CBZ dissolved in 1 ml of methanol was placed inside the high-pressure 
vessel and compressed with CO2 at a rate of 1 bar/minute. During the addition of CO2, the 
solution was subjected to magnet stirring at 600 rpm to facilitate homogeneity. Once 
precipitation was visually observed through the borosilicate window, the value was recorded 
(Table 6) and the vessel was depressurized. This value was determined to be the antisolvent 
crystallization point. Although this methodology does not consider that the batch and 
continuous processes are kinetically different, it provides an indication on the pressure and 
mass ratio of scCO2 to methanol at which supersaturation should occur in the SASD high-
pressure nozzle. Each solubility experiment was performed at least three times to ensure 
repeatability. 
 
Figure 1.  Schematic diagram of the GAS apparatus used for precipitation pressure testing. 1, 
CO2 cylinder; 2, gas compressor; 3, temperature-controlled air chamber; 4, stainless steel 
storage cylinder; 5, magnetic stirrer plate; 6, high-pressure vessel; 7, exit valve; PIC: pressure 
controller; TC: temperature controller. 
 
4.2.4 Supercritical CO2 Antisolvent-Assisted Nano Spray Drying (SASD) 
Figure 2 shows a schematic of the SASD apparatus. The primary spray drying apparatus 
consists of three main zones that are representative of the SASD method. The first zone is the 
high-pressure small-volume stainless steel nozzle (number 5 in Figure 2) using a 120 µm nozzle 
orifice size, where both mixing of CO2 with the CBZ solution, and supersaturation/antisolvent 
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nucleation occur. The mixing volume for this section is 0.01 cm3. These nozzle dimensions are 
presented in greater detail in Figure 3. The second zone is the drying chamber which is a 1000 
cm3 vessel (number 6 in Figure 2) surrounded by a temperature-controlled water jacket which 
facilitates the drying of the solvent once atomized. The final zone is the particle collector, 
which consists of a metal filter (number 7 in Figure 2) and filter nylon paper with 0.2 µm pore 
size. 
During an SASD experiment, CO2 was compressed using a Teledyne ISCO 260D pump. The 
pressure and temperature were controlled as described above. The nozzle was maintained at 
50°C by using heating resistors in close proximity to the nozzle. The CBZ methanol solution 
was pumped by a Waters 515 HPLC pump to the high-pressure SASD nozzle where it mixed 
with the scCO2. After the solution was passed through the nozzle, the CO2 was depressurized, 
and any residual solvent was evaporated during the spray drying step. The samples were 
harvested and stored in a desiccator prior to characterization to prevent exposure to humidity 
which could result in polymorphic conversions over time. 
Three control SASD experiments were performed at different solution flow rates (0.10, 0.25 
and 0.40 ml/min) to identify the polymorphic form of CBZ obtained by the SASD method in 
the absence of additives (Table 2). The pressure selected for these experiments was 120 Bar 
(which corresponded to a solution to SCF ratio of 0.005-0.021) as it was determined to be 
sufficient for antisolvent crystallization (a solution to SCF mass ratio of 0.5 was determined to 
be the maximum value allowable  using a batch supercritical antisolvent method) to occur. 
Upon completion of these experiments , several additives (selected from the work reported by 
Padrela et al.26) were added to the CBZ methanol solutions and processed using the SASD 
method, as reported in Table 3. The pressure selected for these experiments was 170 Bar 
(solution to SCF ratio of 0.011) which was sufficiently over the pressure required for 
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Table 2. List of CBZ Solid Forms Obtained at Different Solution Flow Rates without the 










SASD 1  0.10 0.079 0.005 
SASD 2 0.25 0.198 0.013 
SASD 3 0.40 0.316 0.021 
aFor all SASD experiments listed in Table 2, pressure was kept at 120 Bar and CO2 flow rate 
was kept at approximately 15.0 g/min (30 ml/min). Temperature was 50°C. The concentration 
of active ingredient (CBZ) was 50 mg/ml in methanol. FSolution: solution flow rate; RFlow Ratio: 




Figure 2. Schematic diagram of the continuous SASD apparatus. 1, CO2 cylinder; 2, gas 
compressor; 3, CBZ solution flask connected to pump; 4, temperature-controlled CO2 storage 
cylinder; 5, high-pressure nozzle; 6, drying chamber; 7, filter; 8, Temperature controlled air 
chamber; TC: temperature controller; PIC: pressure controller;. 
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SASD 4 No additive 50.0 170 0.011 












































bFor all SASD additive screening experiments, temperature and solution flow rate was 
maintained at 50 °C and 0.20 g/min (0.25 ml/min), respectively. When additives were used, 
the concentration of each additive in the CBZ solutions was 5% w/w. P: pressure inside the 
high-pressure nozzle; C[CBZ]: concentration of CBZ in methanol. 
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4.2.5 Design of Experiments (DoE) 
When changing the type of additives, as listed in Table 3, 5% w/w of certain additives was 
determined to be a sufficient amount to produce pure polymorphs of CBZ. Two additives, SDS 
and SS were selected for a DoE approach, as shown in Figure 4. This DoE investigated the 
influence of the solution flow rate and % (w/w) additive on the polymorphism of CBZ obtained 
by the SASD method, as reported in Table 4. The pressure used for both of these DoE 
approaches was 120 Bar. This was as a result of higher pressures (170 Bar) from the screening 
runs in Table 3 resulted in blockages of the nozzle due to significant precipitation taking place 
prior to passing through the small volume (0.01 cm3) nozzle. 
 
Figure 4. Design of Experiment schematic to investigate the effect of additive quantity and 
solution flow rate on the polymorphic forms of CBZ obtained by the SASD method. 
 
 
Table 4. Experimental Conditions Used in SASD Runs for a DoE using SDS and SS as 







%Additive                                     
(w/w) 
FSolution   
(ml/min) 







1 SASD 12 SDS 1 0.10 0.079 0.005 I and III 
2 SASD 13 SDS 10 0.10 0.079 0.005 I and III 
3 SASD 14 SDS 10 0.40 0.316 0.021 I and III 
4 SASD 15 SDS 1 0.40 0.316 0.021 III 
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5 SASD 8 SDS 5 0.25 0.198 0.013 I and III 
6 SASD 16 SS 1 0.10 0.079 0.005 I and II 
7 SASD 17 SS 10 0.10 0.079 0.005 I and II 
8 SASD 18 SS 10 0.40 0.316 0.021 I and II 
9 SASD 19 SS 1 0.40 0.316 0.021 I and II 
10 SASD 6 SS 5 0.25 0.198 0.013 II 
cFor all DoE runs, concentration of CBZ in methanol was 50 mg/ml, temperature was 50°C, 
pressure was maintained at 120 bar and CO2 flow rate was kept at approximately 15.0 g/min 
(30 ml/min). %Additive: proportion of additive used in each experimental run; FSolution: solution 
flow rate; RFlow Ratio: mass flow-rate ratio of the solution to SCF (CO2). 
 
4.2.6 Conventional spray drying 
All samples (SD 1 to 6) were spray dried by a Büchi B-290 mini spray dryer. The inert loop 
was enabled in conjunction with a condenser at −20 °C to facilitate the use of organic solvents. 
The CBZ solid particles were collected by a high efficiency cyclone. A 2-fluid nozzle with 0.7 
mm cap was employed for atomizing the methanol solutions containing CBZ with/without 
additives. Nitrogen was selected as the atomizing gas with flow rate of ∼473 NL/h (P = 0.10 
mPa and T = 0°C) and the aspirator was set to 100 % (35.0 m3/h). The final spray dried powders 
were collected and transferred to a desiccator after production until further characterization. A 
list of all the experiments performed using the Büchi B-290 mini spray dryer are reported in 
Table 5. 
Table 5. Experimental Conditions used in Conventional Spray Drying (SD) Runs and List 










SD 1 No additive - 50.0 IV 
SD 2 SS 5 50.0 IV 
SD 3 SDS 5 50.0 IV 
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SD 4 No additive - 17.0 IV 
SD 5 SS 5 17.0 IV 
SD 6 SDS 5 17.0 IV 
d For all runs, outlet temperature was 50 °C. %Additive: quantity of additive used; C[CBZ]:  
concentration of CBZ in methanol. 
 
4.3 Results and Discussion 
4.3.1 Precipitation of CBZ in a Batch Supercritical Antisolvent Process 
The precipitation of CBZ by supercritical antisolvent crystallization was experimentally 
observed in a batch high-pressure vessel, prior to performing SASD experiments. These batch 
precipitation experiments contributed to our understanding of the pressures and the solution to 
CO2 antisolvent mass ratios necessary to induce supersaturation and consequently antisolvent 
nucleation of CBZ in the mixing chamber of the SASD nozzle. A range of ± 5 °C of the 
operating temperature in the batch supercritical antisolvent method was selected to account for 
any possible temperature drop (caused by heat loss in the nozzle due to the Joule-Thomson 
effect) or increase (caused by an overcompensation of the heating resistors in the nozzle). Table 
6 shows that at solution to CO2 ratios between 0.49-0.55, precipitation of CBZ occurred due to 
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Table 6. Experimental Conditions Required for the Precipitation of CBZ in a Batch 
Supercritical Antisolvent Method (GAS)e  
T (°C) P (bar) 
RMass Ratio 
Solution/SCF 
45 87.2 ± 0.4 0.55 
50 96.6 ± 0.1 0.50 
55 101.7 ± 1.0 0.49 
eFor all precipitation tests, concentration of CBZ in methanol was 50 mg/ml, stirring rate was 
600 rpm and pressure was increased at a rate of 10 bar/min until reaching the final pressure. P: 
pressure; T: temperature; RMass Ratio: mass ratio of solution to SCF. 
 
4.3.2 Production of CBZ Particles by the SASD Method with/without 
Additives 
In order to ensure that the primary crystallization mechanism in the SASD method would be 
initiated by antisolvent supersaturation/nucleation in the nozzle, a working pressure of 170 bar 
was selected for all screening experiments (mass flow ratio of solution to supercritical fluid 
was 0.013 which was suitable to induce supersaturation). Despite a short residence time of the 
fluids (CO2 and drug solution), portions of crystals which led to blockages were collected in 
the SASD nozzle during each experiment conducted at this high pressure. As a result, the 
pressure was reduced to 120 bar (mass flow ratio of solution to supercritical fluid is between 
0.005-0.021) for DoE experiments, which is still sufficient to induce supersaturation by the 
antisolvent effect, and helps minimizing any blockages in the SASD nozzle due to crystal 
growth of CBZ.  
 
The aim of this work is to investigate whether CBZ polymorphism can be controlled in a 
continuous supercritical crystallization method, as previously demonstrated in a batch 
supercritical crystallization method26. Padrela et al. showed that form II and form III of CBZ 
could be obtained using a batch supercritical method when using the anionic additives, sodium 
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stearate and sodium dodecyl sulfate, respectively. 26 Prior to investigating whether additives 
could control the polymorphic form of CBZ during the SASD method, three control 
experiments were completed at each of the different solutions rates used in this study without 
the use of additives. It must be noted that the nano/sub-micron size range of the CBZ particles, 
as explained by the Scherrer equation, influences the broadness of the PXRD peaks observed 
throughout this study. 
 
 
Figure 5. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, and 
III) from the Cambridge Structural Database (CSD)64-66 and CBZ samples processed without 
additives by the SASD method at various solution flow rates.  
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Figure 5 shows that the metastable form I, with small impurities from the stable form (III) of 
CBZ was produced at each flow rate without the use of additives. This result would serve as a 
control to investigate if certain additives have an effect on the polymorphism of CBZ using the 
SASD method. The stability of these samples was investigated after eighteen months and 




A preliminary SASD screening with the additives reported in Table 3 appeared to uphold the 
reported results by Padrela et al. for certain additives in their batch supercritical process.26 Each 
experiment presented in Table 3 and Figure 6 was repeated at least three times.  
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Figure 6. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, and 
III) from the Cambridge Structural Database64-66 and CBZ samples processed with additives 
produced by the SASD method (SASD 4-11), reported in Table 3.  
The results obtained from the screening runs presented in Figure 6 show that (1) amorphous 
CBZ was obtained when using ethyl cellulose (SASD 7) as an additive, (2) PXRD-pure CBZ 
form I was obtained when using either maltitol (run SASD 5) or L-eudragit 100-55 (run SASD 
9) as additives, (3) PXRD-pure CBZ form II was obtained when using sodium stearate (SASD 
6) as the additive, and (4) PXRD-pure CBZ form III was obtained when using sodium dodecyl 
sulfate (run SASD 8) as an additive. The anionic additives sodium stearate (which promotes 
the formation of CBZ form II) and sodium dodecyl sulfate (which promotes the formation of 
CBZ form III) were selected for further investigation. A DoE approach was applied for each 
additive to determine if the results obtained would be as robust across a range of distinct 
processing conditions. The processing parameters selected for this DoE study were; i) the % of 
additive (w/w) used and ii) the solution flow rate. Additive quantity was selected as a parameter 
to investigate if a minimum and maximum threshold could be determined where the additive 
would have an effect on the final polymorphic form obtained. Solution flow rate was selected 
as a parameter due to its ability to vary the solution to scCO2 antisolvent mass flow ratio, as 
observed in Table 2. This ratio is expected to affect the supersaturation of the CBZ solution in 
the SASD nozzle, which may influence the polymorph obtained. This ratio may also provide 
an insight into the crystallization mechanism involved in our SASD experiments which will be 
discussed in this chapter. 
 
The primary crystallization mechanism is predicted to be antisolvent nucleation/crystallization, 
induced by high supersaturation levels inside the high-pressure SASD nozzle. This prediction 
stems from the results obtained in the precipitation of carbamazepine in a batch supercritical 
antisolvent method. As the pressure increases, the solvating power and the miscibility of CO2 
with methanol increase, causing CBZ to precipitate. An alternative mechanism for the 
production of these CBZ particles is the evaporation of solvent during the spray drying step in 
the drying chamber. This drying step is necessary in this method to remove the solvent 
(methanol) from the atomized suspension droplets and convert them into a fine dried powder. 
The removal of solvent must be efficient to prevent any polymorphic conversion of CBZ in the 
final samples. In attempts to replicate the antisolvent mechanism observed in the batch 
precipitation process, a solution to CO2 mass flow ratio of 0.011 was used, which falls below 
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the maximum allowed ratio of 0.50 for antisolvent crystallization to occur at a working 
temperature of 50 °C (see Table 6). At the end of these experiments, upon disassembling the 
apparatus, a small portion of fine powder was observed inside the mixing chamber of the SASD 
nozzle, indicating that antisolvent crystallization of CBZ occurred in the nozzle during 
screening experiments.  
 
Figure 7 presents a DoE to investigate the effect of additive (SDS) quantity and solution flow 
rate on the polymorphic forms of CBZ obtained by SASD.  
 
 
Figure 7. a) Design of experiments schematic to investigate the effect of additive (SDS) 
quantity and solution flow rate on the polymorphic forms of CBZ obtained by the SASD 
method. b) Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database64-67 and CBZ samples processed through 
SASD with SDS as the additive. Asterisks (*) represent unidentified peaks (9° 2 Theta) that 
cannot be attributed to any CBZ polymorph or additive. Experimental conditions as described 
in Table 4. 
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Figure 7 shows that the process parameters studied in this DoE (solution flow rate, % of 
additive) do not seem to significantly influence the polymorphic outcome of CBZ. A lower 
solution flow rate decreases the RFlow Ratio, described in table 4, and, thus, increases the 
supersaturation inside the nozzle. However, despite the varying supersaturation levels, no 
significant differences are observed in the final polymorphic form obtained using this method. 
In a batch supercritical antisolvent method, SDS favours the formation of pure form III of CBZ. 
26Similarly, in a continuous antisolvent-assisted nano spray drying method, form III of CBZ is 
consistently obtained for the different ratios of additive (SDS) and solution flow rates used 
(Figure 7). However, Figure 7 shows the presence of small amounts of impurity peaks at ca. 
12° (2 Theta) corresponding to CBZ form I at DoE Points 1,2,3 and 5. This impurity 
corresponds to the dominant form obtained when additives were not used. Interestingly, an 
unknown peak at ca. 9° (2 Theta) appears in the powder X-ray diffractograms of the samples 
produced in the DoE points 1 to 5 (Figure 7). This peak requires further investigation to explore 
the reason for its appearance when using SDS. Obtaining the stable form of an API is of 
particular interest in a spraying process, such as the SASD method, as the crystallization time 
is in the range of milliseconds and typically generates amorphous or metastable forms due to 
high levels of supersaturation experienced in the nozzle. Similarly, conventional spray drying 
is a flash process (without using CO2) that is typically used to produce amorphous samples, 
which represent the least thermodynamically stable forms of an API. This is due to the fact that 
according to Ostwald’s rule, it is not the most stable but the least stable polymorph that 
crystallizes first. The stability of these samples was investigated after twenty months and, in 
general, showed complete conversion to form III, which is the expected result when the stable 
form was initially obtained. Interestingly, DoE point 1 shows an increased proportion of peaks 
corresponding to form I, which is an unexpected result and warrants further investigation. This 
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Figure 8 presents a schematic of the DoE studied when SS was used as the additive in the 
SASD experiments. Table 4 also shows the experimental conditions used for this DoE using 
SS, including the ratio of solution to SCF which will be discussed in further detail later in this 
section. 
 
Figure 8. a) Design of experiments schematic to investigate the effect of additive (SS) quantity 
and solution flow rate on the polymorphic forms of CBZ obtained by the SASD method. b) 
Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III and IV) from 
the Cambridge Structural Database64-67 and CBZ samples processed through SASD with 
sodium stearate as the additive. Experimental conditions as described in Table 4. 
 
Figure 8 shows that the quantity of SS used influences the polymorphism of CBZ particles 
produced by the SASD method. All samples processed with SS result in the generation of CBZ 
form II as the dominant polymorph observed. At low quantities (1%), the presence of small 
CBZ form I peaks are observed while at higher quantities (10%), the intensity peaks 
- 140 - 
 
corresponding to form I impurities begin to decrease but are not completely removed. At the 
mid-point (DoE Point 10), pure form II was observed which may represent the optimum 
quantity of additive required to control the polymorphic form of CBZ. The results from Figure 
8 indicate that the results presented by Padrela et al., who demonstrated that SS results in the 
templating of CBZ molecules to generate form II, are upheld when employing the SASD 
method. Although most samples generated are not PXRD pure, the presence of minor 
impurities (of CBZ form I) from other polymorphic forms are likely the cause of the method 
(SASD) selected. When additives are not used, there is a tendency to generate CBZ form I 
(seen in Figure 5) and this may be the cause of these minor impurities observed in Figure 8. 
Similar to Figure 7, solution flow rate does not appear to influence the polymorphic form 
generated and this may suggest that the additive selected has a greater impact than varying the 
RFlow Ratio, which has an inverse relationship to supersaturation levels. The stability of the DoE 
points 6-10 was investigated after a period of nineteen months and showed the presence of 
CBZ form I, a polymorph that has a greater stability than form II. This detail is discussed in 
section 4.5.7. 
 
4.3.3 SASD versus Conventional Spray Drying 
An important aspect that distinguishes the SASD method from conventional spray drying 
(which typically uses N2 to dry atomized droplets) concerns the unique precipitation 
mechanism induced by the antisolvent effect of scCO2 in the coaxial nozzle. The 
supersaturation/antisolvent mechanism induced by scCO2 provides a unique feature to spray 
drying processes to control drug polymorphism. In a Büchi conventional spray dryer, there is 
no antisolvent crystallization occurring in the nozzle and evaporation of solvent droplets is the 
governing precipitation mechanism during conventional spray drying. The low miscibility of 
the N2 with organic solvent as well as the poor anti-solvent power provides a good assessment 
of the anti-solvent performance of CO2.
68 Therefore, any differences between the polymorphic 
forms of CBZ obtained from conventional spray drying and the SASD method would strongly 
suggest that the mechanism that governs crystallization and polymorphic control in SASD is 
caused by the antisolvent effect.  
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Table 5 shows the experimental conditions used by the SD method where the additives SS and 
SDS were used. Figure 9 presents PXRD patterns for CBZ samples (with/without additives) 




Figure 9.  Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database64-67 and CBZ samples (with/without 
additives) processed by SASD and SD methods. When additives were selected, the quantity 
was 5% w/w (2.5 mg/ml). 
 
Using processing conditions in SD that were as similar as possible to SASD processing 
conditions (outlet temperature of 50°C; 50 mg/ml of CBZ in methanol), it was observed that 
the metastable form IV of CBZ was obtained by SD which differed from the polymorph 
produced using the SASD method (CBZ form I). The result obtained from conventional spray 
drying corresponds well with the results obtained by Halliwell et al. who concluded that this 
- 142 - 
 
method (SD) is a robust approach for the production of form IV of CBZ.23 Interestingly, when 
either SS or SDS were used in the SD experiments, form IV was also obtained. This result was 
different to those obtained by SASD where form II (when using SS as the additive) and form 
III (when using SDS as the additive) were produced. These results suggest that anionic 
additives influence the polymorphism of CBZ specifically when supersaturation is generated 
by the antisolvent effect.  
 
The SEM analysis in Figure 10 confirms the expected shape for each crystal form produced. 
Carbamazepine particles processed with SS by the SASD method display a long needle-shape 
(Figure 10c) which is characteristic of form II. Block-shaped particles (Figure 10d) were 
observed for CBZ samples processed with SDS, which corresponded to the form III. Needle-
shape particles (Figure 10b) in the form of aggregates belonging to form I were produced 
without the use of additives.  
 
Figure 10. Scanning electron microscopy images of raw and CBZ samples produced from 
different SASD runs: a) raw CBZ as form III; b) CBZ form I produced without additives (SASD 
4); c) CBZ form II produced with sodium stearate (SASD 6); d) CBZ form III produced with 
sodium dodecyl sulfate (SASD 8). 
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Particle size analysis varied depending on the polymorphic form obtained. Due to the needle-
like shape of CBZ forms I and II, the width was determined to be the average particle size 
which resulted in a much lower mean particle size than form III particles (block-shaped). SASD 
processed Form I samples showed a mean particle size of 120 ± 37 nm while form II particles 
showed an average size of 94±39 nm. Form III particles showed a mean size of 1 ± 0.42 µm, 
primarily due to the difference in shape. The Gaussian distribution of each sample is provided 
in the Supporting Information (Figs. SI1, SI2, SI3 and SI4). The particle size of the raw CBZ 
samples (form III) was also analyzed, which was determined to be 59 ± 13 µm. This highlights 
the potential of the SASD method for the production of pharmaceutical drugs. There is some 
noticeable aggregation in the SEM images, particularly Figure 10 (d) which can occasionally 
be observed during supercritical atomization methods. 
 
A final confirmation that antisolvent supersaturation/nucleation is likely to occur in the nozzle 
during the SASD experiments relates to the mass flow-rate ratio of solution and supercritical 
CO2 when compared to the mass ratio obtained in a batch supercritical antisolvent process. For 
the precipitation tests presented in Table 6, the mechanism that caused precipitation of CBZ 
was CO2 antisolvent crystallization. The ratio of solution to scCO2 should allow the 
determination of the minimum value needed for antisolvent crystallization to occur. 
Calculating the mass ratios of solution to scCO2 in the batch supercritical method was 
completed, as described in the experimental section. In the batch supercritical antisolvent 
method, there was a mass ratio of solution to scCO2 of 0.49-0.55 (depending on the temperature 
used) required to achieve for the precipitation of CBZ from methanol solutions. At the median 
solution flow rate (0.25 ml/min) and at 50 °C, the flow rate ratio of solution to scCO2 used was 
0.013 (SASD 2 in Table 2), which shows that there is a significantly higher proportion of CO2 
than solution inside the nozzle. As this value is significantly less than 0.50 (the maximum mass 
ratio allowed for antisolvent crystallization of CBZ to occur in a batch reactor at 50 °C), there 
is a strong indication that supersaturation of the CBZ solutions occurs in the SASD nozzle, 
caused by the CO2 antisolvent effect. This supersaturation of the CBZ solutions induced by the 
CO2 antisolvent effect, associated with the presence of each additive, promotes the nucleation 
of a particular polymorph of CBZ in the nozzle, followed by its crystallization in the drying 
chamber. 
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In order to test this hypothesis, the concentration of CBZ in methanol was reduced to 1/3 of the 
initial value (17.0 mg/ml) and processed using the SASD method (see Table 3). If the 
hypothesis is valid, no antisolvent nucleation/precipitation should occur or influence the final 
solid form obtained. Any differences in polymorphic form between low concentration samples 
and those described in Table 4 would suggest that at regular concentrations (50 mg/ml), the 
antisolvent effect is influencing the polymorphic form of CBZ caused by antisolvent 
supersaturation in the nozzle. Figure 11 shows the PXRD diffractograms of CBZ samples 
produced from low concentration CBZ methanol solutions (C[CBZ] = 17.0 mg/ml) by the SD 
and SASD methods.  
 
Figure 11. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database64-67 and CBZ samples processed using SASD 
and SD methods. A low concentration of CBZ in the methanol solutions was used (17.0 
mg/ml), as described in Tables 3 and 5. When additives were selected, the quantity used was 
5% w/w (0.8 mg/ml). 
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The SASD experiments yielded amorphous CBZ samples, regardless of whether an additive 
was used. This shows that as we decrease the concentration of CBZ in the methanol solutions, 
the levels of supersaturation achieved inside the SASD nozzle are significantly reduced which 
does not promote nucleation and crystallization of CBZ. By reducing the concentration of the 
CBZ solutions (to 17.0 mg/ml of CBZ in methanol), supersaturation of CBZ in the SASD 
nozzle is unlikely to occur, which leads to the amorphization of CBZ during the spray drying 
step (after the nozzle exit). This is assisted by the fast crystallization times once the solution 
has passed through the nozzle, preventing the conversion of the amorphous form to more stable 
polymorphs. Using identical concentrations of CBZ in methanol and similar operating 
conditions in a conventional spray dryer resulted in CBZ form IV. As there is no antisolvent 
effect present in the SD method (rather solvent evaporation being the main precipitation 
mechanism in this method), this result further supports our hypothesis that the antisolvent effect 
is the governing precipitation mechanism in the SASD method, influencing the final 
polymorphic form, when using concentrations of 50 mg/ml. The stability of specific PXRD 
files (Figs. 4, 6, 7 and 10) is discussed in the supporting information. The stability of these 
three samples are investigated after a period of sixteen months and shows that crystallization 
of CBZ forms I and III occurs. This is an expected result that is discussed in section 4.5.8 
 
4.4 Conclusions 
This work demonstrates that the polymorphic outcome of CBZ is controllable, with only minor 
impurities, using anionic additives in a continuous SASD method. Both SEM and PXRD results 
show that using sodium stearate promotes the formation of needle-like CBZ form II across a 
range of processing conditions (solution flow-rate and quantity of additive used) in the SASD 
method, while sodium dodecyl sulfate promotes the formation of the block-like stable CBZ 
form III. The results presented herein suggest that the primary mechanism that governs the 
crystallization of CBZ in the SASD method is the occurrence of supersaturation in the nozzle 
caused by the antisolvent effect of scCO2. We propose that the anionic additives used (SS and 
SDS) influence the final polymorphic form through brief interactions with scCO2 in the nozzle, 
resulting in similar polymorphic forms to those obtained using other scCO2 antisolvent 
methods (GAS), described in Chapter 3.  This leads to the crystallization of these respective 
- 146 - 
 
polymorphs (dependant on the additive selected) during the spray-drying step (after the nozzle 
exit). Additionally, the ratio of scCO2 to solution is considerably high in the SASD method, 
providing some insight into the supersaturation levels, when compared to the values obtained 
in the batch supercritical antisolvent experiments, strongly indicating that the antisolvent effect 
is present in the nozzle.  
These results could not be replicated when using similar processing conditions in SD methods 
(where antisolvent supersaturation does not occur).  The distinct differences between the SASD 
and SD mechanisms is clearly observed by the different polymorphic outcomes of CBZ 
obtained. Depending on the additive used, the SASD method produces forms I, II or III, while 
conventional spray drying consistently produces form IV only, irrespective of the additive 
selected. In addition to this, when the concentration of the CBZ solution is reduced, 
supersaturation in the SASD nozzle is unlikely to be achieved and, as a result, antisolvent 
nucleation/crystallization does not occur in the SASD method (amorphous CBZ samples are 
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4.5 Supporting Information 
4.5.1 SEM Images and Particle Size Distribution of CBZ Form I Particles 
Figure SI1 shows the SEM images of CBZ form I particles produced by the SASD method 
without the use of additives. 
 
Figure SI1. SEM images of CBZ form I particles produced by the SASD method without the 
use of additives (SASD 2). (d) Particle size distribution and Gaussian distribution for this 
sample.  
 
Figure SI1 shows the morphology of CBZ form I particles which are described as needle-like 
aggregates. The metastable polymorph (form I) is produced when processing CBZ using the 
SASD method without the use of additives. The particle size distribution is narrow, which is a 
characteristic quality of supercritical spray drying methods. The mean particle size was 
determined to be 120 ± 37 nm. The particle size and Gaussian distribution was calculated using 
NanoMeasure software. 
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4.5.2 SEM Images and Particle Size Distribution of CBZ Form II Particles 
Figure SI2 shows the SEM images of CBZ form II particles produced by the SASD method 
under the influence of sodium stearate. 
 
Figure SI2. SEM images of CBZ form II particles produced by the SASD method using 
sodium stearate as the additive (SASD 8). (d) Particle size distribution of SASD 8.  
 
Figure SI2 also shows needle-like particles which, similar to Figure SI1, is a characteristic 
shape of CBZ form II crystal phase. This form was produced when using the anionic additive 
SS, and is the least thermodynamically stable polymorph (at room temperature) of CBZ. A 
narrow particle size distribution is observed for this sample, similar to Figure SI1. This can be 
seen more clearly when compared to the block shaped particles seen in Figure SI3. The mean 
particle size of this sample was determined to be 94 ± 30 nm. 
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4.5.3 SEM Images and Particle Size Distribution of CBZ Form III Particles 
Figure SI3 shows the SEM images of CBZ form III particles produced by the SASD method 
under the influence of SDS. 
 
Figure SI3. SEM images of CBZ form III particles produced by the SASD method using SDS 
as the additive (SASD 6). (d) Particle size distribution and Gaussian distribution for this 
sample.  
 
Figure SI3 shows CBZ particles of the stable form III. The shape of these particles are block-
shaped and are discussed above. This sample was produced when using the anionic additive 
SDS and is the most thermodynamically stable polymorph of CBZ. The particle size 
distribution and Gaussian distribution is wider than the previous two figures. A potential reason 
for this is that these particles are irregular in shape and can lead to a greater degree of variation. 
Additionally, it also appears as though some particles are aggregated which increases the level 
of error in particle size analysis. The mean particle size of this sample was determined to be 1 
µm ±424 nm. 
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4.5.4 SEM Images and Particle Size Distribution of Raw CBZ Microparticles 
Figure SI4 shows the SEM images of CBZ microparticles purchased from Kemprotec as form 
III. 
 
Figure SI4. SEM images of CBZ microparticles, as purchased, prior to SASD processing. 
Image (d) Particle size distribution and Gaussian distribution for this sample.  
 
Figure SI4 shows CBZ particles as they were purchased. As can be seen from the images above, 
the particles are block shaped, which is the characteristic shape of CBZ form III. The particle 
size distribution and Gaussian distribution compared with all the CBZ samples processed by 
the SASD method. Similarly, to the particle size distribution chart presented in Figure SI3, the 
shape of these block shaped particles is irregular and can lead to a wider distribution when 
compared to regular needle shaped particles (Figs. SI1 and SI2). The mean particle size of this 
sample was determined to be 59.6 µm ± 13µm. 
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4.5.5 Stability of CBZ Polymorphs Processed without Additives 
Figure SI5 highlights the stability of the polymorphs produced from Figure 4, which 
investigated the impact that different solution flow rates had on the final polymorphic form of 
CBZ. From the PXRD data in Figure 4, it was observed that the metastable CBZ Form I was 
the dominant polymorph present within the sample with minor impurities from the stable form 
III. After characterization of these samples in Figure 4, each sample was stored at ambient 
conditions (21°C, approximately 60% humidity) for a period of eighteen months. The results 
in Figure SI5 indicate that polymorphic conversion does take place for each sample produced 
with varying solution flow rates. The dominant polymorph observed transitions to the stable 
form III with small impurities corresponding to form I for samples produced low and high flow 
rates (0.1 and 0.4 ml/min, respectively). For the median flow rate (0.25 ml/min), we observe 
the stable form III without any impurities from metastable polymorphs. This result is predicted 
as polymorphs, particularly in the submicron/nano-sized range, have a tendency to convert to 
the most stable form over time. 
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Figure SI5. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database64-67 and CBZ samples, tested for stability, 
processed without additives by the SASD method at various solution flow rates.  
 
4.5.6 Stability of CBZ Polymorphs Processed with SDS 
Figure SI6 demonstrates the stability of the polymorphs produced from Figure 6, which 
investigated the effect of different solution flow rates and the quantity of a specific additive 
(SDS) added to the drug solution. The initial results from Figure 6 indicated that the dominant 
polymorph observed was CBZ form III, which appeared to be independent from the amount of 
additive added or solution flow rate used. The presence of minor impurities from the metastable 
form I is observed for each experimental condition (DoE Points 1-5) tested with this additive. 
Following the initial characterization of these samples from Figure 6, the samples were stored 
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at ambient conditions (21°C, approximately 60% humidity) for a period of twenty months then 
retested to investigate if any polymorphic transformations has taken place. Metastable 
polymorphs have a high tendency to convert to a more stable form and this appears to occur 
for the majority of samples (DoE Point 2, 3, 4 and 5). One sample (DoE Point 1) shows 
conversion to a less stable polymorph, which involves a 0.1 ml/min solution flow rate and 1% 
w/w addition of SDS. This point shows that the metastable CBZ form I is the dominant form 
with minor impurities from the initially dominant form III. This result differs from the expected 
outcome and warrants further exploration to investigate the cause of this conversion.  
 
Figure SI6. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database64-67 and CBZ samples, tested for stability, 
processed with varying quantities of SDS in an SASD method at various solution flow rates.  
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4.5.7 Stability of CBZ Polymorphs Processed with SS 
Figure SI7 investigates the stability of the polymorphs produced from Figure 7 after the initial 
characterization. This DoE from Figure 7 examined the impact that solution flow rate and 
quantity of sodium stearate added had on the final polymorphic form produced. The results 
from Figure 7 indicate that the dominant polymorph observed was CBZ form II, irrespective 
of the amount of additive added or solution flow rate. The presence of small impurities from 
the metastable form I is apparent at the shoulder peak observed at ca. 12.5 ° (2 Theta) for each 
experimental condition (DoE Points 6-10). Upon completion of the initial characterization in 
Figure 7, the samples were stored at ambient conditions (21°C, approximately 60% humidity) 
for a period of nineteen months then retested to investigate if any polymorphic transformations 
had taken place. Form II is the least stable polymorph of CBZ23, meaning that conversion to a 
more stable form is highly probable. In Figure SI7, we observe this conversion through peaks 
corresponding to form I becoming more intense and visible in the PXRD spectra. However, 
even after nineteen months at ambient conditions, it still appears as though CBZ form II is still 
the primary polymorph present in most samples. One sample (DoE Point 6), which differs 
significantly from the rest shows the disappearance of form II and the presence of peaks 
representative of the stable form III as well as several peaks from form I. This DoE point occurs 
at 1% w/w additive addition and a 0.1 ml/min solution flow rate.  As this sample was the first 
experiment completed within this DoE, the minor increase in storage time may explain why 
the presence of the most stable polymorph of CBZ is observed when compared to other points 




- 155 - 
 
 
Figure SI7. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database64-67 and CBZ samples, tested for stability, 
processed with varying quantities of SS in an SASD method at various solution flow rates.  
 
4.5.8 Stability of CBZ Polymorphs Processed at Low Concentrations  
Figure SI8 highlights one of the major difficulties faced when producing unstable forms of 
polymorphic APIs. Amorphous CBZ was prepared when low concentration solutions (17.0 
mg/ml) were processed by the SASD method. With respect to stability, amorphous forms are 
considered to be the least stable version of any compound meaning that there is a high tendency 
for this compound to convert to any crystalline form, given sufficient time. The results from 
SI8 show that crystallization of the amorphous CBZ samples (described in Table 3) will occur 
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over an extended period.   After characterization of the samples in Figure 10, the samples were 
stored at ambient conditions (21°C, approximately 60% humidity) for a period of sixteen 
months (the shortest storage time investigated) then retested to examine if crystallization of 
these amorphous compounds had occurred. Samples that did not use additives and samples that 
used 5% w/w SDS, show conversion taking place to a mixture of form I and III. Interestingly, 
samples that were produced when sodium stearate was selected as an additive, showed the 
presence of peaks corresponding to form II, the same polymorph that is observed when using 
the SASD method. This result may suggest that SS may influence the crystallization process 
even after samples have been processed by this method. 
 
Figure SI8. Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, III 
and IV) from the Cambridge Structural Database64-67 and CBZ samples, tested for stability, 
processed with low concentration drug solutions (17.0 mg/ml) and each anionic additive (SS 
and SDS).  
- 157 - 
 
The outcome of these stability tests indicates that when additives are not used or when 
antisolvent crystallization does not occur, the conversion of these samples to a more stable 
form is likely to happen. When anionic additives, SDS and SS are selected, they appear to 
provide some stabilization regarding conversion as samples still appear to contain form III and 
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Chapter 5. Generation and Physicochemical 
Characterization of Posaconazole Cocrystals using Gas 
Antisolvent and Supercritical Solvent Methods 
The contents of this chapter have been submitted to The Journal of Supercritical Fluids and 
has received responses from reviewers. 
 
5.1 Introduction 
Chapters 3 and 4 demonstrate solid state control, in the form of polymorphic control, can be 
achieved using scCO2 methods (GAS and SASD). In this chapter, scCO2 methods are employed 
to demonstrate further solid-state control in the form of generating pharmaceutical cocrystals. 
Although pharmaceutical cocrystals have been studied for decades due to their ability to 
improve drug physicochemical and mechanical properties, discussed in greater detail in section 
1.2.5, they have recently attracted attention as they are also capable of extending the patent life 
of high-value drugs.1-2 As discussed in earlier sections, in 2018, the Food and Drug 
Administration (FDA) clarified the classification of a cocrystal requiring these compounds to 
follow the same regulatory requirements as a polymorph of a drug compound, rather than the 
original classification as a drug product intermediate.3 This ruling is expected to encourage 
further research by both academia and the pharmaceutical industry into cocrystal systems as a 
result of the reduced testing required for FDA approval.4 
Despite controversy surrounding the definition of a cocrystal, the FDA, industry and academia 
appear to have agreed on the most recent definition, proposed in 2012.5-6 Cocrystals can be 
divided into two categories: molecular and ionic cocrystals.7-10 Although the popularity of 
molecular cocrystals (MCCs) is evident in academia, when FDA approved cocrystals are 
examined, MCCs only occupy 50% of the 8 approved cocrystals.1, 8-9 Molecular cocrystals can 
be readily prepared by grinding or slow evaporation and offer additional routes to generate 
pharmaceutical materials, particularly when a compound does not produce a salt.10-11 Ionic 
cocrystals, discussed in section 1.2.5.2, are not as common in academia but account for half of 
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the FDA approved cocrystals on the market, highlighting the greater improvement in physical 
properties, relative to MCCs, as a result of stronger intermolecular bonding.10,12-13  
Posaconazole, the API model candidate used in this study is discussed in section 2.1.2, and is 
a highly polymorphic, BCS class II drug.17-18 The crystal structures of this API consist of four 
polymorphs and a methanol solvate, which were only reported in 2019 by McQuiston et al.19 
Even more recently, Kuminek et al. have produced a 2:3 cocrystal of PSZ with 4-aminobenzoic 
acid (4AMB) by a reaction crystallization method and demonstrated a superior solubility 
compared to PSZ.18  Supercritical fluid (SCF) technologies have existed for a long time but 
have only recently been investigated for their ability to generate pharmaceutical cocrystals.20-
26 Active pharmaceutical model ingredients such as carbamazepine, curcumin, naproxen, 
resveratrol and ketoconazole have been used for the generation of cocrystals using scCO2 
solvent methods based on the high relative solubility of these compounds in scCO2.
27-33 The 
GAS method is described in section 1.3.2.2 and is the method employed for Chapter 3 to 
explore the polymorphic control that can be achieved by this method for another API model 
compound (carbamazepine). This method has been shown to exercise control over the solid 
state of API compounds, including through the generation of pharmaceutical cocrystals.23, 27-28, 
32, 36 
Another supercritical method, described in section 1.3.1.2, and first reported as a method to 
generate indomethacin-saccharin cocrystals in 2009 by Padrela et al., utilizes scCO2 as a 
solvent in a process named cocrystallization with supercritical solvent (CSS).37-38 The 
enhanced molecular mobility caused by the scCO2 facilitates intermolecular interactions and, 
as a result, has promoted research to be conducted using this method for the development of 
pharmaceutical compounds such as cocrystals. 37-39 Recently Cuadra et al. reported the 
formation of a pharmaceutical cocrystal of the anticancer drug 5-fluorouracil using this 
methodology.40  This method is described in Chapter 1 but, briefly, works, mechanistically, by 
forming a slurry between the API and coformer, where some starting materials dissolve in 
scCO2 and react to form a cocrystal. This process is repeated until the contents have fully 
reacted, provided sufficient reaction time and suitable operating conditions such as temperature 
and pressure (which influence CO2 density and consequently the amount of API and coformer 
dissolved in scCO2) and stirring rate (which influences homogeneity in the cocrystallization 
medium, which is crucial for the enhancement of the intermolecular interactions between the 
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pure components) 
38 are achieved, and the cocrystal is in the thermodynamically favoured 
phase. The primary advantage of the CSS method, compared to the GAS method, also used in 
this chapter, involves the significant reduction or elimination of organic solvent thereby 
removing filtration and secondary drying steps from the process. However, CSS is constrained 
by the requirement for the starting materials to have a minimum level of solubility in scCO2, 
so that cocrystallization may occur. To the best of our knowledge, the solubility of PSZ in 
scCO2 is not available, however, the solubility of the coformer 4AMB has been reported to 
have a relatively low value compared to other compounds that have been previously processed 
by the CSS method. 23, 44 
In this work both GAS (uses scCO2 as an antisolvent) and CSS (uses scCO2 as a solvent) 
methods were used to investigate if different processing parameters (pressure, temperature and 
stirring rate), which are known to impact the solid state of APIs, can affect PSZ-4AMB 
cocrystallization. The results from both methods are compared using a range of characterization 
techniques such as powder X-ray diffraction, electron microscopy, thermal analysis and 
particle size distribution analysis.  
 
5.2 Experimental Section 
5.2.1 Materials 
Posaconazole was purchased from Kemprotec Ltd. at 98% purity and used without any 
modifications. Acetonitrile, methanol and 4-Aminobenzoic acid were purchased from Sigma 
Aldrich and used without further purification (purity was >99.9%). Both PSZ and 4AMB were 
characterized by PXRD (powder X-ray diffraction) to confirm its raw crystalline form. Carbon 
dioxide (99.98%) was supplied by BOC (Ireland). The molecular structures of PSZ and 4AMB 
and the desired cocrystal, PSZ-4AMB, are presented in Figure 1. The structures of PSZ, 4AMB 
and PSZ-4AMB were drawn using ChemDraw software, version 11. 
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Figure 1. Molecular structures of a) PSZ, b) 4AMB and (c) PSZ-4AMB cocrystal (CCDC 
1941360). 
 
5.2.2 Gas Antisolvent (GAS) and Cocrystallization with Supercritical 
Solvent (CSS) Methods 
Figure 2 presents a schematic diagram of a custom-designed GAS and CSS setup, describing 
the contrasting mechanisms between both methods. In the GAS method, the API and coformer 
are first dissolved in an organic solvent, whereas in the CSS method no organic solvent is used. 
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Figure 2. Schematic diagram of the GAS and CSS apparatus. 1, CO2 cylinder; 2, liquid 
compressor; 3, temperature-controlled air chamber; 4, stainless steel storage coil; 5, pressure 
transducer; 6, high-pressure vessel; 7, magnetic stirrer plate; 8, exit valve.  
 
The high-pressure setup, used for both GAS and CSS methods, presented in Figure 2 consists 
of a 15 cm3 stainless steel storage coil and a 10 cm3 (8.83 cm3 working volume) stainless steel 
high-pressure reaction vessel (where precipitation/crystallization occurs) with monitored 
temperature and pressure using a T-type thermocouple and a pressure transducer (Omega 
model PX603), respectively. The temperature of these vessels was maintained using a 
temperature-controlled air chamber. This ensured that the CO2 remained in a supercritical state 
throughout the experiments and ongoing reactions were conducted at a constant temperature. 
A borosilicate window was fitted on the top of the high-pressure vessel for visualization 
purposes during the experiments. A Teledyne ISCO 260D pump was used to compress the CO2 
before discharging it into the storage coil where it was allowed to remain for a short period of 
time (~10 minutes) until it reached the desired temperature. For GAS experiments, 10 mg of 
PSZ and 3 mg of 4AMB were weighed out and dissolved in 1 ml of Acetonitrile. The amount 
of PSZ and 4AMB used for the GAS method was based on the maximum solubility (10.4 
mg/ml) of PSZ in acetonitrile at ambient conditions so that a saturated PSZ solution could be 
processed. This value was significantly lower than the solubility of 4AMB in acetonitrile at the 
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same conditions (90.6 mg/ml) and was the reason for the low combined quantity of API and 
coformer used in the GAS method. The solutions were subjected to ultrasonic treatment for a 
period of approximately 5 minutes to ensure all starting material had dissolved. Acetonitrile 
was selected as it was the solvent reported by Kuminek et al. during the first report of the 2:3 
cocrystal of PSZ-4AMB using a reaction crystallization method and single crystals were 
obtained using a solvent evaporation method in the same solvent. Other solvents, such as 
methanol, which is frequently used in scCO2 antisolvent processing (such as Chapters 3 and 
4), possess the risk of forming a PSZ-methanol solvate. 18-19 An experiment was conducted 
using methanol to investigate if this solvate would form through supercritical processing. 
PXRD results confirming the formation of PSZ-methanol solvate using the GAS method is 
reported in the supporting information, Figure SI2. The acetonitrile solution containing PSZ 
and 4AMB dissolved was placed inside the 10 cm3 reaction vessel and sealed. Magnetic stirring 
(stirrer bar: 6 mm x Ø 3 mm) was switched on and scCO2 then entered into the high-pressure 
vessel at a rate of 46 g/min until the desired pressure, reported in tables 1 and 2, was reached. 
After approximately 5 minutes, magnetic stirring was turned off and the exit valve (number 8 
in Figure 2) was opened to continuously flush scCO2 through the high-pressure vessel, thereby 
removing the acetonitrile from the high-pressure reaction vessel (number 6 in Figure 2) while 
the precipitated particles remained suspended throughout. The scCO2 was passed through the 
reaction vessel over a 1-hour time frame at a flow-rate of 5 g/min (dependent on the pressure 
and temperature used). For CSS experiments, as no organic solvent was required, 50 mg of 
PSZ and 15 mg of 4AMB (2:3 molar ratio) were weighed and directly placed in the reaction 
vessel and sealed. The addition of scCO2 and magnetic stirring remained the same as described 
in the GAS method. These materials remained suspended inside the high-pressure vessel for 
approximately 1 hour to maintain identical reaction times experienced by the GAS method 
(accounting for flushing of scCO2). Once completed, magnetic stirring was turned off and the 
exit valve (number 8 in Figure 1) was opened to immediately depressurize the reaction vessel. 
Once depressurization of the vessel had concluded for GAS and CSS methods, the resulting 
materials were collected and stored in a desiccator prior to their characterization to minimize 
the occurrence of solid-state transformations. Tables 1 and 2 present the operating conditions 
used in GAS and CSS experiments, respectively. 
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5.2.3 Design of Experiments (DoE)  
A study using a 3-factor 2-level full factorial design of experiments (DoE) was performed to 
investigate the influence of different processing parameters on the formation of PSZ-4AMB 
cocrystals. Three factors on which the DoE was based are pressure, temperature and stirring 
rate. Maximum and minimum values were selected, and their values will be discussed in greater 
detail below. Table 1 describes the operating parameters and values selected for all DoE points 
using the GAS method. Additionally, this table describes if the final form obtained was the 
desired PSZ-4AMB cocrystal or undesired API, coformer or mixture. Each of the DoE 
experiments were performed in duplicate to ensure repeatability. 
 
Table 1. Experimental Conditions Used in GAS Experiments for PSZ-4AMB Formation 












Solid Form Obtained 
PSZ-
4AMB 
1 100 35 100 Cocrystal + Minor PSZ 
Impurities 
 2 200 35 100 Cocrystal + Minor PSZ 
Impurities 
 3 100 65 100 Cocrystal + Minor PSZ 
Impurities 
 4 200 65 100 PSZ 
 5 100 35 1000 Cocrystal + Minor PSZ 
Impurities 
 6 200 35 1000 Cocrystal + Minor PSZ 
Impurities 
 7 100 65 1000 Cocrystal + Minor PSZ 
Impurities 
 8 200 65 1000 Cocrystal + Minor PSZ 
Impurities 
aFor all DoE points; a 2:3 stoichiometric ratio was used between API (PSZ) and coformer 
(4AMB); concentration of initial solution was 10 mg of PSZ and 3 mg of 4AMB dissolved in 
1 ml of acetonitrile and reaction vessel was flushed for approximately one hour with scCO2 at 
a rate of 5 g/min.  
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Table 2 describes the operating parameters, values and solid-state forms obtained for all DoE 
points (9-16) using the CSS method. 
 
Table 2. Experimental Conditions Used in CSS Experiments for PSZ-4AMB Formation 













Solid Form Obtained 
PSZ-4AMB 9 100 35 100 PSZ + 4AMB + Minor 
Cocrystal  
 10 200 35 100 Cocrystal + PSZ + 4AMB 
 11 100 65 100 Cocrystal + PSZ 
 12 200 65 100 Cocrystal + PSZ 
 13 100 35 1000 Cocrystal + PSZ + 4AMB 
 14 200 35 1000 Cocrystal + PSZ 
 15 100 65 1000 Cocrystal + PSZ + 4AMB 
 16 200 65 1000 Cocrystal + PSZ 
b For all DoE points; a 2:3 stoichiometric ratio was used between API (PSZ) and coformer 
(4AMB); 50 mg of PSZ and 15 mg of 4AMB were directly placed in the vessel, immersed in 
scCO2 and stirred for a period of one hour; upon completion, the vessel was immediately 
depressurized and sample collected. 
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5.3 Results and Discussion 
5.3.1 Cocrystallization and Characterization of PSZ-4AMB by a Gas 
Antisolvent Method 
A DoE approach was used and three processing parameters (pressure, temperature and stirring 
rate) were selected to investigate their impact on PSZ-4AMB cocrystal formation. Several 
considerations were taken when deciding the maximum and minimum parameter values which 
are discussed further below. As reported by Chang et al., the density of scCO2 is directly related 
to the pressure used, and a higher pressure (denser scCO2) increases the proportion of organic 
solvent dissolved in scCO2.
41 Prior to conducting this DoE, preliminary experiments were 
performed at the least dense scCO2 values (low pressure, high temperature and low stirring 
rate) to ensure that precipitation at these points, the least likely to induce crystallization, would 
occur. The minimum pressure value selected was 100 bar to ensure that CO2 would remain in 
a supercritical state while 200 bar was selected as the maximum pressure value due to the 
pressure rating of the equipment. The minimum temperature setting employed was 35 °C based 
on the critical temperature of scCO2 of 31.1 °C, while the maximum temperature setting was 
selected based on the maximum value permitted for the equipment. Finally, stirring was 
selected as a process parameter in the DoE as it is known to have an influence on crystallization 
properties such as particle size (using supercritical methods) but has not been investigated for 
its impact on cocrystal formation using GAS.30 From the initial experiments conducted (at 
lowest density scCO2) before examining DoE points, it was discovered that while precipitation 
did eventually occur, it was not immediate and took approximately 2 minutes for it to be 
observed after the desired pressure value was achieved. This delayed precipitation was likely 
caused by the properties (low density) of the scCO2 in addition to the small temperature drop 
that may be experienced as the pressurised scCO2 enters a chamber at atmospheric pressure, as 
described by the Joule-Thompson effect. For this reason, during GAS processing the contents 
of the high-pressure vessel were subjected to stirring for a period of 5 minutes to ensure 
precipitation had taken place. 
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The solid-state form of the GAS samples was determined using PXRD by comparing the 
patterns from each sample to the reported cocrystal pattern by Kuminek et al., and to raw PSZ 
and 4AMB.18 This data is presented in Figure 3.   
 
 
Figure 3. a) Design of experiment schematic to investigate the impact of pressure, temperature 
and stirring rate as the process variables for PSZ-4AMB formation using the GAS method. b) 
Powder X-ray diffraction patterns of raw PSZ, raw 4AMB and the theoretical PSZ-4AMB 
cocrystal from the Cambridge Structural Database18 and DoE samples processed by the GAS 
method. Experimental conditions as described in Table 1 (DoE Points 1-8). Red dotted lines, 
highlighting characteristic cocrystal peaks, are included at 5.5 °, 10.5 °, 13 ° and 22.8 ° 2 Theta.  
 
For the samples produced by the GAS method (DoE Points 1-8), a large proportion of these (7 
out of 8) resulted in the formation of the PSZ-4AMB cocrystal, identified by four characteristic 
peaks described in Figure 3b. From the 7 points that produced the PSZ-4AMB cocrystal, two 
peaks at 8.1° and 27.6° 2 Theta, which correspond to PSZ, can still be identified in five of these 
samples (DoE points 1,2,3,7 and 8); while DoE points 5 and 6 only possess one of these peaks 
at 27.6°. However, this impurity is present in very low amounts and these samples can still be 
considered as high-purity PSZ-4AMB cocrystals. Due to the minor amounts of PSZ peaks 
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detected and absence of 4AMB peaks in all samples, excluding DoE point 4, this result may 
suggest that some of the coformer (4AMB) was removed during the flushing step based on the 
increase solubility of 4AMB (relative to PSZ) in acetonitrile, particularly at increased 
temperatures and pressures. Only one GAS sample (DoE point 4) resulted in PXRD-pure PSZ. 
The conditions for this point were 200 bar, 65 °C and 100 RPM. One possible explanation for 
this result is that the onset of antisolvent supersaturation is slower at 100 RPM than at 1000 
RPM, taking it longer for the CO2 to mix with the PSZ-4AMB acetonitrile solution and 
supersaturate it. Another possibility is that 4AMB is too soluble at this increased temperature 
(65 °C) and remains dissolved in the acetonitrile. This is supported by the presence of a greater 
proportion of impurities of unreacted PSZ at all DoE points (4, 7, 8 and 9) at this temperature 
compared to two DoE points (1 and 2) at lower temperatures. This gradual supersaturation may 
favour the precipitation of PSZ first rather than the cocrystal mixture, as high-purity PSZ-
4AMB is detected for the same conditions at a higher stirring rate (1000 RPM). This 
assumption would require further work into investigating the solubility of both components 
(PSZ and 4AMB) in scCO2 to verify this prediction.  
Figure 4 presents SEM images and PSD analysis of the different samples from the DoE points 
1-8 (Figure 3a) produced by the GAS method. To date, there are no SEM images of this 
cocrystal available in the literature, therefore the crystal habit of this cocrystal is unknown and 
hence, cannot be compared.  
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Figure 4. a) Scanning electron microscopy images of raw PSZ, 4AMB and PSZ-4AMB 
samples (DoE points 1-8) and b) Particle size distribution of PSZ-4AMB samples (DoE Points 
1-8) produced by the GAS method. 
 
From the SEM images in Figure 4a, the crystal habit of the PSZ-4AMB cocrystals appear to be 
plate-like. This crystal habit of PSZ-4AMB is similar to raw PSZ, while raw 4AMB has a rod-
like habit. Distinguishing between PSZ and PSZ-4AMB cocrystals using SEM techniques is a 
challenging task due to similarities in the crystal habit of both (PSZ and PSZ-4AMB) 
compounds. The particles presented in Figure 4a for DoE point 4, which were shown to be 
PXRD-pure PSZ, appear to be visually similar to the other particles produced by this method 
(DoE points 1, 2, 3, 5, 6, 7, 8), emphasizing the similarity between API and cocrystal habits. 
The only noticeable difference in these images is for DoE point 3 which appears to show 
slightly larger particles than other samples, however this is not observed in the PSD for this 
sample in Figure 4b. The particle size analysis for GAS samples are provided in Fig. 4b and 
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demonstrate an average particle diameter range of 19.5 – 43.0 µm. Two DoE points (points 4 
and 8) show a lower but wider than average PSD (D50 of 21.4 and 19.5 µm, respectively) and 
both points share high temperature (65 °C) and high pressure (20.0 MPa) values. Although 
DoE point 4 does not show any evidence of the PSZ-4AMB cocrystal, this should not affect 
the impact of these processing conditions on the particle size measurement and may provide 
some insight into the optimal conditions required for a reduced particle size. Surprisingly, 
stirring rate does not appear to significantly influence the PSD at either of these points. While 
it is expected that two different methods (GAS and CSS) will typically result in a different 
PSD, these conditions (high temperature, high pressure) will be focused on during CSS 
processing to determine if they affect particle size or PSD. The remaining DoE points (points 
1, 2, 3, 5, 6 and 7) demonstrate minimal deviation from the median PSD (35.9 µm) and suggest 
that samples produced at these combinations of processing conditions do not influence the 
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Figure 5 presents the DSC data for PSZ-4AMB samples (DoE Points 1-8) produced by the 
GAS method. 
 
Figure 5. Differential scanning calorimetry thermograms of raw PSZ, raw 4AMB and samples 
for DoE Points 1-8 produced by the GAS method. 
 
The thermal behaviour of the PSZ-4AMB cocrystal, reported by Kuminek et al. describes a 
single endothermic event at 154.1 °C.18 This differs from the thermal behaviour of PSZ which 
demonstrates a nematic-like phase transition at 134 °C followed by a melting point at 168.2 
°C, in addition to the thermal behaviour of 4AMB which melts at 188.3 °C. The results of the 
DSC analysis in Figure 5 shows a melting point at 154 °C for most samples (DoE points 1, 2, 
3, 5, 6, 7 and 8) which showed evidence of cocrystal formation. The GAS sample which 
demonstrated to be PXRD-pure PSZ (DoE Point 4) presented thermal behaviour corresponding 
to raw PSZ.  However, five out of seven DoE points (DoE points 1,2,3,7 and 8) possess a 
shoulder peak at 148 °C which may correspond to small amount of impurities from PSZ, which 
was observed from the PXRD analysis in Figure 3. Two GAS samples (DoE Point 5 and 6) 
- 178 - 
 
demonstrate a single melting point at 154 °C in Figure 5, indicating a sample of greater purity. 
This result is supported by PXRD analysis which report the absence of the PSZ impurity peak 
at 8.1° (2θ) for these two samples in Figure 3. 
 
5.3.2 Cocrystallization and Characterization of PSZ-4AMB by Supercritical 
Solvent Method (CSS) 
In order to compare the effectiveness of the GAS and CSS methods for the formation of PSZ-
4AMB cocrystals, the DoE processing parameters for the CSS method (see Table 2) were kept 
the same as reported in Table 1. The duration that the starting materials (API and coformer) 
were immersed in scCO2 was approximately 1 hour. This duration was selected ensuring that 
there was consistency between the flushing time employed for the GAS method and immersion 
time for the CSS method with all other parameters remaining unchanged. No preliminary 
experiments were completed using this method, unlike in the GAS method, as no visual 
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Figure 6 presents the PXRD data of samples produced by the CSS method compared to the 
reported theoretical pattern for PSZ-4AMB, raw PSZ and 4AMB.  
 
 
Figure 6. a) Design of experiments schematic to investigate the impact of pressure, temperature 
and stirring rate as the process variables for PSZ-4AMB formation using the CSS method. b) 
Powder X-ray diffraction patterns of raw PSZ, raw 4AMB and theoretical PSZ-4AMB 
cocrystal from the Cambridge Structural Database18 and DoE samples processed by the CSS 
method. Experimental conditions as described in Table 2 (DoE Points 9-16). Red dotted lines, 
highlighting characteristic cocrystal peaks, are included at 5.5 °, 10.5 °, 13 ° and 22.8 ° 2 Theta. 
 
In this DoE, only one sample (DoE point 9) produced high purity PSZ with a minor amount of 
cocrystal peaks detected. This sample was processed at the conditions that will dissolve the 
least amount of starting materials (low temperature and pressure) and this is likely to be the 
reason for few PSZ-4AMB cocrystal peaks. Despite peaks at 19, 22 and 25 ° 2 Theta 
corresponding to the PSZ-4AMB cocrystal pattern, the cocrystal is present in small amounts 
for this sample due to the low intensity of peaks detected, relative to peaks corresponding to 
PSZ and 4AMB. The cause of this outcome likely involves an insufficient solubility of PSZ 
and 4AMB in the scCO2 media at the processing conditions used in the DoE point 9, which 
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involved using a lower pressure (100 bar) and temperature (35°C) and thus, a lower CO2 
density. This is supported by Tian et al. who demonstrated that the solubility of 4AMB in 
scCO2 at low pressures (80 bar) can be up to three times lower than solubility values at higher 
pressures (210 bar) across a range of temperatures, similar to those employed for this study.44 
Additionally, the low stirring rate (100 RPM) may have negatively impacted the 
cocrystallization of PSZ with 4AMB. This is supported by Padrela et al. who reported that 
when processing multiple cocrystals by the CSS method without stirring resulted in impure 
cocrystallization, while a stirring rate of 300 RPM resulted in the complete cocrystallization of 
three different APIs (carbamazepine, indomethacin and theophylline) out of six.38 The 
remaining DoE points (points 10-16) at which samples were produced showed a significant 
number of peaks corresponding to the PSZ-4AMB cocrystal alongside several PSZ and 4AMB 
peaks. This result suggests impure PSZ-4AMB samples were generated by the CSS method, 
likely caused by the inadequate solubility of the starting materials in scCO2. Additionally, 
peaks at 13.9 ° and 15.4 ° 2 Theta for DoE points 9, 10, 13 and 15 appear to correspond to the 
raw 4AMB PXRD pattern indicating that incomplete cocrystallization may be the cause of the 
reduced cocrystal purity at these DoE points. The purity of this cocrystal may be improved by 
increasing reaction time38 or by adding a cosolvent to the reaction mixture, as reported 
elsewhere.40 As a result, an additional study using the CSS method where the hold time of two 
samples (DoE points 9 and 10) was increased to 8 hours (instead of 1 hour). The results of this 
study can be found in the supporting information, however, showed no significant differences 
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Figure 7 depicts SEM images and PSD analysis of DoE points (9-16) of PSZ-4AMB samples 
produced by the CSS method 
 
Figure 7. a) Scanning electron microscopy images of raw PSZ, 4AMB and PSZ-4AMB 
samples (DoE points 9-16) and b) particle size distribution of PSZ-4AMB samples (DoE Points 
9-16) produced by the CSS method. 
 
The sample (DoE point 9) which demonstrated a low detection of cocrystal peaks (mostly 
composed of PSZ as analysed by PXRD in Figure 6b) shows long plate-shaped particles. The 
SEM images for the CSS samples from DoE points 10, 11 and 15 shown in Figure 7a present 
the same plate-like particle shapes but slightly smaller, more similar to the GAS samples (DoE 
points 1-8) observed in Figure 4a. The CSS samples produced for DoE points 12, 13, 14 and 
16 appear to demonstrate a smaller particle size than compared to the other points. This may 
be explained by the high stirring rate (1000 RPM) experienced by DoE points 13, 14 and 16 
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which may have caused increased particle breakages. In the CSS method, raw forms of the API 
and coformer with larger particle sizes than each sample (DoE points 9-16) produced, are 
placed in their solid state in the vessel and are more susceptible to particle breakages due to 
only a small proportion of the API and coformer being dissolved in sCO2 during processing. 
In Figure 7b, the PSD of each CSS sample is presented. The average particle diameter for the 
CSS method ranges from 31.9 – 41.9 µm, which is slightly smaller than those produced by the 
GAS method. Although the SEM images in Fig. 7a appear to show differences in particle sizes, 
all CSS samples (DoE points 9-16) show little variation from the median particle size value 
(35.5 µm) and, therefore, it is not possible to suggest that any processing condition influenced 
the PSD, based on this information. The two operating parameters (high temperature and high 
pressure) which produced the smallest particle sizes using the GAS method (Figure 4b) do not 
produce the same below average mean particle diameter when employing the CSS method. 
However, as the PSD variation using this method is relatively narrow, it is difficult to determine 
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Figure 8 presents the DSC data for CSS samples for DoE points 9-16. 
 
Figure 8. Differential scanning calorimetry thermograms of raw PSZ, raw 4AMB and samples 
for DoE points 9-16, produced by the CSS method. 
 
In each of these samples, a melting point at 154 °C accompanied by a shoulder peak at 148 °C 
is observed, the former corresponding to the PSZ-4AMB cocrystal. Kuminek et al. reported 
that the DSC thermograms of the pure PSZ-4AMB cocrystal show a single sharp melting peak 
at 154 °C with no other melting events.18 The shoulder peak shown in Figure 8 may represent 
impurities corresponding to the starting materials (PSZ or 4AMB) which is supported by the 
presence of PSZ PXRD peaks in Figure 6b. The sample corresponding to DoE point 9 which 
produced a majority of characteristic PXRD peaks corresponding to PSZ, unexpectedly showed 
a melting event at 154 °C representative of the cocrystal thermal behaviour. A melting event at 
134 °C, corresponding to the PSZ nematic-like phase transition, can be observed at for all DoE 
points indicating the presence of PSZ, verified by PXRD results in Figure 6b. Additionally, all 
samples possess a shoulder peak at 148 °C indicating the presence of single components 
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(API/coformer) or a physical mixture, also confirmed by the detection of PSZ peaks in the 
PXRD data in Figure 6b. Overall, each sample produced by the CSS method demonstrated the 
presence of impurities, a result supported by the PXRD data from Figure 6b. 
 
5.3.3 Comparison of PSZ-4AMB Material Produced by GAS and CSS 
Methods 
Samples produced by GAS and CSS methods were compared to one another to highlight the 
primary differences between particles of PSZ-4AMB produced by each method. Beginning 
with the PXRD and purity of the samples, it was observed that the GAS method produced PSZ-
4AMB cocrystal samples of higher purity than those prepared by the CSS method. Samples 
produced by the CSS method showed a significant presence of characteristic peaks of PSZ in 
the PXRD patterns when compared to those produced by the GAS method, indicating that the 
reaction between PSZ and 4AMB had not gone to completion. This is supported by the reported 
use of cosolvent or extended reaction times to obtain higher purity samples when using the 
CSS method.40 Reaction time was investigated as a possible reason for these low-purity 
samples but was determined to not be an influencing factor. This result highlights the greater 
likelihood of success for the GAS method and this is evidenced by its popularity, compared to 
the CSS technique which requires additional process optimization and is dependent on the 
solubility of starting materials (API and coformer) in scCO2 which will change based on the 
temperature and pressure of the system. Two samples from each method (DoE points 4 and 9) 
demonstrated a high content of PSZ, indicating that a partial conversion (DoE point 4) or no 
conversion (DoE point 9) had occurred. The only processing condition that both of these DoE 
points shared was a low stirring rate (100 RPM). We propose that at these conditions, there is 
insufficient mixing between scCO2, organic solvent, API and coformer (GAS method) or 
between API and coformer (CSS method) to facilitate cocrystallization. This claim is supported 
by other researchers who have shown that a lower agitation requires a longer time to reach 
equilibria and may lead to incomplete reactions or impure cocrystals. 38, 42  
The SEM images from samples produced by both GAS and CSS methods appeared to be quite 
similar in habit. These habits matched that of raw PSZ, introducing some limitations involving 
identification through this characterization technique. The PSD of both samples were recorded 
- 185 - 
 
and revealed that both methods (GAS and CSS) produced mean particle sizes less than 45 µm. 
The range of these particle sizes appear to correspond to those previously reported for another 
API (e.g. carbamazepine) using the GAS method discussed in Chapter 3.22 However, the 
particles produced in this work by the CSS method appear to be smaller than those reported in 
literature which may be dependent on the cocrystal system or processing variables employed.23 
Padrela et al. and Cuadra et al. reported particle sizes ranging from 50 to 600 µm during the 
cocrystallization of indomethacin-saccharin and 5-fluorouracil cocrystals, respectively, using 
the CSS method.37 When comparing both methods, this analysis showed that the median 
particle size of samples produced by the CSS method (35.5 µm) were marginally smaller than 
those produced by the GAS method (35.9 µm). However, the difference in the median particle 
size between each method was less than 1 µm and, therefore, does not appear to present 
significant differences that can be achieved by either method.   
The DSC data overall showed a melting point at 154 °C, corresponding to the PSZ-
4AMB cocrystal, at all but one DoE points (DoE point 4) for both methods, including the 
sample (DoE point 9) which presented a low presence of PSZ-4AMB from the PXRD data in 
Figure 6b. However, due to the absence of a melting point at 188 °C, corresponding to 4AMB, 
cocrystallization caused during DSC characterization may have occurred. This method was 
first reported by Lu et al. as an approach for the rapid screening of cocrystals and may be the 
reason for the absence of the 4AMB melting point.43 The presence of a shoulder peak at 148 
°C was more apparent and pronounced for samples produced by the CSS method supporting 
the PXRD data that suggested these samples were lower in purity than those produced by the 
GAS method. Two samples which showed the sharpest DSC melting point at 154 °C, indicating 
a higher purity cocrystal, were DoE points 5 and 6, produced by the GAS method. This result 
is supported by the PXRD data which shows the lowest presence of peaks corresponding to 
PSZ from any sample. Overall, these high purity cocrystal samples emphasize that the GAS 
method is the more favourable method to generate the PSZ-4AMB with further optimization 
required to generate similar purity cocrystals by the CSS method. 
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5.4 Conclusions 
Cocrystallization of the antifungal drug Posaconazole with 4-Aminobenzoic acid has been 
achieved for the first time using two distinct scCO2 methods, namely GAS and CSS methods, 
in which scCO2 acts as an antisolvent and solvent, respectively. The PSZ-4AMB cocrystal 
produced from GAS and CSS methods exhibit the same crystal structure and melting point as 
those recently obtained by different methodologies.18  
Starting with the GAS method, a DoE approach was applied to investigate the impact of critical 
processing parameters (pressure, temperature and stirring rate) on PSZ-4AMB formation, size 
and habit.  Out of 8 different processing points, 7 of these produced the PSZ-4AMB cocrystal 
with minor impurities belonging to PSZ. Size and habit did not appear to be significantly 
influenced by any of the three critical processing parameters and a narrow PSD was obtained 
for the majority of DoE points. The only sample which did not produce PSZ-4AMB was 
completed at high temperature, pressure and low stirring rate (65 °C, 200 bar and 100 RPM, 
respectively) which may favour PSZ in a quaternary phase diagram. 
The CSS method demonstrated additional challenges when attempting to generate high-purity 
cocrystal samples. Similar to the GAS method, 7 out of a possible 8 DoE points demonstrated 
a significant number of PXRD peaks corresponding to the theoretical pattern of PSZ-4AMB, 
however these samples also contained significant impurities corresponding to PSZ. The sample 
(DoE point 9) which demonstrated a significant proportion corresponding to PSZ was 
generated using low temperature, pressure and stirring rate (35 °C, 100 bar and 100 RPM, 
respectively). The reduced solubility of API and coformer at these moderate conditions may 
have reduced the solubility of both starting materials in scCO2 causing inadequate interaction 
between PSZ and 4AMB to produce the cocrystal material. The remaining samples 
demonstrated a higher number of peaks matching the characteristic peaks of the PSZ-4AMB 
cocrystal theoretical pattern. However, these samples also presented impurities matching PSZ 
and would require further optimization to achieve a complete cocrystallization of PSZ-4AMB. 
An additional preliminary study investigating an increased reaction time (8 hours instead of 1) 
on some DoE points did not demonstrate any significant improvement towards cocrystal purity. 
Comparing GAS and CSS methods, both approaches generate particles with a mean diameter 
of less than 45 µm, with the CSS method producing marginally smaller samples. Both methods 
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produce a narrow PSD for the majority of DoE points. Posaconazole and the PSZ-4AMB 
cocrystal demonstrate similar plate-like crystal habits using GAS and CSS methodologies.  
Overall, the GAS method has been shown to be a viable method to produce high purity samples 
of the PSZ-4AMB cocrystal. The CSS method was also shown to produce PSZ-4AMB samples 
without the requirement for organic solvent, however these samples were lower in purity than 
those produced by GAS.  An interesting point worth further exploration would be to investigate 
the use of a cosolvent towards optimization of the CSS method. The cosolvent may facilitate 
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5.5 Supporting Information 
5.5.1 High-Pressure Vessel Dimensions 
Figure SI1 describes the dimensions of the vessel used during the study including the magnetic 
stirrer bar and glass window. The working volume of this vessel is 8.83 cm3. 
 
Figure SM1. Dimensions of a) vessel lid, b) borosilicate glass window, c) vessel chamber, d) 
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5.5.2 Powder X-Ray Diffraction of GAS Sample Produced with Methanol 
A solution containing PSZ and 4AMB, using the same quantities as described above, was 
prepared using methanol (instead of acetonitrile) to investigate if formation of the PSZ-
methanol solvate previously reported19 would occur. Figure SI2 presents the PXRD results.  
 
Figure SI2. Powder X-Ray diffraction patterns of theoretical PSZ-Methanol solvate from the 
Cambridge Structural Database and PSZ-4AMB sample produced from a methanol solution 
using the GAS method. 
 
This sample was processed at mid-point conditions relative to the maximum and minimum 
DoE points from Figure 3a. (temperature: 50 °C, pressure: 150 bar and stirring rate: 500 RPM). 
At these conditions, the PSZ-methanol solvate was formed. As a result, the use of methanol 
was no longer considered for use and acetonitrile was selected for GAS processing, as this 
solvent was chosen by Kuminek et al. when PSZ-4AMB was produced by reaction 
crystallization.18 
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5.5.3 Thermogravimetric Analysis of PSZ-4AMB Cocrystal 
Thermogravimetric analysis was completed on one PSZ-4AMB cocrystal sample (DoE point 
6 from Figure 3a) to determine its decomposition temperature, so that a suitable range could 
be employed for DSC analysis. The run parameters are as described in the manuscript. This 
sample was selected as it was considered to have the lowest amount of impurities from PSZ. 
The results of this analysis are presented in Figure SI3. 
 
Figure SI3. Thermogravimetric analysis of DoE Point 6, produced by the GAS method, 
containing high-purity PSZ-4AMB cocrystal. 
 
This sample showed a significant weight loss at temperatures higher than 200 °C, whereby the 
weight loss begins to plateau at 300 °C. As Kuminek et al. showed that the melting points of 
PSZ, 4AMB and the PSZ-4AMB cocrystal all occurred below 250 °C 18, a range of 50 to 275 
°C was selected for DSC analysis.  
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5.5.4 Fourier-Transform Infrared Spectroscopy 
Fourier-transform infrared spectroscopy (FTIR) was used to analyze each sample in Figure 
SI4. Firstly, raw PSZ and 4AMB were characterized, followed by samples from DoE points 1-
8. The typical FTIR band for an O-H group is quite broad, therefore this technique did not 
provide a significant differentiation between the starting materials PSZ and 4AMB and the 
GAS processed samples.   
 
Figure SI4. FTIR spectra obtained for raw PSZ, raw 4AMB and PSZ-4AMB samples 
processed by the GAS method (DoE points 1-8).  
 
Figure SI5 presents the FTIR data for samples produced by the CSS technique, as well as for 
raw PSZ and 4AMB. As suggested in Figure SI5, the O-H band is too broad to be clearly 
identified in these samples and alternative characterization techniques, such as PXRD and DSC 
should be prioritized for the identification of the PSZ-4AMB cocrystal. 
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Figure SI5. FTIR spectra obtained for raw PSZ, raw 4AMB and PSZ-4AMB samples 
processed by the CSS (Cocrystallization with Supercritical Solvent) method (DoE points 9-
16).  
 
5.5.5 Long Hold DoE Study 
In order to investigate the impact that increased reaction time may have on cocrystal purity, 
CSS experiments were completed using similar processing conditions to DoE points 9 and 10 
from Figure 3b but with an increased hold duration (reaction time). In these preliminary 
experiments, the starting materials (PSZ and 4AMB) were allowed to remain immersed in 
scCO2 for an extended period of 8 hours, rather than 1 hour as presented in Table 2. These 
samples were then removed as described in the manuscript. The samples were characterized by 
PXRD and compared to the samples from ‘short hold’ DoE points 9 and 10 from Figure 3b. 
These results are presented in Figure SI6.  
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Figure SI6. Powder X-ray diffraction patterns of PSZ-4AMB samples processed by the 
CSS method (DoE points 9 and 10), completed at short and long hold times (1 hour and 8 
hours, respectively). 
 
For this investigation, two samples (DoE points 9 and 10) were initially tested to examine if 
there was a significant difference between the purity of the samples from the short and long 
hold (1 hour and 8 hours, respectively) runs. The PXRD data in Figure SI6 shows almost no 
differences between DoE point 9 conducted at short and long hold times. The data from DoE 
point 10 highlights differences in intensities of peaks at 14 and 15.5 ° 2 Theta, between short 
and long hold times. However, there are no additional peaks present or peaks removed from 
these samples suggesting that the differences between these two samples were not significant. 
Therefore, hold time was not considered to be a critical processing parameter for the CSS 
technique and was not investigated further. 
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Chapter 6. Conclusions  
 
6.1 Conclusions 
This thesis describes the control and generation of solid-state forms, namely polymorphs and 
pharmaceutical cocrystals, by employing scCO2 in its three unique roles (solvent, antisolvent 
and spray enhancer). In both approaches (polymorphic control and pharmaceutical cocrystal 
generation), scCO2 methods were highlighted as an alternative approach to improving the 
physicochemical properties of poorly soluble APIs in comparison to conventional methods. 
In this thesis, polymorphic control is exhibited for carbamazepine (CBZ), which exists 
in four anhydrous polymorphic forms. This result is achieved by employing a well-established 
approach for controlling polymorphism in conventional methods, namely, through the use of 
additives. In Chapter 3 of this thesis, anionic additives are demonstrated to provide control over 
the final polymorphic form of CBZ generated in a scCO2 batch GAS method across a wide 
range of operating conditions. The stability of CBZ, measured by immersing the drug solution 
in scCO2 for an extended period, is also investigated and the greater presence of metastable 
polymorphic forms at higher temperatures detected is explained by the reduced stability of 
form III (the stable form at ambient conditions) at these conditions. The implications of this 
chapter may indicate that established approaches in conventional methods, such as the use of 
additives to control polymorphism, may also be applied to scCO2 methods and yield similar, if 
not greater, levels of polymorphic control.   
The subsequent chapter describes the conversion of the batch scCO2 method (GAS), 
described in Chapter 3, to a continuous scCO2-assisted spray drying method (SASD). In this 
study, it was demonstrated that the use of the same anionic additives (sodium stearate and 
sodium dodecyl sulfate) yielded similar results when the GAS method was converted to a 
continuous spray drying method. Additionally, this chapter clarifies that the primary 
mechanism that governs the crystallization process is caused by the antisolvent effect in the 
nozzle followed by immediate spray drying which prevents conversion to other, more stable, 
crystalline forms. This is supported by the production of different polymorphic forms when 
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employing conventional spray drying or when reducing the solution concentration below a 
threshold where antisolvent supersaturation can no longer be achieved in the nozzle. This 
chapter describes an approach that is of great interest to the pharmaceutical industry involving 
the transition from a batch to a continuous process, thereby eliminating the requirement for 
scaling up of high-pressure equipment. Additionally, this chapter discusses how the SASD 
method can be applied to existing technology employed for conventional spray drying and 
eliminates the need to purchase costly new equipment required by some scCO2 methods. This 
financial benefit further highlights the potential for the implementation of this technology to 
the pharmaceutical industry.  
The final chapter describes the generation of pharmaceutical cocrystals using scCO2 as 
a solvent and as an antisolvent. In this chapter, extensive characterization of the resultant 
material is performed and a plausible explanation for the difference in purity between a scCO2 
antisolvent method (GAS) and a scCO2 solvent method (CSS) is provided. This explanation 
proposes that the greater levels of purity observed for the GAS method compared to the CSS 
method is related to the greater miscibility of scCO2 with organic solvents relative to the 
solubility of the solutes selected for CSS processing. Overall, this study highlights the benefits 
provided by SCF technology for the generation of pharmaceutical cocrystals, relative to 
conventional cocrystallization methods. These advantages include a reduced quantity of 
organic solvents and smaller particle sizes. However, there are also limitations when the 
solubility of the solutes in scCO2 are low, exhibited in this chapter for the CSS method.  
In summary, this thesis demonstrates that solid-state control can be achieved using SCF 
technology in batch and continuous operation modes, employing each of the three unique roles 
of scCO2. Each of the aims presented in section 1.4 of this thesis have been addressed and are 
discussed in detail during each of the appropriate chapters. Overall, the addition of anionic 
additives, application of a DoE methodology as well as a comparative study between scCO2 
solvent and antisolvent methods is expected to improve the state of the art for scCO2 technology 
as well as showcase each method presented in this thesis as alternative technologies to existing 
conventional approaches that can offer unique advantages to improve the physicochemical 
properties of poorly water-soluble APIs.    
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Chapter 7. Recommendations for Further Study 
 
7.1 Cocrystallization of PSZ-4AMB by Continuous SASD Methods 
Chapter 4 reports the conversion of a batch process (GAS method) to a continuous spray drying 
method (SASD). Although some impurities, inherent of the SASD method, were detected, in 
general the outcome was quite similar to the initial study using the GAS method.  An interesting 
topic worth further investigation involves completing a thorough analysis of the PSZ-4AMB 
system using the SASD method. Some preliminary experiments conducted showed that an 
amorphous product was generated using the SASD method at similar conditions to those 
conducted in Chapter 5. Upon further characterization, specifically DSC, it was observed that 
both PSZ and 4AMB were present in the sample, noted by a exothermic event followed by a 
sharp peak at 154 °C, the reported melting peak for the PSZ-4AMB cocrystal.2 An investigation 
into critical parameters such as pressure, which will vary the ratio of scCO2 (antisolvent) to the 
cocrystal solution and nozzle size, which will be discussed in greater detail below, may yield a 
crystalline product. If crystallization cannot be achieved by this investigation, robust 
characterization of the amorphous product obtained could potentially provide insight into 
whether the samples produced are a physical mixture of both starting materials or are 
potentially a co-amorphous material consisting of PSZ and 4AMB. 
 
7.2 Effect of Nozzle Diameter on Particle Size and Solid-State Form of APIs 
using the SASD Method 
One of the critical parameters that influences particle size and, potentially, solid-state form is 
the droplet size produced after passing through the nozzle in conventional and supercritical 
atomizing processes.3-4 A smaller droplet size generated after passing from the SASD nozzle, 
typically leads to a smaller particle size, thereby improving the dissolution rate of processed 
compounds. Another factor influenced by the size of the droplet includes the drying time with 
larger droplet sizes requiring additional time to remove the solvent from the particle.5 As both 
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conventional and supercritical spray drying methods typically have relatively quick drying 
times, these methods tend to be utilized when amorphous or metastable polymorphs are 
required. This decision to employ these methods follow the mechanisms explained by 
Ostwald’s rule of stages, which states that amorphous or metastable polymorphs will initially 
form and continue to transform to the most stable form if time permits, which is typically not 
the case for spray drying methods.6 Selecting a nozzle with a large orifice will lead to larger 
droplet and particle sizes than those generated by employing a smaller orifice and will typically 
take a longer time for complete solvent removal to occur.4 Based on these drying times, a point 
worth further exploration is to investigate whether these differences in drying times, varied by 
droplet sizes, may have an impact on the final solid-state form obtained such as the polymorph 
of an API produced when antisolvent mechanisms govern the crystallization process. 
Additionally, the use of multi-orifice nozzles may add an additional dimension to this study as 
well as improve the quality and success of these results, as these multi-orifice nozzles can 
alleviate clogging, a common issue experienced in spray drying, particularly at small orifice 
sizes.7 Figure 1 illustrates the effect of various nozzle sizes on the final particle size of a 
proposed PSZ-4AMB system. 
 
Figure 1. Schematic illustrating the potential effect of different nozzle orifices (250, 150 and 
90 µm) on drying time and droplet sizes of PSZ-4AMB. 
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7.3 Scale Up of SASD Method 
The SASD equipment described in Chapter 4 is considered to be a lab-scale setup. It is common 
to see some conventional methods struggle to replicate lab-scale results when scaling up, 
therefore, a worthwhile investigation would involve the repetition of some experiments from 
Chapter 4 using a larger drying chamber in addition to higher solution and scCO2 flow rates to 
study the differences, particularly with respect towards polymorphism and particle size. A 
wider and larger drying chamber may facilitate faster drying (due to less congestion) of the 
atomized spray once it has passed through the nozzle and this faster drying time may lead to 
smaller particle sizes and a greater likelihood of generating amorphous or metastable 
crystalline phases as explained in section 7.2 when applying Ostwald’s rule of stages. 
Additionally, this scaled-up version of the SASD equipment should be compared to the study 
proposed in section 7.1 (investigating the scCO2 spray drying of PSZ-4AMB) for differences 
in the crystalline structure of samples produced which may be affected by the proposed 
differences in drying times. The use of CFD modelling may also provide a greater accuracy 
into the drying properties of these methods.8 
 
7.4 Outlook 
The pharmaceutical sector, a trillion dollar industry9, faces a major challenge with almost 90% 
of drugs in the pipeline displaying poor solubility.10 To address and overcome these challenges, 
alternative strategies to improve the solubility of these materials need to be investigated. Some 
of these strategies include the reduction of particle size of pharmaceutical materials, the control 
of polymorphic forms and the formation of pharmaceutical cocrystals to improve the solubility 
of these new chemical entities. One approach to achieving these strategies involves the 
application of supercritical fluids (SCFs) for processing. This thesis has highlighted that the 
polymorphism of a model API can be controlled using batch and continuous SCF processes. 
Additionally, some of these methods, specifically SASD, can produce material in the nano-size 
range (< 1µm), further improving the solubility profile of these materials. Additionally, this 
thesis describes how scCO2 can be utilized as an antisolvent (GAS) or solvent (CSS) for the 
generation of the pharmaceutical cocrystals such as PSZ-4AMB. These options, specifically 
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the CSS method, can improve pharmaceutical processes by removing the requirement of 
harmful organic solvents and remove time-consuming steps such as filtration and drying. With 
an increased interest in alternative technologies to improve the quality of pharmaceutical 
processing, the growth of this sector (using SCF technology) has the potential to take advantage 
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